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SUMMARY
Historically nitric oxide (NO) was viewed as playing a purely paracrine role in the 
regulation o f vascular tone, acting within the vicinity o f its release. Reactions o f NO in blood 
were consequently assumed only to scavenge and inactivate NO, thus regulating localised 
vasodilatation. However, this view o f NO metabolites changed following the emergence o f an 
endocrine hypothesis proposing that blood borne NO metabolites might conserve bioactivity 
allowing for the storage, transport and potential release o f NO far from its location o f synthesis. 
Today an endocrine role o f blood borne NO metabolites is now widely accepted, although the 
species accounting for the vascular regulatory function still remains in contention. This current 
status mainly reflects controversies and difficulties associated with both the measurement and the 
handling o f biological samples containing dilute metabolite concentrations.
The original aim of this thesis was to analyse the two main NO metabolite hypotheses 
(i.e., SNO-Hb and nitrite hypotheses) to provide a more comprehensive understanding o f their 
potential significance in the human circulation. The rationale was based on making biochemical 
measurements in combination with parallel assessments o f physiological changes in the human 
vasculature. Initially the focus was on developing methods capable o f measuring baseline levels 
o f NO metabolites in human blood. During this work a major confounding factor was identified 
influencing the measurement o f NO attached to red blood cells/haemoglobin, namely the auto­
capture o f NO by cell free haemoglobin in the reaction chamber. A means was developed to 
overcome this via the modification o f one o f the most commonly used assay reagents in the NO 
metabolite field. Subsequently this modified reagent was used along with several other methods 
to analyse NO metabolites in human blood. Ultimately however, levels o f SNO-Hb measured at 
baseline were on the border o f methodological sensitivity, although haemoglobin-bound NO was 
clearly distinguishable (and found to increase at lower oxygen). Consequently my work focussed 
on the potential o f nitrite versus haemoglobin-bound NO per se to act as endocrine NO 
metabolites in the human vasculature. Nitrite metabolism in arterial and venous human whole 
blood was analysed whilst the vasodilatory properties o f nitrite were investigated to assess 
whether this species could account for the relaxation response observed from native red blood 
cells under hypoxic conditions. Finally for the first time ever NO metabolites were 
simultaneously measured across the coronary and pulmonary vascular beds in the human 
circulation to address the potential for NO metabolites (including nitrite) to regulate vascular tone 
at baseline and under conditions o f increased oxygen demand.
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Chapter ONE General Introduction
1.0 Structure and Summary of Chapters
The structure o f this thesis follows a well established template. The general introduction 
offers a comprehensive background detailing issues o f relevance to the rest o f this work. The 
second chapter outlines precise methodological protocols and materials used. Each o f the 
following chapters subsequently combines results and discussion. The first o f these, chapter 
three, is slightly unconventional in that it is devoted to work undertaken investigating and 
developing methods for the measurement o f blood borne NO metabolite species. Within this 
chapter each area thought to contribute to the wide range o f metabolite values reported in the 
literature is addressed along with the experiments performed to determine the final methodology 
used throughout this thesis. The three further results and discussion chapters all focus on the 
potential o f nitrite and red blood cells to act independently or dependently as endocrine NO 
metabolite(s) to elicit vasodilatation. Chapter four offers an in vitro comparison o f the 
metabolism of nitrite and NO in human arterial and venous whole blood. Chapter five utilises the 
ex vivo organ chamber bioassay (in normoxia and hypoxia) to investigate the vasodilator 
properties o f nitrite alone and the possible role o f nitrite in red blood cell induced relaxation. 
Chapter six (the final results and discussion chapter) brings together the work from the previous 
chapters in an in vivo investigation o f blood borne NO metabolites across the coronary and 
pulmonary vascular beds in the human circulation under conditions o f changing oxygen demand. 
The final chapter (chapter seven) attempts to summarise the results obtained in the substantive 
chapters three to six, drawing together conclusions and highlighting perspectives for future 
research.
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Chapter ONE General Introduction
1.1 Chemistry of NO
Nitric oxide (NO), also called nitrogen monoxide, exists as the result o f  a covalent 
interaction between oxygen and nitrogen. This simple diatomic gaseous free radical has a rich 
and varied chemistry much o f which is determined by its electron structure [1].
1.1.1 Electron Structure
Eleven o f the fifteen electrons which make up NO are valence electrons (electrons in the 
outer atomic shell). Six are derived from oxygen and five from nitrogen. These electrons pair up 
forming three fully occupied bonding orbitals, which leaves one unpaired electron in the highest 
occupied molecular orbital (2p anti-bonding orbital) [2] (Figure 1.1). Along with its ability to 
exist independently this unpaired electron characterises NO as a free radical.
Figure 1.1: Molecular orbital diagram fo r  NO in its ground sta te  illustrating the 
arrangement o f the 11 valence electrons. The single 2s and  three 2p atomic orbitals o f  
nitrogen and oxygen combine to form  3 fu lly  occupied bonding orbitals w ith the unpaired 
electron in the antibonding  p orbital. Adapted from  [1]
NO can act as a reducing agent by losing the single unpaired electron or an oxidising 
agent by gaining up to five electrons in the free anti-bonding p orbitals. O f particular relevance in
MDCDCD-C MSXDQ)
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the chemistry, reactivity and metabolism of NO are its one electron oxidation and reduction 
forming the nitrosonium cation (NO+) and nitroxyl anion (NO ) respectively [3] (Figure 1.2).
+ N =  O « ► *N — O -"'C ► N — O’
+ l e  +  l e
Figure 1.2: Representation o f the one electron oxidation and reduction o f NO forming the 
nitrosonium cation (NO+> and the nitroxyl anion (NO) respectively. A dapted  and  
reproduced with kind perm ission o f  Alexandra Milsom.
1.1.2 Oxides o f Nitrogen and Oxygen
Nitrogen (like oxygen) is able to exist in a variety o f oxidation states. This capacity to 
adopt various forms and to perform redox reactions to transfer between these forms explains 
much of the diversity within NO biological chemistry [3]. The following tables (1.1 and 1.2) 
review the nomenclature o f nitrogen oxides (A^-oxides) and oxygen derived radicals relevant to 
the metabolism o f NO.
4
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Table 1.1: Nitrogen oxides relevant to NO metabolism in vitro and in vivo, listed according 
to the oxidation sta te  o f nitrogen [4J.
Chemical name Molecular formula Oxidation state of 
nitrogen
Ammonia/Ammonium ion NH3/NH4+ -3
Hydrazine N2H4 -2
Hydroxylamine n h 2oh -1
Nitrogen n 2 0
Nitrous oxide n 2o +1
Hyponitrous acid/nitroxyl anion HNO/NO +1
Nitric oxide NO +2
Dinitrogen dioxide n 2o 2 +2
Nitrosonium cation NO+ +3
Dinitrogen trioxide n 2o 3 +3
Peroxynitrous acid/peroxynitrite ONOOH/ONOO’ +3
Nitrous acid/nitrite h n o 2/n o 2- +3
Nitrogen dioxide n o 2 +4
Dinitrogen tetroxide n 2o 4 +4
Dinitrogen pentoxide n 2o 5 +5
Peroxynitric acid/ peroxynitrate 0 2N 0 0 H /0 2N 0 0 ‘ +5
Nitric acid/nitrate h n o 3/n o 3- +5
Table 1.2: Oxygen derived species relevant to NO m etabolism in vitro and in vivo, listed  
according to the oxidation sta te  o f oxygen [4J.
Chemical name Molecular formula Oxidation state of 
oxygen
Hydroxyl OH -3
Superoxide anion o2- -2
Hydrogen peroxide/Peroxide anion H20 2/ 0 22' -1
Oxygen o2 0
5
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1.2 Reactivity of NO
Each of the various N-oxides has its own particular reactivity and can react with a number 
o f biological molecules in a potentially bewildering array o f reactions [5]. In terms o f NO, NO+ 
and NO' the main biological reactions are outlined in figure 1.3. These reactions however can be 
simplified into direct and indirect reactions [6 , 7].
n h 2o h  r s -n o
▲ RONO * RR’N-NO
IRSH ro^X. rsh// '/^ r,nh
reduction oxidation
N2O * N O ‘ * -------------------  N O   ► N O
< p s  J o , \  1 I
NO’ ONOO- M-N° ^ ° 2/N2° 3ONOO' M-N 0  NOi-  ONOO- M-N 0
n o 2/ n £  W p S * 0
RS-NO * N02
N03
(N02)
Figure 1.3: Reactivity o f  nitric oxide ( N O ) ,  nitrosonium ( N O +)  and nitroxyl ( N O ) .  O 2  =  
molecular oxygen, O 2 '  = super oxide, O N O O  = peroxynitrite, M  = m etal centre, M - N O  =  
metal nitrosyl adduct, N O 2  = nitrogen dioxide, N 2 O 3  = dinitrogen trioxide, N O 2 -  = nitrite, 
N O 3 -  = nitrate, N 2 O  = dinitrogen oxide, R S H  = thiol, R S - N O  = nitrosothiol, N H 2 O H  = 
hydroxylamine, R O H  = prim ary amine, R O N O  = nitrosamine, R R ’N H  = secondary amine, 
R R ’N - N O  = nitrosamine, H 2 O  = water, H 2 O 2  = hydrogen peroxide. A dapted  from  [8J.
1.2.1 Direct
The direct reactions o f NO in biological systems are with oxygen, free radical species 
(such as superoxide) and metal containing centres. The respective products o f these reactions are 
7V-oxides (N 02, N20 3), peroxynitrite (ONOO') and metal-nitrosyl adducts (M-NO).
1.2.2 Indirect
The products o f the direct reactions can potentially undergo further indirect reactions, for 
example hydration reactions or reactions at nucleophilic centres, forming higher AA-oxides (N 0 2', 
N 0 3’) or S-nitrosothiols (RSNO) respectively.
6
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1.2.3 Classification o f Reactions
The reactions o f NO and its redox related forms can be classified as follows:
Table 1.3: Definitions and species involved in the different reactions o f NO and its
interrelated redox forms.
Reaction Definition Involves
Oxidation Reaction with oxygen NO and related TV-oxides
Nitrosylation
Reaction involving the covalent 
attachment of NO (without change 
in the formal charge of the 
substrate) [9]. NO based 
modification of protein function 
analogous to phosphorylation.
Metal centres, Protein 
thiol side chains
Nitrosation Reaction involving modification by NO+ [9].
Nucleophilic centres of 
nitrogen (e.g., amines), 
sulphur (e.g., thiols), 
oxygen (e.g., superoxide) 
and carbon (e.g., tyrosine)
Trans-
nitrosation
The passing of NO+ between thiol 
groups
Nitration
Reactions in which a nitro group (- 
N 0 2) is added to or substituted in a 
molecule
Aromatic amino acids 
including tyrosine
All o f these reactions are subject to reaction rates and are dependent upon the 
concentration o f reactants and the rate o f competing reactions including the respective 
concentration o f their reactants. This complexity has been simplified into a concept known as the 
reaction target area principle [10], introduced into the NO field by Beckman [11]. According to 
this principle, the relative amount o f a compound (e.g., NO) that reacts with its respective targets 
can be determined by multiplying the reaction rate and the concentration o f the target. Therefore, 
although the reaction o f NO with superoxide is high (~ 1010pM/s), the physiological concentration 
of superoxide is low (~ 0.1-lnM ) [11]. On the other hand, the reaction o f NO with a metal centre 
is much lower (~ 107pM/s), but the concentration o f metal centres is much higher (~ lOpM). This 
makes the reactive exposure for metal centres tenfold higher than that for superoxide ( 108 v 107), 
which means that the former reaction is more likely to occur in vivo. The various products from 
the reactions o f NO have the potential to be either toxic or protective depending on the biological 
environment in which the reactions take place.
7
Chapter ONE General Introduction
1.3 Production of NO
1.3.1 Nitric Oxide Synthases
NO is produced by a family o f enzymes known as the nitric oxide synthases (NOS). To 
date three distinct NOS isoforms have been identified [12, 13], all o f which differ in their 
structure, localisation, regulation and inhibitor sensitivities (Table 1.4).
Table 1.4: Properties o f  the different isoforms o f NOS. NADPH = nicotimamide adenine 
dinucleotide phosphate, FAD = flavin adenine dinucleotide, FMN = flavin mononucleotide, 
BH4 = tetrahydrobiopterin, pm oles = picomoles, nmoles = nanomoles. Reproduced with  
kind perm ission o f  Alexandra Milsom.
NOS Isoform
Type I Type II Type III
Other
designation nNOS/ncNOS iNOS eNOS/ecNOS
Substrates L-arginine, oxygen, NADPH
L-arginine, oxygen, 
NADPH
L-arginine, oxygen, 
NADPH
Co-factors FAD, FMN, BH4 FAD, FMN, BH4 FAD, FMN, BH4
Prosthetic
groups Haem, Calmodulin Haem, Calmodulin Haem, Calmodulin
Expression Constitutive Inducible Constitutive
Inducible by 
calcium Yes No Yes
Levels of NO 
produced Pico moles Nano moles Pico moles
Cellular
localisation
Central and 
peripheral neurones, 
skeletal muscle, 
epithelial cells
Macrophages, 
endothelial cells, 
hepatocytes, 
vascular smooth 
muscle cells, lung 
and gut epithelial 
cells
Vascular 
endothelial cells, 
neurones, epithelial 
cells, heart, skeletal 
muscle
Subcellular
localisation Mainly cytosolic Cytosolic Membrane bound
Major function
Neuronal 
messenger, synaptic 
plasticity
Immuno-
cytotoxicity
Relaxation of 
vascular smooth 
muscle
8
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The NOS enzymes were originally named according to the cell types in which they were first 
located (neuronal, immune and endothelial) these isoforms have since been re-classified (type I, II 
and III respectively) due to identification elsewhere [13, 14].
1.3.1.1 Structure
Active (coupled) NOS forms a homodimer made up o f two identical enzyme subunits 
(Figure 1.4). Each subunit exhibits a bi-domain structure consisting o f an N terminal oxygenase 
domain and a C terminal reductase domain. The reductase domain contains binding sites for 
NADPH, flavin mononucleotide (FMN), flavin-adenine dinucleotide (FAD) and is linked through 
calmodulin (CaM) to an oxygenase domain with binding sites for haem, 6(R)-5,6,7,8- 
tetrahydrobiopterin (BH4) and L-arginine [15].
Reductase Oxygenase
NHNADPH
CaM L-Arg
L-Arg CQOHCaM
NH NADPHFMN
Oxygenase Reductase
Figure 1.4: Scheme o f  the domain structure o f the NOS dim er showing cofactor and
substrate binding sites. Reproduced from  [16].
1.3.1.2 NO Formation
It still remains in question whether NOS directly synthesises NO, some other reactive 
nitrogen species (e.g. NO ) [17, 18], or a combination o f both depending on the conditions [19,
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20]. For the direct production o f NO, NOS has to catalyse a five-electron oxidation o f the 
terminal guanidine nitrogen atom on the amino acid L-arginine [13] (Figure 1.5).
R=NH (L-arginine) + 1.5 NADPH + 1.5 H+ + 2 0 2 -> R=0 (citrulline) + 1.5 NADP+ + 2 HzO + NO
Figure 1.5: Reaction stoichiometry fo r  NOS production o f  NO in its free  radical form.
The reaction is thought to occur in two phases, the first o f which involves electrons from 
the two electron donor NADPH being transferred through the reductase domain o f one NOS 
subunit (via the flavins) to the one electron acceptor haem in the oxygenase domain o f the other 
subunit. This reduces the haem iron in the catalytic centre enabling it to bind and activate 
oxygen. During the second phase the activated oxygen is inserted into L-arginine forming the 
intermediate A°-hydroxy-l-arginine from which NO and citrulline are generated by oxygenation 
[21] (Figure 1.6). Under certain situations such as limiting substrate or co-factor availability, the 
NOS enzyme becomes uncoupled resulting in the production o f superoxide and hydrogen 
peroxide [2 2 ].
1.3.2 Other Sources o f NO
Although the NOS enzymes have been viewed as the classical pathway o f NO generation 
in mammals, it is now clear that several alternative routes also exist in vivo by which the A-oxides 
nitrite (and under certain conditions nitrate) and the oxidative bi-products o f NO in blood can be 
reduced back to NO. In the case o f nitrite, these include non-enzymatic acidic reduction [23], 
reduction by deoxyhaemoglobin in blood [24-27], reaction with xanthine oxidoreductase [28, 29] 
and enzymes o f the mitochondrial respiratory chain [30]. This means that dietary sources of 
nitrite (and nitrate), i.e., meat, vegetables and drinking water, could potentially contribute to the 
bio-available blood borne pool o f NO in vivo [31].
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1.4 Vascular NO
1.4.1 Vascular Anatomy
Blood vessel anatomy changes throughout the cardiovascular tree reflecting specificity o f 
function (Figure 1.6 and Figure 1.7). In general, blood vessels consists o f a hollow centre (the 
lumen) surrounded by three main structural layers, the interna, media and externa. The intima, or 
inner layer, is comprised o f a single layer o f endothelial cells, a basement membrane (sub- 
endothelial layer) and elastic tissue called the internal elastic lamina. The media which surrounds 
the intima is composed primarily of smooth muscle cell layers, the number o f which range from ~ 
25 in large arteries to 1 or 2 in veins. Finally, the outermost layer o f  the vascular wall (the 
externa) consists largely o f collagenous tissue [32].
Tunica in terna
• Endothelium ------
• Subendothelial layer 
Internal elastic lamina
Tunica m edia
External elastic lamina
Tunica ex te rn a
LumenLumen
Artery
Endothelial cells
Capillary
network
Capillary
Figure 1.6: Structure o f large blood vessels and capillaries. Reproduced from
http:/ /w w w . med. howard.edu/physio. biophys/MILLIS%20HOME%20PAGE_files/ Biomed
/ 1 9PPT_lect/262,4, Generalized Structure o f Blood Vessels.
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Figure 1.7: Structure o f  blood vessels throughout the circulation. Reproduced from  
http://facsta .ff. bloomu. e d u /g w a ssm e r/ ap2su m m er2003/ lecturenotes/259,4, Histological 
Structure o f  Blood Vessels.
1.4.2 Endothelium
The vascular endothelium is made up o f a continuous single layer o f cells which line the 
inner surface o f the blood and lymphatic vessels. Originally thought o f  as a relatively inert barrier
12
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between the underlying smooth muscle tissue and the circulating blood, our understanding o f its 
function has changed dramatically over the last 25 years.
1.4.2.1 Endothelial Function
Various substances produced and released by the endothelium play critical regulatory 
roles in maintaining vascular homeostasis; regulating smooth muscle tone, vessel anticoagulant 
and anti-thrombogenic properties, inflammation and immunity and vessel growth and 
angiogenesis [33]. O f particular significance are the chemical mediators which constrict 
(angiotensin II, endothelin, thromboxane A2 and oxygen free radicals) or dilate (NO, prostacyclin 
and endothelial derived hyperpolarising factor) the underlying vascular smooth muscle to regulate 
vessel tone, blood flow and thus oxygen delivery to tissue.
1.4.2.2 Discovery o f the Endothelial Derived Relaxing Factor (EDRF) and NO
The phenomenon of an EDRF was first reported in 1980 with the answer to the apparent 
paradox as to why acetylcholine, an agent known to be a vasodilator in vivo often caused 
vasoconstriction when administered to blood vessels in vitro. Experiments performed with 
dissected segments o f rabbit thoracic aorta mounted on an apparatus for studying vascular 
responses demonstrated that careful handling o f the tissue which preserved the blood vessel 
endothelium always resulted in acetylcholine having relaxant properties (following pre­
constriction with norepinepherine) whereas removal o f the endothelium eradicated this action [34, 
35]. This work consequently led to a race to discover the chemical identity o f the endothelium 
derived substance causing vasodilatation. Although experimental evidence was mounting from 
several laboratories that EDRF possessed pharmacological, biochemical and chemical properties 
that were similar to those for NO, it was not until seven years later that two groups simultaneously 
published definitive studies characterising and identifying EDRF as NO [36, 37]._Following the 
discovery o f EDRF and its identity as NO, what remained in question was how NO exerted its 
physiological effects on cells. However, the search for “NO receptor(s)” had been going on 
concurrently. Ultimately it was this work, which identified the signalling pathway of NO via 
soluble guanylate cyclase (sGC) and cyclic guanosine 3’:5’-monophosphate (GMP) which is what 
finally brought the whole NO story together [38-40].
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1.4.2.3 Endothelium Derived NO
Endothelial derived NO is synthesised by type III NOS which binds to the plasma 
membrane in pockets called caveolae [41, 42]. Here it interacts with the transmembrane proteins 
caveolin-1 and -3, which catalytically inactivate the enzyme. Activation o f endothelial cells 
however results in an increase in intra-cellular free calcium triggering calmodulin binding to NOS 
which displaces caveolin resulting in enzyme activation and NO production [43] (Figure 1.8).
Ca2+
ENDOTHELIAL 
CELL /
Ca2+
ER
Ca-CaMCaM
eNOS
L-arg NO
NO
Figure 1.8: Production o f nitric oxide by endothelial cells. Activation o f  endothelial
receptors (R) by  agonists (e.g., acetylcholine and bradykinin) and the effect o f shear s tress  
results in an increase in the intra-cellular calcium concentration via extra cellular calcium 
influx and inositol triphosphate ( I P 3 )  stim ulated release o f  calcium from  the endoplasmic 
reticulum (ER). Calcium activates calmodulin (CaM) which in turn activates nitric oxide 
syn th ase  (NOS) producing nitric oxide (NO) from  its amino acid pre-cursor (L-arg). A dapted  
from  [44].
Under baseline conditions endothelial derived NO accounts for 25-30% o f human blood 
flow providing constant vasodilator tone against sympathetic vasoconstriction [45]. This 
production o f NO can be enhanced by increasing both expression and activity o f the type III NOS 
enzyme. This occurs in response to several factors including shear stress (i.e., the frictional force 
applied tangentially across the surface o f the endothelium resulting from the pulsatile flow of
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blood), the binding o f agonists to endothelial receptors (e.g., acetylcholine, bradykinin, ATP) and 
hypoxia.
1.4.2.4 Diffusion o f Endothelium Derived NO
The movement o f NO is mainly controlled by free diffusion, which means the net 
movement o f molecules occurs only if a concentration gradient develops. Micro sensor 
measurements made under physiological conditions have given NO a diffusion coefficient of 
3300 pm2 s '1 with the diffusion range approximating 150-300 pm for a time o f 4-15 seconds [46, 
47]. This distance however does not necessarily correspond to a straight line trajectory since the 
movement is totally random. Predictions suggest that for a cell o f radius 4-15 pm it would take 
one NO molecule in the order o f 0.002-0.03 seconds to escape [47]. Theoretically it has been 
calculated that NO can diffuse more rapidly out o f the endothelial cell than the rate at which it 
reacted with targets within it [48, 49]. However, this depends entirely on the concentration of 
targets within and around the cell and their intrinsic rates o f reaction with NO.
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1.5 Metabolic Fate of Endothelium Derived NO
The metabolic fate o f endothelium derived NO is dependent on its concentration, 
diffusibility and the surrounding concentration o f other bio-reactants. Two important routes of 
endothelial derived NO metabolism follow its diffusion to the vascular smooth muscle (where it 
binds to soluble guanylate cyclase in the cytosol to activate the second messenger cGMP) or to 
the blood vessel lumen (where it rapidly reacts with blood constituents).
1.5.1 Regulation o f Vascular Smooth Muscle Tone
Like many o f the biological actions o f NO, relaxation o f vascular smooth muscle is 
mediated through the activation o f soluble guanylate cyclase (sGC). This enzyme converts 
guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) [50]. It remains to be 
fully elucidated how the second messenger cGMP initiates smooth muscle relaxations; however 
the increase in cGMP activates cGMP dependent protein kinases which reduce the intra-cellular 
calcium concentration (via a variety o f different mechanisms) and decrease calcium-calmodulin 
stimulation o f myosin light chain kinase (MLCK). This in turn decreases the phosphorylation of 
myosin light chains (the contractile proteins) thereby decreasing smooth muscle tension 
development causing vasodilatation [51]. cGMP might also lead to myosin light chain de­
phosphorylation via the activation of myosin light chain phosphatase, lower phosphodiesterase 
(PDE) levels thereby increasing the concentration o f cyclic adenosine monophosphate (cAMP) 
and activate potassium (K+) channels, all o f which stimulate vascular smooth muscle relaxation 
[51] (Figure 1.9).
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cGMPGTP
2NaH
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fcAMP
RELAXATION
Figure 1.9: Mechanism o f action o f nitric oxide on vascular smooth muscle, m ediated by  
guanylyl cyclase. Nitric oxide (NO); soluble guanylate cyclase (sGC); guanosin 
triphosphate (GTP); cyclic guanosine monophosphate (cGMP); protein kinases (PK); sodium  
(Na+); calcium (Ca+); receptor (R); sarcoplasmic reticulum (SR); potassium  (K+); 
phosphodiesterase (PDE); cyclic adenosine monophosphate (cAMP). A dapted  from  [44].
1.5.2 Metabolism of NO in Blood
The mode and rate of NO metabolism in blood is dependent on the micro-environmental 
conditions into which NO is released. Important factors include the concentration o f NO itself 
and surrounding conditions such as the p 0 2, the pH, the type and amount o f high energy free 
radicals (e.g., hydroxyl radical, carbon-, oxygen- and nitrogen-centred radicals), the concentration 
o f thiols and the presence o f other traps such as haem proteins (e.g., guanylate cyclase, 
haemoglobin, catalase, xanthine oxidase or superoxide dismutase) [4, 52].
1.5.2.1 Plasma
In plasma the major decomposition pathways o f NO involve reactions with molecular 
oxygen and oxygen derived free radicals. The reaction o f NO with molecular oxygen is known as
17
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the autoxidation reaction [1]. This reaction produces the highly toxic N 0 2 which can either 
dimerise to form N20 4 [2] or couple with an un-reacted NO to form N20 3 [3]. The autoxidation 
reaction is second order with respect to NO and first order with respect to oxygen, i.e., third order 
overall, involving two NO molecules and one oxygen [5, 53]. Consequently the reaction is 
relatively slow at the very low physiological NO concentrations observed in health. However, 
this reaction might assume more relevance within certain micro-environments, e.g., surrounding 
NOS itself, within hydrophobic lipid membranes where the local concentration o f NO and oxygen 
is greatly increased, or under pathophysiological conditions where the NO concentration is raised, 
e.g., in the immediate vicinity o f activated macrophages and neutrophils [54].
2 NO + 0 2 2 N 0 2 [1]
n o 2+ n o 2 <—> n 2o 4 [2]
n o 2 + n o <—> n 2o 3 [3]
Unlike NO which does not undergo any hydration reaction [55] TV-oxides can be further 
hydrolysed to produce nitrite [4] with smaller amounts of nitrate [5].
N20 3 + H20  2 N 0 2' + 2 H+
n 2o 4 + h 2o  -»  n o 2 + n o 3 + h h
[4]
[5]
N -oxides are potent nitrosating agents [6], especially at nucleophilic centres o f which 
thiols are among the most reactive [56]. Amines are also potential targets for nitrosation, 
however physiologic conditions favour the formation of thiol adducts owing to the propensity for 
amines to exist in their un-reactive protonated forms [52]. Potential targets for nitrosation in 
plasma include the proteins albumin and glutathione and low molecular weight thiols including 
cysteine. These species, collectively referred to as plasma S'-nitrosothiols (RSNOs), may also be 
formed by radical-radical reactions [7] [11]. Once the thiol group is nitrosated it is possible for the 
NO to be exchanged between other thiol groups by a process known as trans-nitrosation (see table 
1.3).
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N2O3 + RSH -► h ++ n o 2 + r s n o  [6]
n 2o 4 + r s h  -> h ++ n o 3 + r s n o  [6]
NO + RS- RSNO [7]
NO also reacts with oxygen derived free radical species including superoxide, hydrogen 
peroxide and hydroxyl radicals, all o f which are produced constitutively by mammalian cells. 
Superoxide which results from the one-electron reduction o f molecular oxygen is formed by 
various enzyme systems including NADPH-oxidase, xanthine oxidase, NOS and the 
mitochondrial electron transport chain. It reacts at almost diffusion controlled rates with NO (6.7 
x 109 M '1 s '1) forming the potent oxidant peroxynitrite (ONOO') [8] [57]. ONOO' reacts with 
virtually all classes of biomolecules including proteins, lipids and DNA. ONOO' can further react 
with NO to produce nitrite [9] [58]. However, ONOO' decays rapidly once protonated forming 
peroxynitrous acid (ONOOH)[10] and eventually nitrate [11] [57]:
N 0  + 0 2' -> ONOO' [8]
NO + ONOO -> N 0 2' [9]
ONOO' + H+ -► ONOOH [10]
ONOOH -> N 0 3' + H+ [11]
Enzymatic defence mechanisms in vivo prevent the accumulation o f reactive oxygen 
species. These include the enzyme superoxide dismutase, o f which there are three main forms; 
Cu/ZnSOD localised in the cytosol, MnSOD found in the mitochondria and ecSOD located in the 
extracellular space. These enzymes dismutate the superoxide anion with a very high reaction 
constant (2.9 x 109 M '1 s '1 [59]) into hydrogen peroxide and oxygen. Hydrogen peroxide in turn 
can be converted to hypochlorous acid (HOC1) in the presence o f chloride anion by 
myeloperoxidase or into water and oxygen by the actions o f catalase and/or glutathione 
peroxidase.
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1.5.2.2 Haemoglobin/Erythrocytes
The principle metabolic pathway for the reaction o f endogenous NO in blood is with the 
haem group of oxy- and deoxyhaemoglobin. Both these reactions have relatively high reaction 
rates (~ 107 M '1 s '1) [60, 61]. The reaction between NO and oxygenated haemoglobin (often 
referred to as the oxidation reaction) forms nitrate and methaemoglobin [12]. NO also reacts with 
deoxygenated haemoglobin or deoxygenated haem subunits on partially oxygenated haemoglobin 
(the addition reaction) to form iron nitrosyl haemoglobin (H bN O )[13].
NO + H b02 NOT + metHb [12]
NO + Hb -> HbNO [13]
It has been suggested that nitrite is also able to cross the erythrocyte membrane and can 
react with oxygenated haemoglobin to form methaemoglobin and nitrate [14] or deoxygenated 
haemoglobin to form HbNO and methaemoglobin [15]. In terms o f apportionment o f NO to these 
reactions, this is likely to be limited in comparison to the oxidation or addition reactions because 
of the rate limiting step o f nitrite formation.
4 N 0 2' + 4 H b 0 2 + 4 H + -► 4 metHb + 4 NOT + 0 2 + 2 H20  [14]
N 0 2' + Hb -> HbNO + metHb + H20  [15]
HbNO via its reaction with oxygen [16] and erythrocytic nitrite via a reaction with HbNO [17] can 
potentially also be broken down to methaemoglobin and nitrate.
HbNO + 0 2 NOT + metHb [16]
N 0 2' + HbNO + H+ NOT + metHb + 0 2 + H20  [l7]
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One further reaction o f NO with haemoglobin is the nitrosation o f an amino acid present 
on the p chain o f haemoglobin at position 93 to form S-nitrosohaemoglobin (SNO-Hb). The 
formation o f this RSNO is not fully understood but has been postulated to result from the transfer 
o f NO from P-subunits o f HbNO to the p-93 cysteine residue following conformational change of 
haemoglobin from deoxygenated to oxygenated state, with either oxygen or ferrihaem serving as 
the electron acceptor [62].
1.5.2.3 Whole Blood
NO metabolite formation in whole blood is dependent on the concentration o f NO, 
haemoglobin, oxygen, free radicals and thiols. Assuming all substrates are present without 
significant oxidative stress, free NO would mainly be metabolised to nitrate following its reaction 
with oxygenated haemoglobin, especially given the relatively high oxygen saturation o f 
haemoglobin even in the venous circulation. Any free haems should form HbNO, however the 
oxygenation status o f blood will determine whether or not this is metabolised to nitrate [16]. 
Nitrite should also be formed following the reaction of NO with dissolved oxygen, along with a 
small proportion o f S'-nitrosothiols [63].
A comparison o f exogenous NO and nitrite metabolism in human arterial and venous 
whole blood utilising up to date NO metabolite measurement methodology forms the basis of 
Chapter 4.
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1.6 Roie of NO Metabolites in the Circulation
1.6.1 NO Inactivation by Haemoglobin
Haemoglobin was historically thought to interact with NO solely in a manner that would 
eliminate its biological activity, forming metabolites unable to activate soluble guanylate cyclase 
[50]. It was therefore questioned how NO could function to regulate vascular tone given the rapid 
association rate between haemoglobin and NO (~ 107M~‘s"‘) and the relatively high concentration 
o f haemoglobin in blood (~ 2.5mM) [49, 60, 64]. It was thought that NO would be drawn intra- 
luminally rather than diffusing to the underlying vascular smooth muscle. However, it emerged 
that the rate of NO scavenging by erythrocytes was almost three orders o f magnitude lower than 
that o f an equivalent concentration o f cell-free haemoglobin [65, 66] as a result o f diffusional 
barriers presented by the erythrocyte membrane, the sub membrane protein matrix and an 
unstirred layer around the red blood cell [65, 67]. Furthermore, laminar blood flow was found to 
create an ‘erythrocyte free zone’ adjacent to the vessel lumen (the size o f which was proportional 
to vessel diameter) [66] further reducing the quantity o f NO diffusing intra luminally.
1.6.2 Paracrine Regulator
Originally NO was viewed as playing a purely paracrine role in the regulation o f vascular 
tone, acting within the vicinity o f its release [68]. Those factors limiting the rate o f reaction 
between NO and haemoglobin were generally considered to allow the local concentration of NO 
adjacent to the endothelial cells to increase sufficiently to provide a diffusional gradient for NO to
activate soluble guanylate cyclase in vascular smooth muscle. Reactions o f NO in blood were
consequently assumed only to scavenge and inactivate NO limiting its availability to elicit 
vasodilatation (Figure 1.10).
1.6.3 Endocrine Regulator
In 1992 the endocrine hypothesis emerged with the proposal that blood borne NO 
metabolites might conserve bioactivity allowing for the storage, transport and potential release of 
NO far from its location o f synthesis [69]. This hypothesis was made on the back o f the 
discovery that endogenously produced NO circulated in human plasma primarily complexed as an 
S-nitrosothiol, namely S-nitrosoalbumin [63]. This was further extended to include a reactive
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thiol o f haemoglobin (Cys P 93) which was demonstrated to undergo nitrosylation and sustain NO 
bio-activity under oxygenated conditions and release o f  this NO under low oxygen conditions 
[70].
Although there is increasing acceptance o f the endocrine model (the principle o f which 
has been demonstrated in NO inhalation studies [71] and following infusions o f aqueous solutions 
o f authentic NO [72]) heated debate surrounds the nature o f NO species responsible for this action 
and its mechanisms o f formation and subsequent release. In addition to SNO-albumin and SNO- 
haemoglobin, other putative candidates for endocrine NO species include iron-nitrosylated 
haemoglobin [71, 73], N-nitrosated proteins [74, 75], nitrated lipids [76, 77], and the anion nitrite 
[24, 26-28, 78, 79].
P-Cys93MHO
R (oxy) state R (oxy) state
DeoxygenationOxygenation T (deoxy) state ^  
-Cys93-SH
G SH i'album in
ENDOCRINE VASODILATION
SNOHb hypothesis
Diffusion
barrier
PARACRINE VASOOILATION
w *o vs//////.
Arginine
NO
Hb compartmentalization 
hypothesis
Figure 1.10: Paracrine and endocrine models fo r  the role o f  haemoglobin in modulating  
NO bioactivity. A dapted  from  [80]
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1.6.3.1 SNO-Hb Hypothesis
In 1996 an active role for red blood cells in the transport and delivery o f NO was 
proposed following the discovery that haemoglobin itself sustained S-nitrosylation [70]. The 
binding and stability o f NO at different sites on the haemoglobin molecule was shown to be 
dependent on haemoglobin quaternary conformation [70, 81, 82]. It was proposed that haem 
bound NO on the (3 haemoglobin chain (pHbNO), favoured in T-state (deoxygenated) 
haemoglobin, was transferred to the p chain cysteine 93 (SNO-Hb) in the R-state (oxygenated) 
haemoglobin during haemoglobin oxygenation [83]. Furthermore, deoxygenation destabilised 
this cysteine bound NO facilitating transfer to low molecular weight and membrane associated 
thiols [84] resulting in an increase in the availability o f NO for vasodilatation in the 
microcirculation (Figure 1.10). This novel proposal consequently provided a mechanism for the 
delivery o f relatively unstable NO produced in the larger arteries to the smaller blood vessels 
which regulate blood flow.
1.6.3.2 Nitrite Hypothesis
In 2003 two independent research groups demonstrated that nitrite might potentially act 
as a vasoactive NO metabolite in the human circulation [26, 27]. The rationale for studying nitrite 
was based on mechanisms demonstrating the conversion o f this metabolite species to NO in vivo 
by xanthine oxidoreductase [28, 29] and/or disproportionation [23]. It was therefore hypothesised 
that nitrite might vasodilate the human circulation under exercise stress. Surprisingly intra- 
arterial nitrite infusion caused vasodilatation in the human forearm circulation even at rest at near 
physiological concentrations [26]. This was associated with the rapid formation o f iron-nitrosyl 
haemoglobin across the forearm circulation implying a novel mechanism of nitrite bioactivation 
based on a simple reaction o f nitrite with deoxyhaemoglobin as described by Doyle and 
colleagues [25].
Subsequently it has been demonstrated that vasodilatation via this mechanism occurs 
maximally as haemoglobin unloads oxygen to 50% saturation where there is the optimal balance 
between the availability o f deoxyhaems for nitrite binding (maximal for fully deoxygenated or T- 
state haemoglobin) and the ability o f the haem to donate an electron to nitrite (which is maximal 
for R-state haemoglobin) [85] (Figure 1.11).
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Figure 1.11: Nitrite reductase equilibrium along the A 1 to A 5  arterioles demonstrating that 
the maximal rate o f  nitrite reduction to NO occurs at the Pso. Reproduced from  [86].
1.6.3.3 Need for Further Investigation
Similarities between the SNO-Hb and nitrite hypotheses are quite striking. Both imply 
that 1) an NO equivalent is involved, 2) it is transported in blood, 3) delivery o f  the NO moiety is 
linked to haemoglobin, 4) is allosterically mediated and also 5) involves a thiol based mechanism 
[87]. Despite these commonalities disagreements have abound between groups supporting either 
hypothesis. These have related to the concentrations o f metabolite species measured in the human 
circulation, the presence or not o f  A-V gradients, the methodologies used to measure metabolites 
and so on. Perhaps the most pressing issue related to both hypotheses is the means by which the 
NO equivalent is transferred from the red blood cell to the vessel wall [88]. In terms o f the SNO- 
Hb hypothesis Pawloski et al. [84] have demonstrated in human erythrocytes that SNO-Hb is 
associated predominantly with the red blood cell membrane and principally with cysteine residues 
in the haemoglobin-binding cytoplasmic domain o f the anion exchanger AE1 (Band 3 protein).
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Interaction with AE1 promotes the deoxygenated structure in SNO-haemoglobin, which sub 
serves NO group transfer to the membrane. Furthermore, deoxygenation results in the release of 
vasodilatory activity from this membrane, providing an oxygen-regulated cellular mechanism 
coupling the synthesis and export of haemoglobin-derived NO bioactivity [84].
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1.7 Thesis Aims
The work o f this thesis will provide a clearer understanding o f the physiological
relevance o f blood borne NO metabolites in the human circulation. This will be undertaken on
several levels; methodological investigation into the measurement o f these species, examination 
o f the metabolism/apportionment o f the exogenous addition o f nitrite and NO to healthy human 
arterial and venous whole blood; exploration into the vascular activity o f these species in relation 
to red blood cells and an in vivo investigation using a human model to assess NO metabolites at 
rest a during increased oxygen demand across the coronary and pulmonary circulations.
1.7.1 Specific Aims
• To develop methods capable o f measuring baseline levels o f blood borne NO metabolites
in healthy human subjects. The chemical reagents used to liberate NO from metabolites
will be investigated along with biological sample handling protocols to minimise 
contamination and the loss of less stable NO metabolite species.
• To determine baseline concentrations of the major blood borne NO metabolite species 
and assess the apportionment of nitrite and NO between the various metabolic pathways 
in arterial and venous human blood.
• To investigate the regulation o f vascular tone by native red blood cells and nitrite in 
combination and alone at different oxygen tensions to elucidate whether nitrite plays a 
role in the red blood cell relaxation response observed under hypoxic conditions.
• To examine NO metabolites across the coronary and pulmonary circulations in healthy 
individuals at rest and under conditions o f increased tissue oxygen demand (elicited by 
rapid atrial pacing) under normal conditions and following systemic NO synthesis 
inhibition to determine the physiological relevance o f the NO metabolite reserve in the 
human circulation.
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2.0 NO Measurement Techniques
A range of techniques have been developed to measure NO metabolites based on a 
number o f different principles.
2.0.1 Electrodes
NO electrodes can be used in the aqueous or gas phase. Both set ups require NO release 
from biological samples prior to NO detection by the electrode. In the gas phase, once the NO is 
released it is carried in an inert gas stream (e.g., nitrogen) to the electrode surface. The electrode 
itself comprises a platinum wire ‘working’ electrode (anode) and Ag/AgCl wire as the counter­
electrode (cathode). A constant potential o f 0.9V is applied, which provides the highest 
sensitivity for NO [89] and also determines its selectivity o f measurement (for NO). Direct 
current is subsequently measured from the electrochemical oxidation of NO gas on the platinum 
‘working’ electrode (anode) surface resulting in the generation of a small redox current [90]. The 
redox current flowing between the working and reference electrodes is proportional to the 
concentration o f NO oxidised and is measured amperometrically using an NO meter.
2.0.2 Chemi luminescence
Chemiluminescence involves the emission o f light (luminescence) as a result o f a 
chemical reaction. To use this technique to measure NO from biological samples a method is 
required to release the NO from the sample. Once released the NO is carried in an inert gas 
stream (e.g., nitrogen) to the nitric oxide analyser (NOA) where it can be quantified following its 
chemiluminescent reaction with ozone ( 0 3). This reaction forms nitrogen dioxide (N 02), a 
proportion of which arises in an electronically excited state (N 02*). In the excited state the 
electrons are unstable and they dissipate energy as they regain their original stable ‘ground’ state 
[91]. The excess energy o f N 0 2* is released as a photon (hv; h = Plank’s constant, v = frequency 
of light) emitted in the red and near-infrared region of the spectrum (~ 640-3000 nm) with 
maximum intensity at ~ 1100 nm. A photomultiplier is used to amplify the signal and detect the 
emitted light, which is sensitive to wavelengths below 900 nm [92]. Nevertheless, the amount of 
light emitted by the NO + 0 3 reaction in the 640-900 nm range is still sufficient to make 
chemiluminescence one of the most sensitive NO measurement techniques available. Provided 0 3
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is present in excess and reaction conditions are held constant the intensity o f light emitted is 
directly proportional to NO concentration [91].
2.0.3 Fluorimetrv
Fluorimeters belong to a class o f instruments called luminometers, which are essentially 
light detectors. Fluorometry is a method for detecting and measuring fluorescence in compounds 
using ultraviolet light to stimulate a compound to emit visible light. In NO measurement specific 
probes are used that upon reaction with NO produce a product that fluoresces following excitation 
at a set wavelength.
2.0.4 Colourimetrv
Colourimetry is a technique for measuring the concentration o f a solution by comparison 
o f colours. Absorbance is an example of colourimetry. For a set wavelength, absorbance is 
determined by comparing the intensity of light which irradiates a sample (incident light) to the 
intensity of light exiting a sample (transmitted light). This method has previously been used 
throughout the NO metabolite research field to measure nitrite and nitrate (following its 
conversion to nitrite) in plasma samples (Griess Reaction) and in this thesis has been used to 
determine haemoglobin concentration in blood samples.
2.1 Biochemical Measurement Protocols
2.1.1 Biological Sample Collection
Unless otherwise stated all blood samples were collected in a syringe and then 
immediately injected into EDTA vacutainers. These were centrifuged at 600g (with time and 
temperature experiment specific). The red cell fraction and plasma were immediately separated 
(taking care to remove the ‘buffy’ coat) and either measured fresh or snap frozen in liquid 
nitrogen and stored at - 80°C for subsequent analysis. Upon analysis frozen red blood cell and 
plasma samples were thawed in a water bath at 37°C for 3 minutes.
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Table 2.0: Summary table o f techniques u sed  to m easure NO metabolites.
Metabolite(s) Measured NO Measurement Technique Assay/Reagent
Sample
Pretreatment
Plasma NOx
Fluorescence
Electrode
Chemiluminescence
DAN Assay 
Vanadium Chloride 
Vanadium Chloride
Various
None
None
Plasma NO (excluding nitrate) ElectrodeChemiluminescence
Tri-iodide 
Tri-iodide
None
None
Plasma protein-bound NO ElectrodeChemiluminescence
Tri-iodide 
Tri-iodide
Sulphanilamide
Sulphanilamide
Red blood cell NO ElectrodeChemiluminescence
Modified tri-iodide 
Modified tri-iodide
Water dilution 
Water dilution
Red blood cell Hb-bound NO ElectrodeChemiluminescence
Modified tri-iodide 
Modified tri-iodide
Sulphanilamide
Sulphanilamide
2.1.2 Plasma NOx (Nitrate and Nitrite) by Fluorescence
This assay, based on a previously described method [93] works via the N-nitrosation of 
2,3-diaminonaphthalene (DAN), forming the fluorescent product l-(//)-naphthotriazole (Figure 
2.0). Nitrite is converted to NO+ under acidic conditions and this reacts rapidly with DAN. To 
measure nitrate it has to first be converted to nitrite by a nitrate reductase. Fluorescence was 
measured using excitation and emission wavelengths o f 365nm and 450nm, respectively.
NaNO-
DAN (2 ,3 -d iam inonaph thalene) l(H )-naph tho triazo le
Figure 2.0: Reaction o f  2,3-diaminonaphthalene (DAN) forming the fluorescent product 1- 
(H)-naphthotriazole. Reproduced from  [93].
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2.1.2.1 Chemicals. Reagents and Equipment
Vivaspin eppendorf filters (500pl; 10,000Mr cut-off) from VivaScience, UK and white 
opaque 96-well plates from Dynatech Laboratories, Inc. (Chantilly, VA) were used to optimise 
measurement o f fluorescent intensity. Reagents were prepared at room temperature in HPLC 
grade water to reduce background nitrite. For composition of reagents and buffer see Table 2.1.
2.1.2.2 Protocol
Plasma samples were filtered to remove contaminating plasma proteins and remaining 
haemoglobin.
Table 2.1: Composition o f  reagents fo r the flurometric analysis o f  NOx. All solutions were  
prepared fresh  on the d a y  o f the experim ent
Sodium
phosphate
buffer
Stock solution 1.4M (8.06 grams Na2HP04, 2.08 grams 
NaH2P042H20  in 50ml water). Working solution 14mM. Dilution of 
stock solution in water
NADPH Stock solution 30pM (0.3 grams in 1ml buffer). Diluted with buffer to 10pM working solution.
GIucose-6-
phosphate
Stock solution 50mM (in buffer). Diluted in buffer to a 5mM working 
solution
Glucose-6-
phosphate
dehydrogenase
Stock solution 100 units/ml (in buffer). Diluted in buffer to 1.6 
units/ml working solution
Nitrate
reductase
Stock solution 5 units/ml (in buffer). Diluted in buffer to 0.8 units/ml 
working solution
Enzyme
mixture
Equal quantities of sodium phosphate buffer, glucose-6-phosphate, 
glucose-6-phospate dehydrogenase and nitrate reductase.
HC1 Diluted in water to a 0.62M working solution.
DAN
Stock solution 0.5mg ml'1 (in 0.62 HC1). Diluted with 0.62 HC1 to 
0.05mg ml'1 working solution and stirred for 30 min before use. Both 
solutions protected from light.
NaOH Diluted in water to a 2.8N working solution.
lOpl o f lOpM NADPH was added to all 50pl samples in a 96 well plate. For nitrate 
measurement, 40pl of an enzyme mixture containing 5mM glucose-6-phosphate, 1.6 units/ml 
glucose-6-phosphate dehydrogenase and 0.8 units/ml nitrate reductase in 14mM sodium 
phosphate buffer was added. For nitrite measurement the relevant duplicate samples received
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40pl 14mM sodium phosphate buffer only. Samples were incubated for 1 hour at 37°C. After 
incubation lOpl of 0.05mg ml"1 DAN in 0.62M HC1 was added with a further incubation for 10 
minutes at room temperature protected from light. The reaction was halted by adding 5pl o f 2.8N 
NaOH solution, which also optimises flurophore. Fluorescence was measured after 10 minutes 
using a Perkin Elmer luminescence spectrophotometer.
2.1.2.3 Calibration
Calibration was achieved using a fresh stock solution o f sodium nitrate made up on the 
day o f the experiment as a lOmM stock solution (to increase accuracy) and further diluted to a 
concentration range o f 0.1 - 50pM. The standard curve o f sodium nitrate is linear to 100pM. 
When compared against a standard curve o f sodium nitrite, the nitrate recovery (i.e., efficiency of 
the nitrate reductase) was ~ 88% at lOOpM as demonstrated from our laboratory in Figure 2.1.
300-i
Nitrite 
r2 = 0.978
200 -
M 1 0 0 - Nitrate 
r2 =  0.989
0 25 50 75 100
Concentration (^M)
Figure 2.1: Standard curve o f sodium nitrite (Top line) and sodium  nitrate (Bottom line). 
Data are presen ted  as mean ±  SEM (n = 10).
2.1.2.4 Potential Confounding Factors
• NADP/NADPH can interfere with fluorescence. However, standard curves of nitrite 
performed with and without NADPH showed this effect to be negligible (< 5%).
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• The anti-coagulant heparin has an inhibitory effect on nitrate reductase activity; therefore 
care must be taken to sample blood using an anti-coagulant such as EDTA.
• Azide, commonly used as a preservative in some filters, inhibits the enzymatic reduction 
of nitrate to nitrite. In this assay the vivaspin filters were washed three times with HPLC 
grade water to remove sodium azide from the membranes prior to use.
• Other compounds known to interfere with this assay are phenol red, plasma proteins, 
haemoglobin and dithiothreitol.
2.1.3 Plasma NOx bv Electrode/Ozone Based Chemiluminescence
Vanadium III chloride in hydrochloric acid reduces nitrate, nitrite and protein-bound NO 
back to NO which can be detected in the gas phase using an NO electrode or ozone based 
chemiluminescence.
2.1.3.1 Chemicals. Reagents and Equipment
A saturated solution of VC13 in 0.8M HC1 was prepared fresh (0.785 grams of VC13; 20ml 
water; 80ml of 1M HC1). The solution was left to stir for 10 minutes before being filtered prior to 
use (once filtered the solution appeared turquoise blue). The reagent (8ml plus 20pl anti-foam) 
was placed in a glass purge vessel.
Oxygen-free nitrogen gas (100% Nitrogen) was bubbled through the reagent mix, which 
was heated to 85°C (± 1°C) in a water bath on a thermostatically controlled hotplate. A chemical 
trap containing 25ml of IN sodium hydroxide (16g NaOH/400ml HPLC grade water) was placed 
between the reagent vessel and the NO analyser (Sievers NOA 280i, Analytix, UK) or electrode 
(ami 700pm NO electrode Harvard apparatus, USA) to prevent damage to the NOA or electrode 
from hydrochloric acid vapour. The carrier gas (oxygen free nitrogen) was maintained at a 
constant flow rate by two adjacent flow meters (Figure 2.2).
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Figure 2.2: Experimental set-up fo r  electrode and ozone based chemiluminescence
determination o f  NO metabolites. The original injection system  is demonstrated.
Throughout this thesis (as will become evident in the following chapter) a number o f 
developments were made to measurement protocols. During this process a new reaction cell and 
injection system was developed. In the early experiments an NO electrode was used. With this 
system samples were injected into a reaction cell injection port through a three way tap. 
Consequently plastic 1ml syringes were used. This changed with the development o f a custom 
made glassware system comprising a replaceable rubber septum (Jones Chromatography, UK), 
which allowed the introduction o f samples with a Hamilton gas-tight micro-syringe. Please refer 
to chapter 3 section 3.3.1 for full details o f these developments.
The release o f NO was digitally recorded from the electrode using commercially available 
data acquisition and analysis software (Duo 18™, World Precision Instruments) or from the NOA 
using the associated Liquid program. All signals were subsequently transferred to Origin version
7.0, where they were smoothed using adjacent averaging (to improve the signal to noise) and 
subsequently measured using a peak analysis package (Origin 7.0).
To the Electrode or Nitric
O xide Analyser
Row Meter
G as Outli
Bung
Sample
InletG as Inlet
Bung
1M NaOH
Water
Jacket 13-Reagent
Stir Bar
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2.1.3.2 Protocol
Materials and Methods
Plasma samples without pre-treatment were injected directly into the VC13 reagent.
2.1.3.3 Calibration
Calibration was performed with sodium nitrate made up on the day o f the experiment as a 
lOmM stock solution (to increase accuracy) and further diluted to a concentration range o f 2.5 - 
40pM (50pl injections; 125 - 2000 pmoles NO) (Figure 2.3).
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Figure 2.3: Standard curve o f sodium nitrate in vanadium chloride. Data are presen ted  
as mean ±  SEM (n = 6).
2.1.3.4 Potential Confounding Factors
•  At times fresh reagent added to the reaction vessel produced peaks even when no 
injection was made, as a consequence of the slow conversion o f materials in the reagent 
to species that react with ozone. These signals disappeared with continued purging of the 
reagent.
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• Unless anti-foam was added to the reagent plasma addition caused severe foaming. Only 
~ 400pl o f plasma could be added to the reagent before foaming occurred (even with 
added anti-foam)
2.1.4 Plasma NO and Plasma Protein-bound NO bv Electrode/Ozone Based 
Chemiluminescence
The original tri-iodide reagent was used to measure plasma nitrite and plasma protein- 
bound NO (for reasons highlighted in chapter 3; section 3.2.2.5).
2.1.4.1 Chemicals. Reagents and Equipment
A stock solution of tri-iodide reagent (90ml) was prepared fresh each day (70ml Glacial 
acetic acid, 650mg iodine, 20ml HPLC grade nitrite free water, 1 gram potassium iodide) [94]. 
This solution was left to mix for 30 minutes prior to use. The same set up was used as for plasma 
NOx determination by ozone based chemiluminescence (Figure 2.2) the only difference being the 
temperature of the reaction cell was maintained at 50°C (± 1°C).
2.1.4.2 Protocol
Plasma samples without pre-treatment were injected directly into the tri-iodide reagent to 
measure combined plasma nitrite and plasma protein-bound NO. A duplicate sample was treated 
with a 10% volume of acidified sulphanilamide (500mg sulphanilamide in 10ml o f IN HC1; 
resulting in a final 0.5% sulphanilamide and 0.1N HC1) and incubated for 15 minutes in the dark 
before injection into tri-iodide to specifically measure plasma protein-bound NO (Figure 2.4). 
The acid with the sulphanilamide converts nitrite to NO+ which then reacts with the 
sulphanilamide forming a stable diazonium salt that goes undetected in the tri-iodide reagent [95]. 
The difference between the two signals was taken to represent plasma nitrite. Following the two 
plasma injections (i.e., without and with sulphanilamide) the reagent was replaced.
2.1.4.3 Calibration
Calibration was performed with sodium nitrite made up on the day o f the experiment as a 
lOmM stock solution (to increase accuracy) and further diluted to a concentration range o f 62.5 -
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lOOOnM (lOOfil injections; 6.25 - lOOpmoles NO) for chemiluminescence protocol and 60 - 
960nM (900pl injections; 54 - 864pmoles NO) for the electrode protocol (please refer to section 
3.2.1.1; Figure 3.0 for an electrode standard curve and section 3.2.1.2; Figure 3.3 for an ozone 
based chemiluminescence standard curve).
Sm oothed
Raw
Time (seconds)
Figure 2.4: Representative trace o f plasm a measurement protocol. Combined plasm a  
nitrite and protein-bound NO measurement followed by ju st p lasm a protein-bound NO 
measured in tri-iodide. Undiluted plasm a (200 pL) followed by plasm a incubated with 
acidified sulphanilamide for 15 minutes in the dark (200 pL)
2.1.5 Red Blood Cell NO and Haemoglobin-bound NO bv Electrode/Ozone Based 
Chemiluminescence
A modified tri-iodide reagent with added potassium ferricyanide was used to measure red 
blood cell associated nitrite and haemoglobin bound NO. This was developed in order to prevent 
the auto-capture of NO released within the reagent mix by cell free haem (please refer to chapter 
3; section 3.2.2).
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2.1.5.1 Chemicals. Reagents and Equipment
A stock solution o f tri-iodide reagent (90ml) was prepared fresh each day (as outlined 
above) along with a 250mM stock solution o f potassium ferricyanide (823mg in 10ml HPLC 
water; kept on ice). The same set up was used as for plasma NOx determination by ozone based 
chemiluminescence (Figure 2.2) the only differences being that 7.2ml o f tri-iodide reagent was 
added to the reaction vessel along with 800pl of potassium ferricyanide - just prior to being 
connected to the system - and 20pl of anti-foam). Furthermore the temperature o f the reaction 
cell was maintained at 50°C (± 1°C).
2.1.5.2 Protocol
For the determination of red blood cell NO (i.e., combined red blood cell associated 
nitrite and haemoglobin-bound NO the red blood cell sample was lysed 1:4 in water (Mini-Plasco 
water for injection BP; Braun, Germany - found to give the smallest signals from all diluents or 
HPLC grade nitrite free water) and 200pl o f the lysate was injected immediately into the modified 
tri-iodide reagent (with added potassium ferricyanide). As a control for potential contaminating 
nitrite in water (and prior to the blood injection) 160pl of the water diluent was injected. The 
signal from water was subtracted from the red blood cell lysate signal to give red blood cell NO 
(Figure 2.5).
To determine red blood cell haemoglobin-bound NO alone, red blood cells were lysed 1:4 
in water to which a 10% volume of acidified sulphanilamide was added (to remove nitrite). The 
sample was then incubated in the dark for 15 minutes before 200pil o f the lysate was injected. 
Prior to the blood injection 160pl of the sulphanilamided water in which the sample was lysed 
was injected. This never gave a signal because the nitrite in the water is removed by the 
sulphanilamide. Pre-treatment o f the water in this manner also prevented any possible 
contamination o f the blood sample via the addition o f exogenous nitrite (Figure 2.6). The 
difference between the two signals (i.e., red blood cell NO and red blood cell haemoglobin-bound 
NO) was taken to represent red blood cell associated nitrite. This terminology reflects the fact 
that the nitrite might only be associated with the red blood cell membrane and not come from 
within the red blood cell.
Following each duplicate blood injection (i.e., without and with sulphanilamide) the 
reagent was replaced.
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Figure 2.5: Representative trace o f red blood cell NO measurement (i.e., combined red 
blood cell haemoglobin-bound NO and red blood cell associated nitrite) in tri-iodide with 
added  K3Fem(CN)6 . Water injection (160 pL) followed by red blood cells lysed  1:4 in water  
(200 pL).
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Figure 2.6: Representative trace of haemoglobin-bound NO measurement in tri-iodide with 
added K3Fein(CN)6.. Sulphanilamided w ater injection (160 pL) followed by red blood cells 
lysed 1:4 in sulphanilamided w ater (200 pL) after 15 minute incubation in the dark.
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2.1.5.3 Calibration
Calibration was performed with sodium nitrite made up on the day o f the experiment as a 
lOmM stock solution (to increase accuracy) and further diluted to a concentration range o f 62.5 - 
lOOOnM (lOOpl injections; 6.25 - lOOpmoles NO). No differences were observed in the sodium 
nitrite standard curves obtained from the original tri-iodide reagent or the modified reagent with 
added potassium ferricyanide (Figure 2.7).
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Figure 2.7: Comparison o f nitrite standard  curves in the original tri-iodide reagent and the 
modified reagent used  for red blood cell NO m easurem ents to which potassium  
ferricyanide w as added  (to prevent auto-capture o f NO by cell free  haem). Data presen ted  
as mean ± SEM (n = 6). A t the lower NO amounts data points directly overlap.
2.1.5.4 Concentration o f Haemoglobin in the Sample
The haemoglobin concentration o f each injected sample was determined using the 
cyanomethaemoglobin method [96]. The reagent, comprising KCN (0.77mM), K3Fem(CN)6 
(0.6 ImM), potassium dihydrophosphate (1.03mM) and lOOpl Triton X was made up each month 
and tested to ensure that it produced a blank signal compared with water and also maintained a
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neutral pH. 40pi o f sample was added to the reagent and following a ten minute incubation 
period the absorbance was measured at 540nm using the stock solution on its own as a blank.
2.2 Bioassavs
2.2.1 Organ Chamber Bioassav
Male, New Zealand white rabbits (~ 2-2.5kg) were terminally anaesthetised with an 
intravenous injection o f sodium pentobarbitone (0.75 ml/kg). A transverse incision was made 
into the abdominal cavity using blunt-ended scissors. The diaphragm was then cut and the rib 
cage opened to allow the thoracic aorta to be exposed. Taking care not to stretch the tissue, the 
aorta was excised and placed directly into fresh Krebs buffer (Table 2.2). The aorta was then 
cleaned o f fat, blood and connective tissue before being cut into 2mm wide rings on a purpose 
built apparatus using equidistant upturned razor blades.
Experiments were performed with endothelium denuded and intact rings. To denude the 
vessels, the luminal surface was gently rubbed with a rounded wooden applicator. The aortic 
rings were subsequently mounted in 8ml tissue baths containing 5ml Krebs buffer and gassed with 
95% 0 2 /  5% C 0 2 at 37°C (Figure 2.7). A resting tension o f 2.1-2.3g was set. After a one hour 
equilibration period during which time the tension was reset (to allow for stretch induced 
relaxation) all rings were exposed to phenylephrine (PE, lpM ) to induce constriction. When a 
steady plateau was reached acetylcholine (lOpM) was added to check the viability o f the 
endothelium (functional endothelium was assumed by the presence o f at least a 50% relaxation 
response; vessels in which this was not achieved were excluded from analysis). Following this 
the rings were washed re-equilibrated and repeat PE constrictions performed until a reproducible 
constriction was achieved. Various experiments were subsequently performed with differing 
protocols (Chapter 5).
42
Chapter TWO Materials and Methods
Force 
Transducer
Perfusion
gas
(experim ent
dependent)
TISSU E BA TH
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Figure 2 .7: Schematic diagram o f the isometric tension recording apparatus. Aortic rings 
are mounted on sta in less s tee l hooks in 8ml tissue baths containing Krebs buffer (gassed) 
at 37°C and se t to a  resting tension betw een 2.1 -2 .3  grams.
Table 2.2: Composition o f  Krebs Buffer.
Chemical Concentration (mM) Grams/L
NaCl 138 6.38
KC1 5.3 0.2
KH2P 0 4 1.2 0.16
M gS047H20 1.2 0.3
N aH C03 15 2.1
Glucose 24 1.98
CaCl2 1.5 0.22
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2.3 NO Donors
Materials and Methods
In a controlled manner these compounds generate and release NO or 7V-oxides that may 
be converted to NO. Structural differences between various compound classes promote diversity 
in NO formation, release kinetics and resulting chemistry (reviewed in [97]). The following 
commercially available compounds were used in this thesis; the diazeniumdiolate MAHMA 
NONOate (noc-9), the S-nitrosothiol S-nitrosoglutathione (GSNO) and inorganic sodium nitrate 
and sodium nitrite.
2.3.1 NONOates
The NONOates are adducts o f NO and nucleophiles. The generation o f NO from these 
donors is dependent on pH, temperature and the chemical nature o f the nucelophile. Under strong 
alkaline conditions NONOates are relatively stable however rapid decomposition occurs as the pH 
value approaches the physiological range (pH ~ 7.4) with NO release being almost instantaneous 
under acidic conditions. Noc-9 was selected because o f its predictable rate o f NO release which 
is unaffected by biological reactants [98] (Figure 2.8). At 37°C and pH 7.4, noc-9 has a half-life 
(t V2) o f 1.5 to 2 minutes. Decomposition follows first-order kinetics yielding 2 moles NO per 
mole o f the donor. By-products o f NO release are NO+, NO', nitrite and the free nucleophile 
(C2H5)3NH3' (reviewed in [99]).
Figure 2.8: Chemical structure ofMHAMA NONOate (noc-9).
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Pre-weighed (5mg) vials o f noc-9 powder were stored in the freezer (-20 °C). Fresh vials 
were prepared on a daily basis with the addition o f one millilitre o f 0.1 M NaOH (prepared using 
HPLC grade water) to the 5mg o f powder (24mM stock). Stock solutions were stored on ice 
(4°C) and protected from light. For experimental protocols in which noc-9 was added to 
biological matrices final dilutions were prepared in assay buffer immediately prior to application.
2.3.2 ff-nitrosoglutathione (GSNO)
Nitrosation o f sulphur residues of thiols and proteins results in the formation o f S- 
nitrosothiols. These endogenously produced compounds can release NO, NO+, or NO' depending 
upon the reaction conditions and process o f decomposition. The stability o f /S-nitrosothiols in 
solution varies as a function o f temperature, pH, nucleophiles, redox-active species, the trace 
metal content o f the incubation solution and exposure to light.
S — N =  0
COOHHOOC
NH-
Figure 2.9: Chemical structure o f S-nitrosoglutathione (GSNO).
Pre-weighed (25mg) vials o f GSNO were stored in the freezer (-20 °C) protected from 
light. Fresh vials of lOmM stock (25mg in 7.44ml lOOpM DTPA; DTPA 15.7mg/400ml HPLC 
water; used to increase the stability o f the compound). Aliquots o f the stock were stored in light 
protected vials in the freezer (-20 °C). Once thawed, vials were stored on ice (4°C). For 
experimental protocols in which GSNO was added to biological matrices, final dilutions were 
prepared in assay buffer immediately prior to application.
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2.3.3 Sodium Nitrate/Nitrite
Materials and Methods
The stability o f the inorganic sodium nitrate and sodium nitrite makes them ideal 
standards for the calibration o f assays. These donors only release NO or related 7V-oxide species 
following chemical reduction. Stock solutions (lOmM) were made up daily in HPLC water 
(69mg/100ml sodium nitrite; 84.9mg/100ml sodium nitrate).
2.4 Chemical Inhibitors
Chemical inhibitors not only allow the relevance o f different signalling pathways to be 
determined, they also provide identification o f specific pathways via which compounds work.
2.4.1 Inhibition o f NOS
The biosynthesis o f NO by NOS may be inhibited by naturally occurring or 
pharmacologically administered compounds. The most widely known NOS inhibitors are the L- 
arginine analogues, formed via the methylation o f the amino acid L-arginine (Figure 2.10). 
Inhibitors, such as L-NMMA compete for the L-arginine binding site which means that they are 
non selective for the different NOS isoforms. However, L-NMMA preferentially inhibits Type III 
> Type I > Type II NOS isoforms [13].
L-arginine NG-methyl-L-arginine (L-NMMA)
Figure 2.10: Chemical structures o f L-arginine and the active site  NOS inhibitor N°- 
methyl-L-arginine (L-NMMA).
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The selectivity o f L-NMMA is determined by its interaction with the substrate binding site o f the 
NOS enzyme [100]. In this thesis L-NMMA was only used in clinical protocols. Specific details 
are outlined in the relevant chapter (Chapter 6).
2.4.2 Inhibition o f Soluble Guanvlate Cvclase
Compounds have been developed that irreversibly oxidise prosthetic haem groups. 1H- 
[1,2,4] oxadiazolo[4,3-a]quinoxalin-l-one (ODQ) is an example o f such a compound which 
selectively inhibits guanylyl cyclase thus preventing NO mediated vascular smooth muscle 
relaxation. Pre-weighed (50mg) vials o f ODQ were stored in the freezer (-20 °C). Fresh vials 
were prepared monthly with the addition o f 2.67ml DMSO to the 50mg o f powder (lOOmM 
stock). Prior to addition, final dilutions were prepared in assay buffer.
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2.5 Chemicals and Other Agents
Table 2.11: Chemicals and agents u sed  and sources.
Product Source
NO Donors
MHAMA NONOate (Noc-9) Alexis Bio-chemicals UK
S-nitrosoglutathione (GSNO) Alexis Bio-chemicals UK
Sodium Nitrite (NaN02) Sigma Aldrich UK
Sodium Nitrate (NaN03) Sigma Aldrich UK
Sodium Nitroprusside (SNP) Sigma Aldrich UK
3-nitro-L-tyrosine Sigma Aldrich UK
Chemical Inhibitors
NG-methyl-L-arginine (L-NMMA) Clinalfa, Germany
1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-l-one (ODQ) Sigma Aldrich, UK
Reaeent Chemicals
HPLC Grade Water Fisher Scientific UK
Glacial Acetic Acid Fisher Scientific UK
Hydrochloric Acid Fisher Scientific UK
, Potassium Iodide (KI) Sigma Aldrich UK
Iodine (I2) Sigma Aldrich UK
Cuprous Chloride (CuCl) Sigma Aldrich UK
L-Cysteine (CSH) Sigma Aldrich UK
Sodium Hydroxide (NaOH) Fisher Scientific UK
Potassium Hexacyanoferrate (K3Fem(CN)6) Sigma Aldrich UK
Potassium Cyanide (KCN) Sigma Aldrich UK
Sulphanilamide Sigma Aldrich UK
Mercury Chloride (HgCl2) Sigma Aldrich UK
2,3-diaminonaphthalene (DAN) Fisher Scientific UK
Diethylenetriaminepentaacetate (DTPA) Sigma Aldrich UK
Phenylepherine (PE) Sigma Aldrich UK
Acetylcholine (Ach) Sigma Aldrich UK
Antifoam 204 Organic Sigma Aldrich UK
Triton X Sigma Aldrich UK
Vanadium Chloride (VC13) Sigma Aldrich UK
Dimethyl Sulfoxide (DMSO) Fisher Scientific UK
Sodium Hydrogen Phosphate (Na2HP04) Sigma Aldrich UK
Sodium Dihydrogen Phosphate (NaH2P04) Sigma Aldrich UK
Glucose-6-phosphate Sigma Aldrich UK
Gllucose-6-phosphate dehydrogenase Sigma Aldrich UK
NADPH Sigma Aldrich UK
Nitrate Reductase Sigma Aldrich UK
Krebs
Sodium Chloride (NaCl) Fisher Scientific UK
Potassium Chloride (KC1) Fisher Scientific UK
Potassium Dihydrogen Orthophosphate (KH2P04) Fisher Scientific UK
Magnesium Sulphate (MgS047H20 ) Fisher Scientific UK
Sodium Hydrogen Carbonate (NaHC03) Fisher Scientific UK
Glucose Fisher Scientific UK
Calcium Chloride (CaCl2) Fisher Scientific UK
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3.0 Introduction
The chemical reactivity o f free NO makes its detection in biological systems 
extremely challenging. Equally as demanding are measurements o f NO metabolites in 
biological matrices due to the diversity o f species, dilute concentrations (at the lower end o f 
sensitivity o f many techniques), various stabilities, complex interactions and reactivity. The 
wide range o f reported baseline human NO metabolite concentrations in the literature lay 
testament to these difficulties.
The NO metabolite research field is somewhat unique with regard to the limited 
agreement over measurement methodologies. A variety o f analytical approaches have been 
utilised yielding vastly divergent measurements o f the same produces). This has led to 
unreliable conclusions being made which have unfortunately served to confuse rather than 
enlighten. O f late general consensus has it that these contrasting reports o f metabolite values 
have resulted from the use o f different measurement methodologies, that is; various NO 
measurement techniques, means o f NO release from metabolites and biological sample 
handling protocols [9,101-103].
3.0.1 General Principle o f NO Metabolite Measurement
All metabolite measurement techniques combine a method o f  detecting NO (or a 
related redox species or reaction product o f NO) with a means o f releasing NO from the 
biological metabolite to allow its detection (or subsequent reaction prior to detection).
3.0.2 Variability Introduced by NO Measurement Techniques
Numerous techniques including spectrophotometry [104, 105], fluorimetry [106-108], 
electron paramagnetic resonance (EPR) spectroscopy [104], chemiluminescence [26, 69, 72, 
73, 78, 83, 109-114] and amperometric electrodes [115] have been utilised for NO metabolite 
measurement (Table 1). Whilst each technique has its own significant individual advantages, 
all suffer from the usual limitations including lack o f sensitivity or specificity or interference 
by factors such as proteins and suspended materials commonly present within biological 
media.
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Table 3.0: B aseline human NO m etabolite concentrations determ ined w ith  different 
m easurem ent techniques. Values reported a s  nM concentrations. a = serum ; b = below  
detection lim it;c = foeta l blood sam ples; OBC = ozone b a sed  chemiluminescence; HPLC 
= high perform ance liquid chromatography; GC-MS = g a s  chrom atography m ass  
spectrom etry; HgCh = mercury chloride; KI = po ta ssiu m  iodide; 3C s  = cupric 
ch loride/cysteine/carbon  monoxide; CuCl -  cupric chloride; CSH = cysteine.
Metabolite NO measurement 
technique
Means of NO 
release RefSNO-Hb Plasma RSNO
Arterial Venous Venous
8000 ± 3000 Fluorimetry HgCl2 [106]
7190 ±5730 OBC Photolysis [63]
6500± 1925 7175± 1875 Electrode Tri-iodide [115]
5930 ± 750 Spectrophotometry HgCl2 [104]
3625 ± 1650° 5470 ± 3025° Spectrophotometry HgCl2 [105]
4200± 1000 Fluorimetry Photolysis [116]
2500 ± 1000 300 ± 700 OBC Photolysis [83]
930 ± 360‘ OBC CuCl/CSH [109]
450 ± 450 Fluorimetry HgCl2 [107]
250-560 45-325 OBC 3Cs [114]
250 ± 200 OBC KI/Acetic acid [110]
220± 190 HPLC Griess [117]
156 ±64 GC-MS HgCl2 [118]
161 ±42 142 ± 29 63 ± 13“ OBC Tri-iodide [78]
62 ±24 HPLC Griess [108]
110 ±40 130 ±60 OBC Tri-iodide [73]
< 100b Fluorimetry HgCl2 [108]
46 ± 17 69 ± 11 OBC Tri-iodide [H I]
< 50b < 50b OBC Tri-iodide [261
40 ± 7 OBC CuCl/CSH [721
28 ±7 OBC Tri-iodide [951
15 ± 6 OBC Tri-iodide [1121
< l b < l b 7.2 ± 1.1“ OBC Tri-iodide [113]
3.0.3 Variability Introduced bv Means o f  NO Release
Much o f the early work on NO metabolite measurement was performed utilising UV- 
light induced photolysis to liberate NO (specifically S-nitrosothiols; RSNOs) [63, 70]. It has 
since been demonstrated under extremely high energy conditions that photolysis can release 
NO from nitrosyl haems, nitrite and from nitrate in the presence o f reduced thiol [119], which 
might explain why such high levels o f S'-nitrosoalbumin and SNO-Hb were originally reported 
[63, 70]. More recently chemical reduction has become a more favoured method o f cleaving 
NO from biological matrices. Several chemical reagents have been developed, the majority o f 
which reduce NO related species back to NO gas in strong acid [27]. However, as the
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reducing properties o f these solutions vary greatly so does the efficiency o f reduction and the 
selectivity o f metabolite species [120]. This complexity is reflected in the fact that for many 
o f the chemical reagents the exact metabolite species detected and the reaction processes 
involved still remain to be fully elucidated.
Even where the same NO measurement technique has been used as in the case o f 
ozone based chemiluminescence, the various means o f NO release have induced variance in 
the results obtained (Table 3.1).
Table 3.1: B aseline concentrations o f  human NO m etabolites m easured  w ith  the sam e  
technique (ozone b a sed  chemiluminescence) but different m eans o f  NO release from  
metabolites. All values reported a s  nM concentrations. a = serum; b = below  the 
detection limit; c = foeta l blood sam ple; 3C s  = cupric chloride/ c y ste in e / carbon  
monoxide; CuCl = cupric chloride; CSH  = cysteine.
Metabolite
Means of NO 
release RefSNO-Hb HbNO
Plasma
RSNO
Arterial Venous Arterial Venous Venous
7190 ±5730 Photolysis [63]
2500 ± 1000 300 ± 700 2500 ± 500 5000 ± 1250 Photolysis [83]
930 ± 360a CuCl/CSH [109]
250-560 45-325 3Cs [114]
250 ± 200 KI/Acetic acid [HO]
161 ±42 142 ± 29 63 ± 13a Tri-iodide [78]
110 ±40 130 ± 60 150 ±80 160 ± 50 Tri-iodide [73]
81 ±36 103 ± 32 Acetic acidJ Ferricyanide [27]
46 ± 17 69 ± 11 Tri-iodide [H I]
<50b < 50b <50b < 50b Tri-iodide [26]
40 ± 7 CuCl/CSH [72]
28 ± 7 Tri-iodide [95]
15 ± 6 Tri-iodide [112]
< l b < l b < l b < l b 7.2 ± 1 .1 “ Tri-iodide [113]
3.0.3.1 Tri-iodide
Tri-iodide is possibly the most widely used chemical reductive reagent in the NO 
metabolite literature [26, 73, 78, 95, 111-113]. It was developed from a reaction mix 
comprising potassium iodide (KI) at acidic pH which was used to reduce nitrite to NO via the 
formation o f  nitrous acid [121].111
[1] 2 H N 02 + 2 HI -► 2 NO + I2 + 2 H 20
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Uncontrolled formation o f free iodine (I2) from the reaction [11 resulted in poor reproducibility 
o f the NO yield from RSNOs. This issue was resolved with the addition o f  crystalline iodine 
to the reagent which controlled the amount o f free iodine in solution and thus tri-iodide 
formation, resulting in the stoichiometric release o f  NO from RSNOs [121].
Reported NO yields o f the various metabolite species with tri-iodide are ~  100% for 
low molecular weight RSNOs, ~ 78% for SNO-albumin, -8 1 %  for HbNO and ~ 67-105% for 
RNNO compounds [74, 120]. However, whilst the reactions involved in the cleavage o f 
RSNO have previously been outlined l2J*l5J [121], the underlying reaction mechanisms for the 
release o f NO from RNNO/nitrosyl haem species still remain in question.
I2 + I --*13
I3* + 2 RS-NO 3 T + 2RS- + 2 N O +
2RS- -► RS-SR 
2 N O + + 2 T -► 2 NO + I2
3.0.3.2 Cuprous Chloride/Cvsteine
Another chemical reagent used in conjunction with ozone-based chemiluminescence 
comprises cuprous chloride and cysteine (CuCl/CSH). This was developed to specifically 
measure RSNOs, exploiting trans-nitrosation reactions between biological SNOs and the 
liberation o f NO from nitrosothiols in the presence o f Cu+ l<5], with the re-reduction o f Cu2+ by 
CSH [7'8] [109, 122, 123].
[2]
[3]
[4]
[5]
RSNO + Cu+ -► C S + N O ­
GS* + Cu2+ -► GS'*Cu2+
G S*C u2+ -► GS- + Cu+
Cu2 + Cu+*GS*
GSH
GSH, AscH*, Cys
Cu+
GSNO GS- + NO-
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The neutral pH o f the reagent ensures that nitrite, nitrate, and 3-nitrotyrosine are not detected, 
thus maintaining specificity for RSNO. NO yields from this reagent are reportedly 
stoichiometric for low mass SNOs; however, the yield from SNO-albumin is low (** 33.9%), 
probably reflecting a sheltering o f the SNO bond inhibiting trans-nitrosation to cysteine [109].
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3.1 Aims
In order to address the significance o f a NO reserve in the circulation it was 
imperative to use techniques and develop assays with the capability o f  measuring baseline 
human NO metabolite concentrations. This work was undertaken to:
•  Identify the most sensitive NO measurement technique within our laboratory
•  Investigate the chemical reagents used to liberate NO from metabolites
•  Develop biological sample handling protocols to minimise contamination and loss o f 
less stable metabolite species
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3.2 Results
The first objective was to analyse NO measurement techniques within the laboratory.
3.2.1 Established Techniques used in the Laboratory
At the outset o f  this thesis several established NO measurement techniques were 
employed in our laboratory. For red blood cell metabolites an NO electrode was used in 
conjunction with the tri-iodide chemical reagent to measure total haemoglobin bound NO, 
HbNO and SNO-Hb. EPR spectroscopy was also used for HbNO quantification. Plasma 
RSNO measurements were made with the spectrophotometric Saville assay, whilst nitrite and 
NOx (nitrite plus nitrate) measurements were made with a fluorometric assay. Amongst all 
these methods, only the electrode had the sensitivity to measure the lower levels o f  baseline 
red blood cell and plasma NO metabolite concentrations reported in the literature. The 
fluorescence assay was sensitive enough for NOx measurements due to the presence o f 
pmol/L concentrations o f  nitrate in plasma. However, baseline levels o f  the other metabolite 
species were below the sensitivity o f the corresponding NO measurement techniques. 
Consequently these were only useful for the analysis o f in vitro chemistry conducted at 
elevated analyte concentrations.
3.2.1.1 Assessment o f Amperometric NO Electrode
In this set up the tri-iodide reagent was used to liberate NO from the sample. 
Released NO was subsequently carried in a stream o f nitrogen gas to the NO electrode where 
it was detected following its electrochemical oxidation on the electrode surface.
Standard curves indicated that the NO electrode had the sensitivity to detect baseline 
levels o f red blood cell and plasma NO metabolites reported in the literature (Figure 3.0). 
However the electrode was challenging to work with because o f  its sensitivity to gas flow and 
temperature changes which meant it took ~ 2 hours at the start o f  the day and ~ 15-20 minutes 
each time the assay reagent was replaced to reach a steady baseline. Furthermore signals 
often did not return to baseline so peak height had to be used to determine NO concentration. 
Despite the fact that an excellent correlation could be obtained between peak height and NO 
concentration across the range o f a nitrite standard curve, this did not hold for red blood cell 
samples in part due to the broadening o f  the signals in the presence o f haemoglobin (see 
Effect o f Haemoglobin in the Reaction Chamber on NO Detection in Tri-iodide, section
3.2.2.1).
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Figure 3.0: S tandard curve o f  nitrite injected into tri-iodide (8ml) in conjunction w ith  
the NO electrode in the g a s p h a se  (Top). Correlation betw een  NO injected an d  signal 
height (Bottom). B elow  each p e a k  on the trace is  the am ount o f  nitrite injected in 
picomoles. Values p resen ted  a s  m ean ±  SEM (n = 3  curves on separa te  days).
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Further anomalies also persisted with the electrode:
1. The first injection o f the day (water for the standard curve) was always significantly 
higher than subsequent water injections (Figure 3.1).
2. The first injection o f red blood cell sample (lysed red blood cell or haemoglobin from 
a Sephadex G25 separation column) into fresh assay reagent consistently gave a 
signal whilst repeat injections into the same reagent rarely did (see, Effect o f 
Haemoglobin in the Reaction Chamber on NO Detection in Tri-iodide, section
3.2.2.1).
These experiments outlined were performed with a custom made reaction cell 
comprising an injection port with a three-way tap, venflon needle (allowing sample injection 
to the bottom o f the reagent), gas inlet (through which oxygen-free nitrogen gas flowed to the 
bottom o f the reagent) and gas outlet allowing flow to the NO electrode via a sodium 
hydroxide (NaOH) trap. Samples were introduced into the tri-iodide reagent using a plastic 
syringe which interlocked with the three way tap (Figure 3.2 - Left).
 *_____________
 *_____
4o-i i r
3 0 - 
20- 
10-
0 ---------- 1--------------------- i*'1" . - ------- ^ —
First Second Third
Water injection
Figure 3.1: Signal heights from  the first, second and third w ater injections (400/liL) into 
tri-iodide reagent (8ml) using the NO electrode in the gas phase , (n = 5 experim ents; 
Repeat m easures ANOVA * p  < 0.001).
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The dead space within the venflon needle inevitably caused the introduction of air 
prior to the sample, which was ultimately found to produce an electrode signal. Therefore 
every initial injection comprised a mixture of air and sample and each subsequent injection 
was diluted equivalently by the fluid left in the needle. The signal from air was found to 
equate to the difference between the first and second water injections into fresh tri-iodide 
reagent. In terms of blood measurements, the three way tap and venflon injection needle were 
cleaned and dried after each injection. This meant that all blood measurements comprised the 
air signal leading to an over-estimation of NO levels. This explains in part why pmol/L whole 
blood concentrations of SNO-Hb and HbNO were reported from our laboratory at that time 
[115]. Interestingly these values were in close agreement with reported levels from other 
groups using totally different NO measurement techniques and means of NO release [83, 
105].
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Figure 3.2: The original injection system  (Left) and the custom m ade glassw are
reaction cell system  (Right) u sed  with the NO electrode and ozone based  
chemiluminescence.
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The issue o f the air injection was subsequently overcome with the development o f a 
custom made glassware reaction cell system designed with a rubber septum injection port. 
This allowed the introduction o f samples with a gas tight Hamilton syringe, preventing the 
injection o f air and interference from previous sample injections (Figure 3.2 - Right). 
Utilising the same electrode set up with the custom made glassware system no signals from 
human blood samples were obtained. However, this was in accord with the findings from 
other groups in the literature at that time using ozone based chemiluminescence [26, 113].
3.2.1.2 Assessment o f Ozone Based Chemiluminescence
Based on the results already outlined, our laboratory invested in a Sievers Ozone 
based chemiluminescence Nitric Oxide Analyser (NOA). The data obtained with the NO 
electrode was compared under the same conditions with that derived from the NOA. The 
NOA was found to be ~ 10 times more sensitive than the electrode (Figure 3.3) and also more 
practical in terms o f the time taken to set up and measure samples. Furthermore signals 
always returned to baseline allowing the more accurate analysis o f area under curve rather 
than signal height. However as with the NO electrode, when using our custom made 
glassware reaction cell system barely detectable signals (and in a lot o f  cases, no signals) were 
observed from human red blood cell samples injected into tri-iodide. Although this was in 
accord with reports from some groups, it went against others using the same NO measurement 
technique (ozone based chemiluminescence), with a different means o f  liberating NO (namely 
photolysis) and handling/processing the biological sample.
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3.2.2 Analysis o f NO Release from Metabolites
In order to ascertain why barely detectable/no signals were obtained from red blood 
cell samples injected into tri-iodide, the chemical reagent itself was analysed along with its 
related methodology. At the same time the CuCl/CSH assay was also assessed as it was 
intended to use this reagent to provide a means by which to directly measure SNO-Hb and 
compare metabolite values obtained with tri-iodide. The specific aim was to identify 
potential confounding factors that could influence the sensitivities of these chemical 
assays. This involved an investigation into the effect of:
• Haemoglobin in the reaction chamber on NO detection
•  Plasma in the reaction chamber on NO detection
•  Biological sample handling on the recovery o f NO from human blood
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3.2.2.1 Effect o f Haemoglobin in the Reaction Chamber on NO Detection in Tri-iodide
The NO donors sodium nitrite (N aN 02‘) and S-nitrosoglutathione (GSNO) were 
injected into tri-iodide in the presence/absence o f haemoglobin in the reaction chamber. The 
chemiluminescence signal heights from N aN 02‘ (Figure 3.4) and GSNO (Figure 3.5) were 
found to be inversely related to the concentration o f haem in the reaction chamber. The 
relationship o f reduced signal height with increasing addition o f haem was similar whether red 
blood cell lysate or haemoglobin was added to the reagent [124].
Haem auto-capture o f NO in the tri-iodide reagent had previously been acknowledged 
and postulated to occur as a result o f  the rapid (~ 107M‘1s‘1) re-capture o f  metabolite derived 
NO by cell free haem in the reaction chamber inhibiting its passage in the carrier gas to the 
NO analyser [120]. Due to the reagent being held under anaerobic conditions (purged with 
oxygen free nitrogen gas) the resulting interaction between cell free haem and NO was 
thought most likely to form HbNO. As tri-iodide reportedly cleaved this species, the effect 
was suggested only to broaden the NO signals from red blood cell samples [120]. This held 
true with relatively high NO addition (lOOpmoles) as signal height was diminished across a 
range o f haem concentrations, but area under curve analysis remained unaffected (Figure 3.6 - 
Top). However, with lower amounts o f NO (10 pmoles) more in line with that anticipated 
from a processed red cell sample, both signal height and area under curve diminished (Figure
3.6 - Bottom), i.e., where haem was in vast excess o f free NO, auto-capture was o f much 
greater relevance with practical detection being severely hampered. The onset o f this 
phenomenon occurred at an NO:haem ratios o f ~ 1:50,000, equating to an NO:Hb ratio o f ~ 
1:12,500.
This data not only emphasised the need to change reagent between blood injections 
when utilising tri-iodide (which was already being undertaken to prevent excessive foaming of 
the reagent) it also provided a potential explanation to why, after the first blood injection 
using our electrode system, subsequent injections into the same reagent rarely produced a 
signal.
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3.2.2.2 Overcoming Auto-capture o f NO by Haemoglobin in Tri-iodide
In order to prevent auto-capture o f NO by deoxygenated cell free haem in the reaction 
chamber a method had to be developed to slow the reaction between the two. It was rationalised 
that adding potassium ferricyanide (K3Fem(CN)6) to the original tri-iodide reagent would oxidise 
haem from its ferrous Fe(II) to its ferric Fe(III) form producing methaemoglobin that would bind 
NO less rapidly (~ K^M'V1) [61] and thus be a less potent scavenger, allowing NO time to 
escape re-capture [124].
Different means o f inactivating the haem within the tri-iodide reagent were assessed 
utilising reagents containing potassium cyanide (KCN), K3 Fe,n(CN)6 and both cyanides together. 
It was found that the addition o f K3 Fein(CN)6 worked best to inhibit NO auto-capture (Figure 3.7 
and 3.8).
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Figure 3.7: M easurement o f  red blood cell lysate in different reaction mixtures. Reagents 
include tri-iodide alone; tri-iodide p lus potassium  cyanide (KCN); tri-iodide p lus potassium  
ferricyanide (K3Fem(CN)6) and tri-iodide p lus both cyanides. Example traces o f  
chemiluminescence signals and the sam e data smoothed fo r  analysis with Origin version
7.0.
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Figure 3.8: M easurement o f  red blood cell lysate in different reaction mixtures. Reagents 
include tri-iodide alone; tri-iodide plus potassium  cyanide (KCN); tri-iodide p lus potassium  
ferricyanide (K3Fein(CN)6) and tri-iodide plus both cyanides. Area under curve values 
obtained from  the smoothed data are presented as mean ± SEM (n = 3 - frozen aliquots o f 
the sam e blood were tested  in the different reagents).
K3Feni(CN)6 had previously been used as part o f a cocktail o f chemicals added to red 
blood cell samples when collected, postulated to selectively cleave HbNO and/or stabilise SNO- 
Hb. Those groups using this pre-treatment have since suggested that the K3Fein(CN)6 within the 
chemical mix is enough to prevent NO rebinding to haem [125], however this has yet to be 
demonstrated experimentally.
The modified tri-iodide reagent with added K3Fein(CN)6 was tested with NO donor 
standards (N aN 02‘ or GSNO) in the presence/absence o f haemoglobin. The broader signals 
observed from haem auto-capture o f NO in tri-iodide were inhibited following the addition of 
K3Fein(CN)6 to the reagent (Figures 3.9 and 3.10 respectively) [124],
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Signals from red blood cell lysate and haemoglobin were compared in both reagents. 
Nothing was detected in the original tri-iodide reagent (Figures 3.9A and C, 3.10A and C - at 300 
seconds) however signals were observed in the modified reagent mix (Figures 3.9B and D, 3.10B 
and D - at 300 seconds). Also red blood cell-bound NO measurements were compared from lysed 
red blood cell samples (one part red blood cells to four parts EDTA made up with HPLC grade 
water) injected into both reagents. Whereas the chemiluminescence signal was indistinguishable 
in the original reagent, a clear signal was observed in the modified mix (3 repeat experiments 
using different frozen aliquots of the same red blood cell sample) (Figure 3.11) [124].
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Figure 3.11: R ed  blood cell-bound NO m easurem ent in the original and  modified tri-iodide 
reagent w ith  added  K3Feln(CN)6. R aw  chemilum inescence signals observed from  200pl 
injections o f  lysed  red blood cells 1:4 in EDTA (HPLC grade water). Signals in tri-iodide 
(Left) and signals in tri-iodide p lu s po tassium  ferricyanide (Right). All injections were at 
one minute.
3.2.2.3 NO Species Detected in the Modified Tri-iodide Reagent
It was considered a possibility that the larger signals observed with the modified tri­
iodide reagent might have arisen from more complete NO release from products already detected 
in the original tri-iodide reagent or the release o f NO related products essentially inert in the 
original reagent. The reductive potential o f the reagents under standard conditions were analysed 
by testing several major NO species including nitrate, nitrite, GSNO, N-nitrotyrosine, the iron 
nitrosyl sodium nitroprusside (SNP) and also plasma. There was no difference between the two
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reagents in the yields obtained from any o f these species. Essentially nitrite, GSNO and plasma 
were returned 100% of theoretical, whilst nitrate, N-nitrotyrosine and SNP returned < 0.1% of 
theoretical. Others have since reported that the yields obtained from the biological RSNOs S- 
nitrosoalbumin and SNO-Hb are the same in both assays, with the only difference being a more 
complete recovery o f nitrosylhaemoglobin (HbNO) in the modified reagent (100% o f theoretical 
in comparison to a 60-80% yield in the original reagent) [126]. It has also been demonstrated 
that injections o f nitro-linoleic and nitro-oleic acid standards yield very similar recoveries of < 1% 
in either reaction mixture [126].
These results demonstrate that the cleavage and reductive potential o f the original and 
modified tri-iodide reagents are very similar. Consequently the clearer signals observed in the 
modified reagent result in part to the improved detection o f HbNO and also the inhibition o f NO 
auto-capture by cell free haem.
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3.2.2.4 Effect o f Haemoglobin in the Reaction Chamber on NO Detection in CuCl/CSH
Having developed the modified tri-iodide reagent (to be used with minimal sample pre­
treatment) to obtain a measure of total red blood cell NO, it was intended to use the CuCl/CSH 
reagent to provide a direct measure of SNO-Hb. Consequently the CuCl/CSH reagent was 
analysed in the same manner as tri-iodide. The NO donor GSNO was injected into the RSNO 
specific CuCl/CSH reagent in the presence/absence o f haemoglobin in the reaction chamber. The 
chemiluminescence signal heights and area under curve analysis from GSNO were found to be 
inversely related to the concentration o f haem in the reaction chamber. These relationships with 
increasing addition o f haem were similar whether red blood cell lysate or haemoglobin was added 
to the reagent.
Haem auto-capture of NO in the CuCl/CSH reagent was even more avid than in tri-iodide 
(compare x axis scales in figures 3.6 and 3.13). This probably reflects the fact that S-nitrosothiol 
decomposition in the CuCl/CSH reagent releases NO in its radical form (reaction [6] page 53) 
which would be more avidly scavenged and secondly free haem is not denatured under the neutral 
conditions of the CuCl/CSH reagent and is potentially a more potent scavenger than in tri-iodide.
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With increasing haem addition not only did signal height but also the area under curve declined. 
This suggested that the species created by the auto-capture o f NO by haem was HbNO which 
went undetected in the RSNO specific CuCl/CSH reagent. Consequently greater haem in the 
reaction chamber resulted in less NO escaping auto-capture and thus smaller signals, both in 
terms of signal height and area.
2)22.5 Overcoming Auto-capture of NO bv Haemoglobin in CuCl/CSH
At the same time that the auto-capture effect o f haemoglobin within the tri-iodide reagent 
was observed within our laboratory, the same effect was reported independently by another group 
with regard to the CuCl/CSH reagent [114]. To overcome this effect in the CuCl/CSH reagent the 
authors changed the carrier gas within their chemiluminescence set up to carbon monoxide (CO). 
By saturating the reagent with CO, free haem was inactivated via the production of 
carboxyhaemoglobin [114].
The 3Cs assay (CuCl/CSH/CO) was set up within our laboratory as outlined in the 
literature. However, instead of mixing CO with helium as in the original method a pre-mixed 
cylinder containing 90% CO balanced with nitrogen was used. Unfortunately we could not 
achieve the same inhibitory effect of CO on haem. The effectiveness o f CO gas to inhibit auto­
capture was tested both at 20pM haem final concentration in the reaction chamber (to represent 
the final haem concentration widely reported by the majority o f laboratories [94, 111, 120]; 
Figure 3.14) and lpM  haem final (Figure 3.15). Although an inhibitory effect was observed with 
CO, this was only ~ 40% across all doses o f GSNO with 20pM final haem concentration and ~ 
65% across all doses o f GSNO with the lpM  final haem.
In order to solve this issue a visit was arranged to the laboratory where the 3Cs assay was 
developed (Charlottesville, VA). Working with the assay it became apparent that for CO to fully 
inhibit haem auto-capture the reagent cell (where the CuCl/CSH reagent was housed within the 
system) had to be maintained at positive pressure; to produce a high enough concentration o f CO 
in the reagent (Figure 3.16 Bottom). As was the case with our system in the UK, even with the 
original set up in the USA 100% CO at normal NOA system pressure only inhibited ~ 50% of 
auto-capture with a lpM  final haem concentration (compare Figures 3.15 Bottom and 3.16 Top).
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A higher reagent cell pressure was also tested (~ 240 mmHg) but this did not improve recovery 
further. In addition, the signal from GSNO in the absence o f haem decreased as CO pressure 
increased. This was attributed to the CO pressure slightly increasing the pressure in the reaction 
cell (where the reaction between NO and 0 3 occurs within the NOA itself) affecting the 
sensitivity o f the machine.
Unfortunately our custom made glassware reagent cell system in the UK could not run at 
the pressures required for CO to work at its best.
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3.2.2.6 Effect o f Plasma in the Reaction Chamber on NO Detection in Tri-iodide
Experiments were performed with the addition o f the NO donors N aN 02' and GSNO into 
tri-iodide in the presence/absence of plasma. Chemiluminescence signals from N aN 02' and 
GSNO were unaffected by the presence of plasma in the tri-iodide mix (Figure 3.12), 
demonstrating the limited capacity o f plasma in tri-iodide to auto-capture NO and also providing 
evidence o f limited red blood cell lysis as a result of our blood sampling protocol [124]. As 
plasma added to the tri-iodide was not demonstrated to auto-capture NO, K3Fein(CN)6 was not 
added to the reagent for plasma measurements.
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Figure 3.12: A bsence o f  NO scavenging by p la sm a  in the tri-iodide reagent. Area under  
curve values p resen ted  as m ean ± SEM  (n = 4) (Top). Exam ple trace o f  chemiluminescence 
signals observed from  repeat 25pm ole sodium  nitrite injections before and after (100 and  
600 seconds respectively) a 200 /jI p la sm a  injection (Bottom).
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3.2.3 Analysis o f Biological Sample Handling Protocols
Various biological sample handling protocols have been developed in conjunction with 
the different measurement techniques and processes of releasing NO from metabolites. The idea 
behind these are several fold; to ‘stabilise’ individual metabolite species via the blocking of 
potential reactants [94, 125], prevent artificial ex vivo metabolite formation [94] and allow 
differentiation between individual metabolite species through elimination o f all but the species o f 
interest [94, 95, 121]. However, it is through these processes that much of the variability in 
metabolite measurement is thought to derive as a result o f the addition o f contaminant [113, 127], 
loss of less stable metabolite species [27], destruction of the physiological sample and disturbance 
of the NO metabolite equilibrium/homeostasis [101, 103].
Much of the earlier work on NO metabolite measurement within our laboratory 
involved the utilisation of stablisation solutions and chemical pre-treatment processes. 
However upon working so closely on the methodologies the pitfalls associated with these 
processes became more evident which led to the aim of developing methodologies which 
minimised these processes.
3.2.3.1 Acidified Sulphanilamide
Acidified sulphanilamide sample pre-treatment was developed as a means to eliminate 
nitrite from biological samples. This was an important development for the tri-iodide assay, due 
to the abundance o f this species (readily reduced to NO in this reagent) in most biological 
samples. The pre-treatment process involved the addition o f a 10% volume of acidified 
sulphanilamide to a biological sample followed by a short incubation period. During this process 
nitrite forms NO+ under the acidic conditions, which binds to sulphanilamide forming a stable 
diazonium salt that is not converted to NO in the original tri-iodide reagent [95].
Preliminary experiments demonstrated the ability o f acidified sulphanilamide to remove 
large quantities o f free nitrite in solution (up to lOOpM) almost instantaneously in the original tri­
iodide reagent and in our modified tri-iodide with added K3Feni(CN)6 (data not shown). Similar 
experiments were performed with plasma and lysed red blood cell samples to identify the 
incubation times necessary for the removal o f added nitrite from biological samples (data not 
shown). Complete removal of added nitrite was found to take up to 15 minutes, which is in line 
with reports from other laboratories [127].
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3.23.2 Stabilisation Solutions
Stabilisation solutions were originally developed in order to prevent the natural decay of 
metabolite species in biological matrices. The majority o f these solutions include K3Feni(CN)6 to 
oxidise species that potentially react with the metabolite(s) o f interest. In addition, KCN is often 
included to redox inactivate haem. However, the powders of these chemicals (even obtained to 
the highest purity) contain nitrite, as mentioned in passing by others [94]. This contamination can 
be observed upon the injection o f these chemicals into tri-iodide, which following pre-treatment 
with sulphanilamide eliminates the signal (data not shown). If  samples are incubated with 
chemicals which introduce nitrite contamination, this can result in the artificial formation o f 
metabolite species in vitro [127]. One further issue with the chemical pre-treatment of samples is 
the fact that it is difficult to ascertain that all chemicals have been removed prior to sample 
injection. This is normally assumed following the passing o f samples through a sizing column 
(Sephadex G25).
3.2.3.3 Freezing Samples
When obtaining blood samples from a clinical setting it is often not possible to analyse 
them immediately. Consequently samples have to be frozen. Where this was necessary samples 
were frozen in liquid nitrogen and subsequently stored at -80°C until analysis.
The effect o f sample freezing on NO metabolite stability was analysed in red blood cell 
and plasma samples. Whole blood was centrifuged at 600 g for 5 minutes followed by immediate 
separation of plasma and red blood cells. One sample was measured immediately (fresh) and the 
rest were frozen in 300fil aliquots for future analysis at time points up to 3 months for red blood 
cell samples and 6 months for plasma samples. Upon analysis frozen samples were thawed at 
37°C for three minutes prior to undergoing the set protocols (red blood cell protocol; Chapter 2 
Section 2.1.5 and plasma protocol; Chapter 2 Section 2.1.4).
Freeze thawing (i.e., fresh v 1 day frozen) had no effect on any o f the measurements. 
Combined red blood cell haemoglobin-bound NO/red blood cell associated nitrite and combined 
plasma nitrite/protein-bound NO were not affected over the total period o f storage. However, a 
trend was observed towards lower levels o f plasma protein-bound NO over the six months and red 
blood cell haemoglobin-bound NO diminished significantly after one month of freezing. As the 
total signals were not affected it was understood that over time the plasma protein-bound NO and 
red blood cell haemoglobin-bound NO most likely lost NO to form nitrite in the sample.
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3.3 Discussion
3.3.1 Why did Methods Become a Focus?
It was never the intention o f this thesis to focus so intently on methodology. However 
given the scrutiny o f methods throughout the NO metabolite field during this thesis in 
combination with both the results reported from our laboratory at the time (which were at the top 
end of values in the literature [115]) and findings from my early experiments (outlined in this 
chapter), there appeared little choice in the matter.
My initial work identified several methodological issues with the means o f measuring red 
blood cell/haemoglobin bound NO. Firstly in relation to the NO measurement technique 
employed (i.e., the NO electrode), secondly with the injection port/reaction cell utilised with this 
system and finally with the means of introducing the sample for analysis. As a result of these 
findings a new reaction cell was developed, a cleaner means o f introducing the sample was 
employed (gas tight Hamilton syringes) and an investment was made in a new NO measurement 
technique (ozone based chemiluminescence NOA). With these advances the signals observed 
from untreated red blood cell samples (i.e., fresh red blood cells lysed in HPLC water) declined to 
barely detectable levels as sources o f contaminant were slowly identified and eliminated and 
awareness of the potential pitfalls associated with red blood cell NO measurement became more 
evident. During these developments it was noted that the sensitivity o f the tri-iodide reagent (that 
had been used all along) was affected by cell free haem auto-capture o f NO in the reaction cell. 
This was investigated as a potential confounding factor influencing the detection o f red blood cell 
derived NO.
3.3.2 Measuring Total Red Blood Cell NO
Numerous experiments with NO standards in the presence and absence of haemoglobin in 
the reaction chamber were performed to demonstrate auto-capture o f NO by cell free haem. To 
overcome this issue it was rationalised that the addition o f ferricyanide to the reagent would 
oxidise haem from its ferrous Fe(II) to its ferric Fe(III) form creating a less potent scavenger; 
therefore allowing NO to escape the reaction chamber and be detected by the NOA. It was also 
hypothesised that the addition o f ferricyanide to tri-iodide might improve the yield o f NO from 
HbNO, facilitating the release of haem NO via the oxidation of HbNO to nitrite [27]. The
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improved detection of HbNO from ~ 60-80% in the original reagent to ~ 100% in the modified 
reagent was later demonstrated by others [126]. Clearer signals observed with the modified tri­
iodide reagent have consequently been attributed in part to the improved detection of HbNO but 
more so to the inhibition o f NO auto-capture in the reaction cell.
One point o f contention raised in the literature regarding NO auto-capture in tri-iodide 
relates to the concentration of haem utilised in experiments to demonstrate this phenomenon 
[126]. The haem concentration alone however provides no insight into this issue. It is the ratio of 
NO:haem which is the important parameter. As the data herein reveals, at physiological 
NO:haem ratios auto-capture is an issue in the original tri-iodide reagent.
3.3.3 Measuring Individual Red Blood Cell Species
Having developed a pre-treatment free means to measure baseline levels o f total red blood 
cell NO in human blood samples, the next objective was to split the signal into its component 
parts and identify specific sources of red blood cell NO. Previously this had been achieved in our 
laboratory utilising various chemical pre-treatment processes outlined in the literature [73, 94]. 
However, the artificial formation of metabolites in vitro was a major concern. This had been 
demonstrated by others following the incubation o f biological samples with nmol/L levels of 
nitrite; equivalent to the trace amounts o f nitrite observed in chemicals or from filter/column 
diluent [127]. Another concern regarding pre-treatments was the loss o f less stable metabolite 
species as a result o f sample handling time prior to measurement [27, 101, 103]. For these 
reasons a decision was made to try and avoid all stabilisation solutions and chemical pre­
treatment protocols. Instead, other means of differentiating individual metabolite species were 
explored, including the 3Cs assay.
3Cs was identified as the most promising means to measure SNO-Hb because it provided 
a direct measure, it was s^ c ff lc ^ lT lS N O  (with nitrite remaining undetected due to the neutral 
pH of tKe feagenT~ pH 6.5) which in turn meant that no sample pre-treatment was required. 
Unfortunately in our laboratory CO was only partially effective at inhibiting auto-capture o f NO 
by cell free haem in the reaction chamber. During a visit to the laboratory where the 3Cs assay 
was developed, it was discovered that to achieve the greatest inhibition o f haem by CO, the
reaction cell had to be maintained at pressure to produce a high enough concentration of CO in
the CuCl/CSH reagent. Unfortunately it was not possible to run our reaction cell system at the 
pressures required. Furthermore even at pressure CO was found to be ineffective at blocking just
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l|iM  final haem in the reaction chamber, well below the amount o f  haem thought necessary to 
observe a SNO-Hb signal from a baseline human blood sample. Consequently other means o f 
determining SNO-Hb were assessed.
An attempt was made to measure SNO-Hb in the modified tri-iodide reagent using 
previous pre-treatment protocols. This involved the incubation o f blood samples with and without 
HgCl2 (to cleave and convert SNO to nitrite) in conjunction with acidified sulphanilamide (to 
remove nitrite) [94]. A dozen baseline red blood cell samples were analysed (6 arterial/6 venous), 
seven o f which produced negative SNO-Hb values, i.e., the red blood cell samples treated with 
HgCl2 followed by dilution in sulphanilamided water 1:4 (representing HbNO) produced larger 
signals than the red blood cell samples just diluted in sulphanilamided water 1:4 (a combined 
measure o f SNO-Hb and HbNO) (Figure 3.20).
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Figure 3.20: Representative trace demonstrating the measurement SNO-Hb using
previously published sample pre-treatment protocols. The red blood cell sam ple w as  
either diluted 1:4 in sulphanilamided water for 15 minutes (to measure HbNO + SNO-Hb) 
or pre-treated with HgCh (5mM final concentration) to convert SNO to nitrite for 3 minutes 
before being diluted 1:4 in sulphanilamided water for 15 minutes (to measure ju st HbNO). 
Note the second peak  has a larger area under curve (AUC) which results in a negative 
value for SNO-Hb.
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From these findings it was decided not to attempt to split the haemoglobin-bound NO signal into 
its constitutive elements (HbNO and SNO-Hb) but to report a total red blood cell NO 
measurement and a separate haemoglobin-bound NO measurement. The only way to obtain the 
haemoglobin-bound NO signal involved the use of acidified sulphanilamide. The subtraction of 
haemoglobin-bound NO from the total red blood cell NO provided a measure of nitrite in the 
sample, which throughout this thesis has been termed “red blood cell associated nitrite”. This 
reflects the fact that nitrite might not necessarily be found within the red blood cell, only 
associated to the red blood cell membrane. Finally it is acknowledged herein that the treatment of 
biological samples with acid is far from ideal. However, whilst it has been implied that 
metabolite species could be destroyed following such pre-treatment [103], to date no experimental 
evidence demonstrating this has been published [126].
The concentrations of red blood cell NO and the proportions of haemoglobin-bound and 
red blood cell associated nitrite are examined in more detail in the following chapter, however it 
is important to note that with the methodology outlined, red blood cell NO and more specifically 
haemoglobin-bound NO could be detected in baseline human blood samples.
3.3.4 Measuring Plasma Species
Plasma injected into the tri-iodide reagent was found not to affect the signal from nitrite 
or GSNO. This demonstrated the limited capacity of plasma in tri-iodide to scavenge NO. 
Consequently, the original tri-iodide reagent was used to measure plasma samples. In order to 
obtain a difference measurement, plasma samples were incubated with acidified sulphanilamide 
for 15 minutes to remove nitrite. The remaining sulphanilamide stable signal has been termed 
throughout this thesis ‘plasma protein-bound NO’ (incorporating species such as RSNO and 
RNNO). This signal was subtracted from an undiluted plasma signal to provide a measure of 
plasma nitrite.
Ideally protein-bound standards should be used to determine the concentration of protein- 
bound NO metabolites. However, throughout this thesis concentrations o f protein-bound NO 
were determined from a standard curve o f nitrite. This was undertaken for two reasons, firstly 
because the majority of NO observed from plasma samples was found to come from nitrite and 
secondly due to the difficulties associated with making a physiologically representative protein- 
bound NO standard.
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3.3.5 Storage o f Blood Samples
The data in this chapter demonstrates that total NO signal in modified tri-iodide for red 
blood cell measurements and the original tri-iodide for plasma measurement remains stable 
following the freeze/thaw cycle and storage of samples in the freezer, so long as the sample is 
thawed only once. Due to the fact that red blood cell lysate usually exhibits lower signal rnoise 
(compared to plasma signals), greater variability is observed. Whilst the total signal remained 
constant, haemoglobin-bound NO from red blood cell samples and plasma protein-bound NO 
declined over time. However, the fact that the total signal remained constant suggests that NO 
lost from these species most likely formed nitrite. As a result o f these findings all red blood cell 
samples were analysed within one week o f collection and all plasma samples within one month.
3.3.6 Conclusion
Progress in the understanding o f NO biology hinges on the accuracy and specificity of 
methods used to measure NO metabolites. This work has added to this knowledge base 
emphasizing the need for all assays of red blood cell or haemoglobin-bound NO to incorporate a 
means to prevent free haem rebinding NO in the reaction chamber. Other future goals should 
address the development o f assays which measure only the species o f interest in order to minimise 
the need for sample processing/pre-treatment which will allow maintenance o f sample integrity 
thus limiting the possibility o f contamination, loss o f less stable metabolite species and disruption 
to the NO metabolite equilibrium. Only when the same answers are achieved from multiple NO 
measurement methodologies can we be satisfied that we have the true levels o f NO metabolites in 
human blood.
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SUMMARY
• When used in the gas phase the NO electrode is hyper sensitive to changes in 
gas flow and temperature and it also produces a signal upon the injection of 
air. Signals observed often don’t return to baseline so peak height has to be 
used to determine NO concentration. Chemiluminescence is not only a more 
sensitive NO measurement technique but it is also more practical in terms of 
time taken to set up and measure samples.
• Assays used to determine red blood cell/haemoglobin metabolites must 
incorporate a means of preventing NO auto-capture by cell free haem in the 
reaction chamber. This issue affects both the tri-iodide and CuCl/CSH 
reagents (and most probably other methodologies). It can be overcome via 
the addition of ferricyanide to tri-iodide or by changing the purge gas through 
the chemiluminescence system to CO. However, in order for CO to work at 
its best the reaction cell has to be maintained under pressure to obtain a high 
enough concentration of CO in solution.
• Samples can be snap-frozen and stored for analysis as long as they are 
processed within a short time frame. The freeze thaw process has no effect on 
metabolite stability. However, whilst total red blood cell and plasma signal 
remains constant over time in the freezer, red blood cell haemoglobin-bound 
NO and plasma protein-bound NO are lost, most probably to nitrite.
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4.0 Introduction
Endothelium derived NO produced by type III NOS which diffuses into the bloodstream 
is rapidly metabolised [52]. The reactions and products formed are dependent on the 
concentration of both NO itself and other bio-reactants. Erythrocytes are known to represent a 
major sink for NO as a result o f the following reaction pathways:
• Co-oxidation reaction o f NO with oxyhaemoglobin to form methaemoglobin and nitrate, 
recognised as the major inactivation pathway of NO in vivo [4, 128].
• Nitrosylation o f deoxyhaemoglobin or deoxygenated haem groups on partially 
oxygenated haemoglobin to form iron-nitrosyl haemoglobin (HbNO).
• Nitrosation o f specific thiol groups (Cys93) on the (3-haemoglobin chains to form S- 
nitrosohaemoglobin, either by direct reaction of NO or o f a higher oxidation product 
(N 02, N20 3 or N 0 2') or from the inter-conversion o f NO from HbNO.
NO also interacts with plasma constituents, the main reactions being:
• Oxidation o f NO via the formation of iV-oxides (including N 0 2 and N20 3) to nitrite and 
nitrate. Nitrite in plasma reacts with erythrocytic oxygenated haemoglobin to form nitrate 
and methaemoglobin [52].
• Nitrosation o f plasma protein thiol and amine groups forming S-nitrosothiols (RSNO) and 
7V-nitrosamines (RNNO) respectively. 7V-oxides formed from the reaction of NO with 
oxygen are potent nitrosating agents.
4.1 Aims
This work was undertaken to:
• Determine baseline concentrations of the major blood borne NO metabolite species in 
arterial and venous human blood utilising the most up to date and sensitive methodologies 
available.
• Investigate routes of metabolism of nitrite (because of its association as a potential 
bioactive metabolite store) and NO (representing the physiological situation) in human 
whole blood.
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• Assess the effect of oxygen (which regulates nitrite bioactivity) on pathways of
metabolism via analysis in arterial and venous whole blood.
4.2 Subjects
Due to the semi-invasive requirements o f the study, samples were obtained from eleven 
subjects undergoing electrophysiology (EP) testing in the cardiology department o f St Peters 
Hospital Chertsey; a procedure diagnostic for paroxysmal arrhythmias. Although all subjects had 
no past history o f ischemic heart disease, smoking, diabetes mellitus, hypertension (blood 
pressure > 140/90mmHg) or hypercholesterolemia (total cholesterol > 5.2mmol/L), potential 
underlying pathologies might have induced greater variance than a control population. All 
patients on nitrite or nitrate therapy were excluded from this study. All individuals underwent an 
8 hour fast prior to blood taking during which time they were allowed water. Subjects gave fully 
informed written consent approved by the relevant local research ethics committee.
4.3 Protocol
Parallel blood samples were drawn from the femoral artery and femoral vein into 20ml 
syringes. Blood was transferred immediately after blood gas analysis (Hemoximeter OSM3, 
Radiometer) into four or five 4ml ice chilled EDTA vacutainers. Nothing was added to one 
vacutainter (to give baseline measurement), saline only was added to another (as NO donor 
addition was administered in saline) and different concentrations o f noc-9 (t XA  =1.5-2 minutes at 
37°C) or sodium nitrite (t Vi in blood =1 .5  minutes at 37°C [52]) (Alexis, UK) were added to the 
rest to provide final concentrations o f 0, ~ 2.4, ~ 4.7 and ~ 9.4pM NO. All samples were 
incubated in a water bath at 37°C for 6 minutes before being transferred to ice and centrifuged at 
600g for 5 minutes at 4°C. Both plasma and the red cell fractions were separated, snap frozen in 
liquid nitrogen and stored at -80°C for subsequent analysis.
Within this study it must be highlighted that baseline samples were treated in exactly the 
same manner as all other samples, to which NO was added. The effect o f the incubation period 
must therefore be considered in relation to the baseline NO metabolite measurements. 
Furthermore, although bloods were maintained within vacutainers throughout the majority o f the 
study, ultimately samples were transferred into eppendorf tubes in room air. Others have 
previously demonstrated the effect of blood sample processing in room air compared to a glove 
box where the native sample p 0 2 is maintained [83].
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4.4 Determination of NO Metabolites
Plasma NOx was measured by ozone based chemiluminescence in combination with the 
vanadium chloride reagent as detailed in chapter 2; section 2.1.3. Plasma nitrite and plasma 
protein-bound NO was measured by ozone based chemiluminescence using the tri-iodide reagent 
as detailed in chapter 2; section 2.1.4. Haemoglobin-bound NO and red blood cell associated 
nitrite were quantified by ozone based chemiluminescence using our modified tri-iodide reagent 
as detailed in chapter 2; section 2.1.5.
4.5 Statistical Analysis
All data are presented as mean ± SEM. A two tailed p value o f less than 0.05 was 
considered statistically significant. Differences between group means (noc-9 versus nitrite 
additions) were compared by unpaired student t test. Differences between means within each 
group (arterial versus venous blood) were compared by paired student t test. Bivariate 
correlations were performed using Pearson’s coefficient.
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4.6 Results
4.6.1 Baseline Measurements
Baseline NO metabolite levels were measured in five subjects, two male and three female, 
aged 53 ± 7 years (Table 4.1). Mean arterial and venous H b02 (%) were 95.8 ± 1.7% and 60.1 ± 
8.2% respectively.
Table 4.1: Baseline NO metabolite concentrations in human arterial and venous blood (n -  
5). Values are presented as mean ± SEM. Star(s) denote where mean is significantly 
different from the arterial sample; * p  < 0.05.
Metabolite Species Arterial Venous
Plasma Nitrate 37.3 ± 13.5 |J,M 33.4 ± 11.2 nM
Plasma Nitrite 200.7 ± 76.6 nM 95.1 ± 22.4 nM
Plasma Protein-bound NO 10.5 ±5.9 nM 27.4 ± 15.6 nM
RBC Associated Nitrite 43.2 ± 26.3 nM 17.0 ± 10.4 nM
RBC Hb-bound NO 27.5 ± 8.9 nM 43.3 ± 12.2 nM*
4.6.1.1 Plasma NO Metabolites
In both arterial and venous blood, plasma nitrate made up by far the largest component of 
the total NO metabolite pool (> 99%). This reflects its in vivo half life (~ 5-8 hours) and various 
sources o f formation, both NOS dependent (e.g., type III NOS NO metabolism) and independent 
(e.g., diet, saliva). Plasma nitrite formed the second largest component o f the total metabolite 
pool (< 0.55 %), with the rest being made up o f protein-bound NO (including RSNOs and N- 
nitrosamines) forming < 0.1% of all NO metabolites (Figure 4.1).
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Figure 4.1: Baseline proportions o f  all NO metabolite species including nitrate (Top) and  
excluding nitrate (Bottom) as a percentage o f the total NO metabolite pool in arterial and  
venous blood.
4.6.1.2 Red Blood Cell NO Metabolites
Red blood cell NO metabolites (haemoglobin-bound NO and red blood cell associated 
nitrite) made up < 0.25% o f the total NO metabolite pool in both arterial and venous blood 
(Figure 4.1).
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4.6.1.3 Relationship o f Baseline Metabolite Apportionment to Oxygen
At baseline no significant difference was observed across artery to vein in plasma nitrate, 
plasma protein-bound NO, total red blood cell NO or red blood cell associated nitrite. However a 
trend was observed towards higher plasma nitrite plus protein-bound NO (p = 0.0952) possibly 
reflecting higher plasma nitrite levels in arterial blood (p = 0.0625). Haemoglobin-bound NO was 
significantly higher in venous blood (p < 0.05) (Figure 4.2) with a trend towards an inverse 
correlation between haemoglobin-bound NO and H b02 sat (%) (Figure 4.3), reflecting the wider 
availability of free haem groups able to participate in the addition reaction at lower H b02 sat (%).
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4.6.2 Metabolism of Exogenous NO and Nitrite
Arterial and venous whole blood samples from eleven subjects (Table 4.2) were incubated 
with either exogenous NO or nitrite (administered in saline).
Table 4.2: Subject characteristics. No parameters were different between groups.
Noc-9 Addition Nitrite Addition
Subjects 6 5
Gender (male/female) 3/3 3/2
Age 54 ± 6 years 47 ± 11 years
Arterial Hb02 (%) 96.0 ± 1.4% 97.3 ± 0.3%
Venous Hb02 (%) 62.4 ±7.1% 72.8 ± 5.2%
4.6.2.1 NO/Nitrite Addition - Comparison to Baseline
The addition o f saline on its own had no significant effect on the concentrations of 
metabolites or the apportionment o f NO between species (data not shown). In arterial blood the
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addition of exogenous NO resulted in the non nitrate portion o f the total metabolite pool 
increasing ~  7% and ~  39% following nitrite addition (Figure 4.4). In venous blood the 
corresponding figures were ~  10% with NO addition and ~  30% with nitrite addition (Figure 4.5). 
This demonstrates reactions competing with the oxidation reaction, resulting in the formation of 
potentially bio-available forms o f NO. The higher levels o f  nitrate free signal following nitrite 
addition mainly reflected the accumulation o f plasma nitrite.
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Figure 4.4: Comparison o f NO metabolite apportionment (averaged across all doses) from  
baseline following NO and nitrite addition to arterial blood. Values presented  as mean 
across all doses o f  added NO and nitrite ± SEM.
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4.62.2 Recovery o f Exogenously Added NO and Nitrite
An average o f 94.5 ± 21.7% and 96.3 ± 23.3% o f total added NO (Figure 4.6) and 135.5 ± 
41.8% and 100.5 ± 22.1% o f total added nitrite (Figure 4.7) was recovered across all doses in 
arterial and venous blood respectively. This suggests that the metabolite species measured within 
this study represent not only the main metabolic pathways for NO and nitrite but also the main 
metabolites in human blood.
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4 .6 .2 .3  N O  and N itrite  M etab o lism  in A rterial B lo o d
In arterial b lood  the m etabolism  o f  N O  and nitrite w as sim ilar. C om parable le v e ls  o f  
plasm a-protein -bound N O , red b lood  ce ll h a em og lob in -b ou n d  N O  and red b lood  ce ll a ssocia ted  
nitrite w ere recovered . T he o n ly  sig n ifica n t d ifferen ce  b etw een  nitrite and N O  m etab o lism  in 
arterial b lood  w as the h igh er percentage o f  added  nitrite ob served  as p la sm a  nitrite (p  <  0 .0 1 )  
reflectin g  the relative stab ility  o f  th is sp ec ie s  in w h o le  b lood  in com p arison  to  N O  (F igu re 4 .8; 
T able 4 .3 ).
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Table 4.3: NO metabolite concentrations in arterial blood following addition o f  nitrite (Top) 
and NO (Bottom). Values presented as mean ± SEM. Star(s) denote where mean is 
significantly different from  the NO addition; ** p  < 0.01.
II Nitrite 
Final Plasma N 0 3' Plasma N 0 2'
Plasma
Protein-bound
RBC Hb- 
bound
RBC associated
n o 2
Saline 20.2 ± 3 gM 54.3 ±21 nM** 19.3 ± 5 nM 18.8 ± 1 nM 11.6 ± 4 nM
2.4gM 23.3 ± 4 gM 1.3 ±0 .2  gM** 21.1 ± 9 nM 23.8 ± 4 nM 99.8 ± 29 nM
4.7gM 23.2 ± 5 gM 2.5 ±0 .2  gM** 34.0 ± 12 nM 32.3 ± 3 nM 133.8 ± 36  nM
| 9.4gM 26.6 ± 2 gM 4.9 ±0.5 gM** 23.9 ± 7 nM 48.2 ± 8 nM 310.6 ± 106 nM
NO
Final Plasma N 0 3‘ Plasma N 0 2'
Plasma
Protein-bound
RBC Hb- 
bound
RBC associated
n o 2
Saline 31.6 ± 10 gM 184.4 ±32 nM 27.4 ± 16 nM 34.1 ± 8 nM 27.3 ± 11 nM
2.4gM 35.3 ± 10 gM 296.1 ± 39  nM 42.3 ± 10 nM 43.1 ± 10 nM 43.1 ± 15 nM
4.7gM 34.4 ± 8 gM 409.8 ± 33 nM 47.4 ± 13 nM 47.1 ± 6  nM 92.8 ± 9 nM
9.4gM 38.2 ± 10 gM 591.3 ±77  nM 55.1 ± 17 nM 67.7 ± 5 nM 123.4 ± 17 nM
4.6.2.4 NO and Nitrite Metabolism in Venous Blood
In venous blood, the metabolism o f NO and nitrite were very different. More plasma 
protein bound NO (p < 0.01), red blood cell associated nitrite (p < 0.05) and red blood cell 
haemoglobin-bound NO (only at the highest dose; p < 0.05) was formed in venous blood to which 
NO was added (Figure 4.9; Table 4.4). However, a higher percentage o f plasma nitrite was 
observed following nitrite addition (p < 0.01) reflecting the relative stability o f  exogenously 
added nitrite in whole blood even at lower oxygen tensions.
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Table 4.4: NO metabolite concentrations in venous whole blood following addition o f 
nitrite (Top) and NO (Bottom). Values are presen ted  a s  mean ± SEM. Star(s) denote where 
mean is significantly different from  the NO addition; * p  < 0.05, ** p  < 0.01.
-----------
Nitrite
Final Plasma N 0 3' Plasma N 0 2'
Plasma
Protein-
bound
RBC Hb- 
bound
RBC associated
n o 2
Saline 21.1 ± 3  \iM 42.0 ± 10 nM** 28.6 ± 9 nM 18.0 ± 5 nM ** 9.6 ± 5 nM
2A[iM 23.4 ± 3  nM 0.6 ± 0.04 nM** 21.9 ± 4 nM** 71.5 ± 15 nM 64.2 ± 15 nM*
4.7fiM 25.5 ± 3 fiM 1.2 ±0.1 ^M** 20.5 ± 8 nM** 110.3 ±21 nM
124.4 ±22  
nM**
9.4nM 24.5 ± 5 nM* 2.5 ±0.3 nM** 21.7 ± 7 nM**
167.8 ±32  
nM* 274.9 ±42 nM*
NO
Final Plasma N 0 3" Plasma N 0 2'
Plasma
Protein-bound
RBC Hb- 
bound
RBC
associated
n o 2
Saline 31.3 ± 10 \iM 123.4 ± 17 nM 14.3 ± 5 nM 39.0 ± 4 nM 24.8 ± 11 nM
2.4^M 33.3±9\xM 232.3 ± 25 nM 50.9 ± 7 nM 96.3 ± 9 nM 110.6 ± 13 nM
4.7(iM 35.4 ± 8 fxM 329.2 ± 36 nM 85.7 ± 14 nM 171.6 ± 24 nM 222.6 ± 24 nM
9.4|iM 40.8 ± 10 \iM 410.8 ±55 nM 104.2 ± 16 nM 277.5 ± 36 nM 430.7 ± 70 nM
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4.6.2.5 Effect o f Oxygen on Exogenous NO and Nitrite Metabolism
Significantly more NO across all doses was metabolised to plasma nitrite (p < 0.05) in 
arterial blood. In venous blood more NO was metabolised to plasma protein-bound NO, red 
blood cell associated nitrite and red blood cell haemoglobin-bound NO (p < 0.05). Similarly, 
following nitrite addition more plasma nitrite was observed in arterial blood (p < 0.05) whilst in 
venous blood more nitrite was metabolised to red blood cell haemoglobin-bound NO (p < 0.05). 
However, no significant difference was observed between arterial and venous blood in the 
proportion o f nitrite metabolised to plasma protein-bound NO or red blood cell associated nitrite.
Across all added doses o f NO and nitrite (but not the saline addition) positive correlations 
were observed between plasma nitrite and Hb02 sat (%) (Figure 4.10) and inverse correlations 
between haemoglobin-bound NO and H b 0 2 sat (%) (Figure 4.11). However, upon NO addition 
an inverse correlation was observed between red blood cell associated nitrite and H b 0 2 sat (%), 
but no correlation was observed between these parameters with nitrite addition (Figure 4.12).
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following the addition of saline, 2.5, 5 and lOpM NO (Top) and nitrite (Bottom) to whole 
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0.19: p  = 0.60; 2.5pM r= 0.77: p  = 0.009; 5pM r= 0.87: p  = 0.001; 10pM r= 0.87: p  = 
0 .001 .
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4.7 Discussion
Nitric Oxide Metabolites in Human Blood
4.7.1 Baseline Measurements
The trend towards baseline A-V gradients in plasma nitrite and red blood cell associated 
nitrite could be taken to back the hypothesis that nitrite provides a source o f bio-available NO in 
vivo. Such gradients have previously been presented as evidence o f NO delivery from nitrite 
across a vascular bed [26, 78, 125]. However, the assumption that gradients o f any metabolite 
species solely provide an index o f NO delivery is a common misconception [129]. This is based 
upon an association being made between oxygen and NO/nitrite gradients [129, 130]. The 
accuracy of this interpretation relies on similarities between the circulatory sources and sinks for 
oxygen and NO/nitrite. Unlike oxygen where there is just one source (i.e., the lungs), NO/nitrite 
production and consumption are dispersed throughout the cardiovascular circuit [129]. Therefore 
at any one site the amount and apportionment o f metabolite species represents the balance 
between NO formation, NO consumption and interplay within the metabolite pool regulated by 
H b02 sat (%) (demonstrated by the effect o f oxygen on NO metabolism in this chapter, section 
4.7.3). With specific regard to nitrite, which has previously been shown to provide an excellent 
marker o f NOS activity [131, 132], higher concentrations in arterial blood should reflect the 
balance between production (artery > vein; NOS activity) in addition to consumption (vein > 
artery; nitrite reductase activity) [130, 133].
Baseline concentrations o f the major NO metabolites in human arterial and venous blood 
(other than plasma nitrate) fell within the ~ 10 to 200nM range. These concentrations are in line 
with recent measurements made by a number o f groups using similar methodologies (see table 
3.0; chapter 3). Interestingly levels o f plasma nitrite were five times larger than red blood cell 
associated nitrite. This finding contradicts a more recent report suggesting that erythrocytes 
represent the major intravascular storage site for nitrite in human blood [125]. One significant 
difference between these two studies concerns the biological sample handling protocols used. 
Herein sample pre-treatment was kept to a minimum with only the dilution o f red blood cells 
either in water or sulphanilamided water prior to measurement. In the work o f Dejam et al. [125] 
whole blood or red blood cells were mixed with a ferricyanide-based ‘stabilization-solution’ (5:1 
volivol; designed to limit ex vivo nitrite reactions) containing ferricyanide, NEM and NP-40. In 
addition to this samples were de-proteinated with methanol (1:1 vokvol) before injection into tri­
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iodide. Interestingly, no mention is made o f the control for the addition of contamination via 
these chemicals and reagents.
The baseline NO metabolite values reported herein are generally much lower than those 
upon which the original metabolite theories were founded (pM  concentrations o f SNO albumin 
[63] and SNO haemoglobin [70]). This follows a recent trend in the literature towards lower 
reported metabolite concentrations measured by a number o f groups, mainly reflecting greater 
awareness o f potential contaminants and more widespread use o f similar methodologies (i.e., tri­
iodide reductive ozone based chemiluminscence). However, lower reported metabolite 
concentrations have no bearing on the physiological relevance o f these species. Within NO 
biology amount does not reflect importance [103]. If  this were so NO itself would be regarded as 
inconsequential being that it cannot be directly measured in blood or tissue. So long as enough 
related NO moiety is available to regulate physiological processes (e.g., to activate soluble 
guanylate cyclase; EC50 ~ 20nM [134]) actual bio-chemically measured levels o f baseline 
metabolite species tell us little about their significance.
4.7.2 NO and Nitrite Metabolism
NO and nitrite were metabolised in a similar manner in arterial blood. The major 
difference appeared to be the relative stability o f exogenously added nitrite in arterial whole 
blood, reflected by its accumulation in the plasma compartment. Identifying why a major 
proportion of added nitrite remained in the plasma compartment was not possible because no 
other species declined to account for this, as reflected in the fact that the overall return o f NO 
across all nitrite additions to arterial blood was ~ 135% (Figure 4.7). This excessive return o f NO 
in itself could potentially come from red blood cell nitrate (a metabolite species not measured 
throughout this thesis as no current methodology exists) leaching from the red blood cells into 
plasma (where nitrate has been measured in this study). Nitrate can be measured in plasma but 
not in red blood cells due to the effect o f haemoglobin auto-capturing NO (previously 
demonstrated in Chapter 3 in the tri-iodide and CuCl/CSH reagents) and the fact that within the 
nitrate assays no method currently exists to prevent this process. In venous blood on average 
across all added doses more NO than nitrite was metabolised to plasma nitrate, plasma protein- 
bound NO, red blood cell haemoglobin bound NO and red blood cell associated nitrite. However, 
once more a large proportion o f added nitrite remained in the plasma compartment. Taken 
together these results in both arterial and venous blood imply a difference in the ability of NO and
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nitrite to cross the red blood cell membrane, with nitrite consequently being protected from the 
red blood cell associated reactions (i.e., the oxidation and addition reactions). Whilst the charge 
neutrality o f NO is assumed to facilitate its free diffiisibility across cell membranes [135] it is 
possible that the negative charge o f nitrite restricts entry into the red blood cell. As yet the 
mechanisms involved in nitrite uptake by human red blood cells remain to be resolved, however 
the anion exchanger AE1 appears to have been ruled out in this process [125, 136].
Although exogenous NO/nitrite added to whole blood was predominantly metabolised via 
the oxidation reaction, other reactions were shown to compete with this (even in arterial blood) 
resulting in the conservation rather than the consumption o f NO. This was demonstrated by the 
non nitrate percentage o f the total metabolite pool increasing in comparison to baseline ~ 7-10% 
following NO addition and ~ 30-39% with nitrite addition (mainly reflecting nitrite in the plasma 
compartment) in whole arterial and venous blood. These findings are in agreement with others 
who have previously demonstrated under physiologically relevant experimental conditions 
preferential reaction mechanisms forming metabolites which preserve rather than destroy NO 
bioactivity [137].
4.7.3 Effect o f Oxygen on NO/Nitrite Metabolism
The fact that set amounts o f NO and nitrite were metabolised differently in arterial and 
venous blood demonstrates the role that oxygen plays in the regulation o f the metabolite pool. 
This adds to the complexity o f analysing and interpreting A-V NO metabolite gradients as it 
implies that even were the production and consumption o f NO to be the same in vivo across the 
vascular circuit from artery to vein (which we know it is not) different A-V NO metabolite 
profiles would be observed.
Levels o f plasma nitrite were significantly greater in arterial blood following the addition 
o f both NO and nitrite. With NO addition plasma nitrite levels reflected the balance between 
nitrite formation and metabolism. Conversely following nitrite addition plasma nitrite levels 
solely reflected metabolism, which was enhanced in venous blood as evidenced by the lower 
concentration o f nitrite remaining in the plasma compartment. The only metabolite species to 
increase in venous blood alone following nitrite addition was haemoglobin-bound NO, 
implicating the reduction o f nitrite by deoxyhaemoglobin as the mechanism accounting for 
venous nitrite loss from the plasma compartment. From this reaction either iron-nitrosyl
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haemoglobin or as more recently suggested (via the same reaction mechanism) SNO-Hb [138] 
could have formed.
Following NO addition to whole blood an inverse correlation was observed between red 
blood cell associated nitrite and H b02 sat (%), however no correlation was observed following 
nitrite addition. This reflects the fact that red blood cell associated nitrite accumulated to a 
similar extent in both arterial and venous blood upon the addition o f nitrite, however much lower 
levels of red blood cell associated nitrite were observed in arterial blood following the addition of 
NO.
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SUMMARY
• Baseline concentrations o f all NO metabolite species other than plasma nitrate 
(which itself is in the ~ 20-50pM range) fall within the ~ 10 to 200nM range. 
Apart from the level o f red blood cell associated nitrite, these concentrations 
are in line with recent measurements made by a number o f groups using 
similar methodologies.
• NO and nitrite were metabolised similarly in arterial blood, the only 
difference being greater plasma nitrite accumulation following nitrite 
addition. However, in venous blood across all added doses a greater 
percentage o f NO than nitrite was metabolised to plasma nitrate, plasma 
protein-bound NO, red blood cell haemoglobin-bound NO and red blood cell 
associated nitrite. Taken together these results in arterial and venous blood 
possibly reflect the differing ability o f NO and nitrite to cross the red blood 
cell membrane.
• The different metabolism o f set amounts o f NO/nitrite in arterial and venous 
blood demonstrate the regulatory function o f oxygen in determining the 
relative proportion o f species within the NO metabolite pool. This adds to the 
complexity o f analysing and interpreting A-V NO metabolite gradients.
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5.0 Introduction
The vascular regulatory properties o f blood transported NO are generally agreed to be 
enhanced in hypoxia [26, 45, 103, 129] potentially accounting for the hypoxic vasodilator 
response in vivo (the relaxation o f vascular smooth muscle in regions o f low tissue p 0 2) which 
acts to enhance blood flow to match oxygen delivery with metabolic demand [139, 140]. What 
elicits the hypoxic vasodilator response still remains to be conclusively proven. Several diverse 
NO independent and NO dependent hypotheses have emerged to explain this phenomenon [86, 
129, 141, 142]. More recently studies have identified that the release o f NO bioactivity from red 
blood cells plays a part in this process [26, 70, 83, 114, 115, 143, 144]. In these models 
haemoglobin is proposed to act as the hypoxic sensor coupling decreasing oxygen tension to 
increased vessel dilatation via the release or formation o f NO related moiety. Two different 
metabolite species have been proposed to account for this NO mediate response; the S-nitrosothiol 
SNO-Hb [70, 83] and more recently the anion nitrite, following its conversion to NO via the 
reductase activity of deoxyhaemoglobin [26, 27]. Interestingly both these hypotheses imply that 
1) an NO equivalent is transported in the blood, 2) NO delivery occurs in regions o f hypoxia, 3) a 
haemoglobin based mechanism is involved in the regulation o f the bioactive equivalent and 
therefore 4) that red cells have the potential to regulate vascular tone [87]. These similarities lend 
support to the idea o f linkage between the metabolite hypotheses, previously outlined following 
the suggestion that the nitrite reductase reaction o f deoxyhaemoglobin contributes to SNO-Hb 
formation [83, 133, 138]. Specifically this chapter focuses on the potential role that nitrite plays 
in red blood cell mediated regulation o f vascular tone.
The biological properties o f nitrite have been studied for over a century [145]. Early 
organ chamber work demonstrated nitrite to be orders o f magnitude less potent than many 
bioactive substances [146], with in vitro levels required to elicit a response typically a hundred 
fold greater (hundred-pM to mM range) than circulating concentrations measured in vivo (< lpM ) 
[147]. These findings in combination with an in vivo study which demonstrated no effect of 
arterially infused nitrite in the human forearm circulation [131] all but ruled out nitrite as a 
potential source of bioactive NO in the human circulation. However, more recently reports o f A- 
V nitrite gradients in vivo [78, 125, 148, 149] in combination with demonstrated vasodilator 
activity o f nitrite in the human forearm circulation at near physiological concentrations [26] have 
reignited interest in this compound and specifically the nitrite-reductase reaction o f haemoglobin 
[24-27] which has been postulated, via the release o f free NO, to independently mediate hypoxic 
vasodilatation.
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5.1 Aims
This work was undertaken to:
• Investigate the effect o f oxygen on red blood cell mediated regulation o f vascular tone.
• Analyse the direct vasoactive properties o f nitrite at different oxygen tensions.
• Verify whether nitrite enhances red blood cell induced vasodilatation.
5.2 Protocol
5.2.1 Aortic Ring Preparation
The thoracic aorta o f male New Zealand white rabbits were dissected and prepared as 
described in chapter 2 section 2.2. Experiments were performed with endothelium denuded and 
intact rings. To denude the vessels, the luminal surface was gently rubbed with a rounded 
wooden applicator. The aortic rings were subsequently mounted in 8ml tissue baths containing 
5ml Krebs buffer and gassed with 95% 0 2 / 5% C 0 2 at 37°C. A resting tension o f 2.1-2.3g was 
set. After a one hour equilibration period during which time the tension was reset (to allow for 
stretch induced relaxation) all rings were exposed to phenylephrine (PE, lpM ) to induce 
constriction. When a steady plateau was reached acetylcholine (lOpM) was added to check the 
viability o f the endothelium. Following this the rings were washed re-equilibrated and repeat PE 
constrictions performed until a reproducible constriction was achieved.
5.2.2 Blood Samples
Blood samples (from healthy volunteers within the laboratory) were drawn from the 
antecubital vein and immediately transferred into 4ml ice chilled EDTA vacutainer(s). For 
experiments with native red blood cells, samples were spun at 600g for 5 minutes at 4°C. The 
plasma and buffy coat were removed and discarded and the red cells subsequently washed in an 
equal volume of saline and spun at 2000g for 5 minutes at room temperature. Saline was removed 
and 20pl o f the red blood cell pellet was injected into the 5ml bath (final haemoglobin 
concentration 20pM; 80pM haem; final haematocrit 0.4%). For incubation experiments with noc- 
9 and nitrite, saline only (500pl) was added to one vacutainer (as NO donor addition was 
administered in saline) and different concentrations of noc-9 (t Vi = 1.5 minutes at 37°C) or
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sodium nitrite (t Vi — 1.5 minutes at 37°C [52]) were added to the other vacutainers to provide 
final concentrations o f ~ 2.4 and ~ 9.4juM NO. All samples were incubated in a water bath at 
37°C for 6 minutes before being transferred to ice and centrifuged at 600g for 5 minutes at 4°C. 
The plasma and buffy coat were removed and discarded and the red cells subsequently washed 
three times in an equal volume o f saline and spun at 2000g for 5 minutes at room temperature. 
Saline was removed and replaced following each washing. After the final spin the saline was 
removed and 20pl o f the red blood cell pellet was injected into the 5ml bath.
5.2.3 Oxygen Tension
Experiments were performed at different oxygen tensions by varying the oxygen ( 0 2) 
perfusing the Krebs buffer bathing the tissues. Vessel tension experiments at low 0 2 were 
performed using 0% 0 2 (i.e., 95% N 2, 5% C 0 2 gas mix) and at high 0 2 using 95% 0 2 (i.e., 95% 
0 2, 5% C 0 2 gas mix). All gases contained 5% C 0 2, essential for maintaining pH in bicarbonate 
buffered systems [150]. Due to 0 2 back-diffusion from the atmosphere, solution 0 2 tensions do 
not reflect perfused gas tensions. Previously in our laboratory the 0 2 tension o f the gassed buffer 
at 0% 0 2 had been measured with an 0 2 electrode and was found to equate to 1.0 ± 0.3% 
(approximate tissue p 0 2 o f ~ 8 mmHg) [144]. At 95% 0 2 the measured 0 2 tension equated to an 
approximate tissue p 0 2 o f 700 mmHg. Throughout this chapter all experiments performed with 
0% 0 2 are termed ~ 1% (representing the measured 0 2 percentage in the tissue bath and 
experienced by the tissue) and 95% 0 2 are termed 95%. All tissue equilibration was performed at 
95% 0 2. For experiments at ~ 1% vessels were subjected to 10 minutes at 0% 0 2 prior to 
contraction with PE.
In organ chamber bioassays the standard protocol for assessment o f vasoactivity involves 
a pre-constriction o f blood vessels to a preset initial tone. As 0 2 affects the constrictor tone, 
different doses o f PE had to be used to elicit the same gram tension (i.e., more PE at lower 0 2; as 
demonstrated in this chapter). Therefore a 1 x 1(T6 mol/L final PE concentration was used in all 
experiments performed at 95% 0 2 (representing ~ 70% maximal tension) and a 3 x 10-6 mol/L 
final PE concentration in all experiments performed at ~ 1% 0 2. Upon reaching a constriction 
plateau (i.e., maximal tension) blood, nitrite or both were added to the rings (see individual 
experiments). Relaxations (and additional constrictions) were calculated as the change in tension 
relative to sub-maximal constriction (as a percentage). In some experiments ODQ (\H - 
[l,2,4]oxadiazole[4,3-a] quinoxalin-l-one; 10-5 mol/L; Alexis) was added to baths (30 minutes 
prior to PE) to inhibit soluble guanylate cyclase (sGC) mediated relaxation o f smooth muscle.
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5.3 Statistical Analysis
All data are presented as mean ± SEM or as original traces. A two tailed p value o f less 
than 0.05 was considered statistically significant. Differences between group means were 
compared by unpaired student t test, whilst differences between means within each group were 
compared by paired student t test. A one way ANOVA (Bonferrini post hoc test) was used for 
comparisons featuring more than two groups.
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5.4 Results
5.4.1 Oxygen Dependent Responsiveness o f Aortic Rings
To demonstrate the 0 2 dependent responsiveness o f  aortic rings, the same final 
concentration o f PE (1 x KT6 M final) was added to rings at 95% and ~ 1% 0 2. The maximal 
tension observed was significantly higher in the rings maintained at 95% (Figures 5.0 and 5.1). It 
was found that the final concentration of PE required to elicit the same gram tension observed at 
95% with vessels maintained at ~ 1% was 3 x lO^M PE (Figures 5.0 and 5.1). Therefore in the 
following experiments the lower concentration o f PE was used in all experiments performed at 
95% 0 2 and the higher PE concentration at experiments performed at ~ 1% to invoke similar 
vessel gram tension at the different oxygen tensions.
5.4.2 Native Human Red Blood Cell Responses
Venous red blood cells added to PE constricted endothelium intact rings perfused at 95% 
0 2 elicited a marked vasoconstriction, resulting from scavenging o f endothelial derived NO by 
haemoglobin. However, at ~ 1% a prompt and transient relaxation response was observed, 
followed by vasoconstriction (Figures 5.2 and 5.3). In experiments performed with denuded 
vessels (to remove the influence o f the vascular endothelium) the vasoconstrictor response at 95% 
was abolished due to the removal o f vessel NO production. However, the vasodilator response 
was not significantly different to that observed in endothelium intact vessels, highlighting the 
endothelium independence o f the relaxation response (data not shown).
To inhibit soluble guanylate cyclase mediated relaxation o f smooth muscle, ODQ was 
added to two baths in each o f these native red blood cell experiments. The addition o f ODQ had 
no effect on vessel constriction, however the relaxation response from venous red blood cells at ~ 
1% was abolished demonstrating sGC involvement in the red blood cell relaxation response 
(Figure 5.3).
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Figure 5.0: Raw aortic ring traces demonstrating the different maximal tension observed  
at 95% and ~ 1% oxygen using (1 x lO 6 M final) PE concentration. The sam e gram tension 
observed at 95% w as achieved following the addition o f (3 x  I d 6 M final) at ~ 1% oxygen.
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Figure 5.1: Maximal phenylephrine induced tension in endothelium intact aortic rings 
perfused at 95% oxygen (PE = 1 x I d 6M final) and ~ 1% oxygen (PE = 1 x I d 6M and 3 x 
I d 6 M PE final). Values presen ted  a s mean  ± SEM (n = 5). ** p  < 0.01; One w ay ANOVA 
with Bonferroni p o st hoc test.
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Figure 5.2: Raw aortic ring traces following the addition o f PE and venous red blood cells 
to aortic rings perfused at 95 and  ~ 1 % oxygen with intact endothelium.
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Figure 5.3: Venous red blood cell response in endothelium intact aortic rings perfused at 
95% and ~ 1% oxygen and at ~ 1% oxygen in the presence o f ODQ. Values presented as 
mean ± SEM (n = 5) **p  < 0.01; One w a y  ANOVA (Bonferronipost hoc test).
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5.4.3 Immediacy o f  Red Blood Cell Response
Relaxation and constriction responses (at ~  1% and 95% 0 2 respectively) observed in 
endothelium intact vessels upon the addition o f  venous red blood cells were in the order o f 
seconds (Figure 5.4). In total, relaxation responses at low 0 2 continued over a period o f ~  20 
seconds until the vasodilatory capacity o f  the red blood cells was spent.
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Figure 5 .4: R aw  aortic ring traces dem onstrating the response o f  endothelium  intact aortic 
rings at 95 and ~ 1% oxygen to venous red blood cells.
5.4.4 Slow and Long Lasting Nitrite Relaxations
Nitrite alone at high doses relaxed PE pre-constricted aortic rings. However, this 
response was slow and long lasting, acting over tens o f  minutes (Figure 5.5). With no comparable 
immediate relaxation response to that observed from red blood cell samples, the measurement o f 
nitrite induced relaxation was taken 5 minutes post nitrite addition. In those experiments 
performed with red blood cells in combination with nitrite, the transient red blood cell relaxation 
was measured along with the vessel response after 5 minutes.
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Figure 5.5: Raw aortic ring tension traces demonstrating the relaxant properties o f nitrite 
(lpM; 10/iM and lOOpMfinal concentrations) in PE pre-constricted aortic rings without 
endothelium at ~ 1% oxygen.
Internal control vessels (to which nothing was added) held at ~ 1% 0 2 over an extended 
period demonstrated a relaxation response following PE constriction (Figures 5.5) which was not 
observed in vessels maintained at 95% 0 2 (data not shown). Controls were therefore run with 
each nitrite experiment at ~  1% to account for the oxygen dependent loss in vessel tension
5.4.5 Influence o f Oxygen on Nitrite Relaxation
Nitrite relaxation was enhanced at low 0 2 tension in both endothelium denuded (Figure 
5.6) and endothelium intact vessels (data not shown). This follows the same trend observed for a 
number o f NO donors which have been demonstrated to show enhanced responsiveness in vessels 
maintained at low oxygen tensions [144, 151].
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Nitrite [fiM]
Figure 5.6: Percentage o f maximal tension following the addition o f  different nitrite doses  
in endothelium denuded aortic rings at 95% and ~ 1 % oxygen. Values presen ted  as mean 
± SEM (n = 1-7 for each concentration).
5.4.6 Inhibition o f N itrite Relaxation bv Endothelium
Nitrite induced relaxation at ~  1% 0 2 was greater in endothelium denuded than in intact 
rings (Figure 5.7), implying that the endothelium  provides a barrier to nitrite induced relaxation.
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Figure 5.7: Percentage relaxation o f 1 0 5M nitrite in endothelium intact and denuded  
aortic rings at ~ 1% oxygen. Values presen ted  a s  mean ± SEM (n = 7  with endothelium  
and 20  without endothelium). **p  < 0.01; Student’s  paired t test.
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5.4.7 Effect o f  Nitrite in Combination with Red Blood Cells
The addition o f  nitrite (10'5M) immediately prior to the addition o f  red blood cells to 
aortic rings at ~  1% 0 2 had no effect on the transient red blood cell induced relaxation response. 
This was the same in endothelium intact (Figure 5.8) and denuded vessels (data not shown).
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Figure 5.8: Percentage red blood cell relaxation response in the presence or absence o f  
added exogenous nitrite in endothelium  intact aortic rings a t ~ 1% oxygen. Values 
presented as m ean ± SEM  (n = 4).
5.4.8 Effect o f Red Blood Cell Pre-incubation with Nitrite and NO
Incubation o f  venous whole blood with nitrite or NO resulted in a dose dependent 
increase in relaxation response observed. At each dose there was no difference in the relaxation 
observed between red blood cells incubated with nitrite or red blood cells incubated with NO 
(Figure 5.9). Also there was no difference in the long term relaxation response as measured after 
five minutes (data not shown).
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Figure 5.9: Percentage red blood cell relaxation response from  whole blood sam ples  
incubated with NO or nitrite in endothelium  denuded  aortic rings at ~ 1% oxygen. Values 
presented as mean ± SEM (n = 3).
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5.5 Discussion
The organ chamber bioassay has provided the foundation for much o f our understanding 
of the mechanisms that control vascular homeostasis and blood flow. More recently it has been 
utilised in conjunction with the manipulation o f 0 2 tension to allow a unique insight into the 
potential role o f red blood cells in the hypoxic vasodilator response [70, 83, 115, 143, 144, 150].
5.5.1 Effect o f Oxygen on Vascular Tone
One of the complexities associated with the manipulation o f 0 2 in the organ chamber 
bioassay related to the variability in constrictor tone elicited by the same dose o f PE (Figures 5.0 
and 5.1). To account for this different doses o f PE were used at ~ 1% 0 2 and 95% 0 2 to obtain 
the same gram tension. This ensured that all relaxants worked against the same constrictor force 
and within the same tension range o f the vessel. Although the percentage change in tension 
relative to sub-maximal constriction can be used to compare responses from vessels with different 
maximal constrictions, these calculations assume a linear responsiveness o f the vessel across its 
whole tension range, which has been questioned by some [130].
Rabbit aorta maintained at low oxygen tension (~ 1% 0 2) for extended periods 
demonstrated a loss o f PE induced constriction. This 0 2 dependent response (not observed in 
vessels maintained at 95% 0 2) could reflect the inhibition o f cytochrome c oxidase/mitochondrial 
respiration and adenosine trisphosphate (ATP) production, upon which vascular 
contraction/dilation ultimately depends [150]. Loss o f constrictor tone was only observed in the 
nitrite experiments which required aortic tissue to be left at low 0 2 for long periods (due to the 
slow relaxation response). For this reason the relatively short five minute time point was taken to 
analyse all nitrite relaxations. To account for the loss o f tension, all experiments performed at 
low 0 2 included a control (to which nothing was added) that was subsequently subtracted from all 
relaxation responses.
Conventionally, experiments performed to assess the effect o f hypoxia on relaxation 
responses have involved comparisons at fixed p 0 2s. More recently a novel experimental protocol 
has been developed to specifically address the question at what p0 2 vessels start to dilate in 
response to different treatments [150]. This involves the comparison o f relaxation in vessels 
exposed to a progressively declining p 0 2. In light o f the variability associated with constriction
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responses in vessels at maintained at set 0 2 tensions it is difficult to comprehend how reliably 
interpretable data could be obtained from experiments in which the rate o f decline in 0 2 might 
potentially vary from chamber to chamber. More importantly the rate and extent o f relaxation is 
not linked to chamber p0 2 but rather p0 2 in the muscle interior which could potentially vary from 
strip to strip as a function o f muscle thickness, adventitial content and deoxygenation rate [130].
5.5.2 Red Blood Cell Mediated Regulation o f Vascular Tone
In endothelium intact vessels at 95% 0 2, red blood cells elicited marked vasoconstriction, 
representing the scavenging o f endothelial produced NO. At ~ 1% 0 2 representative o f the p 0 2 
observed within the cardiovascular system (e.g., coronary venous p 0 2 ~ 10-20mmHg) a prompt 
vasorelaxation was observed followed by a delayed vasoconstriction once the endogenous NO 
bioactivity had been spent. These responses demonstrated the capacity o f native red blood cells to 
contribute to both hyperoxic vasoconstriction and hypoxic vasodilatation, as previously 
demonstrated by others [83].
In endothelium denuded vessels the response at ~ 1% was similar to that observed in 
endothelium intact vessels, establishing that the red blood cell relaxation response was 
endothelium independent. Furthermore the inhibition o f sGC (by ODQ) totally eradicated the red 
blood cell relaxation response proving that the observed effect was sGC dependent. These 
findings which are in line with reports from other laboratories [83, 143] provide a strong case that 
the release o f NO bioactivity from red blood cells plays some part in mediating hypoxic 
vasodilatation. In order to further investigate the potential role o f nitrite in this vasodilator 
response its relaxation properties were investigated further.
5.5.3 Direct Vasoactive Properties o f Nitrite at Different Oxygen Tensions
Nitrite alone was demonstrated to relax thoracic aorta in a dose dependent manner at 95% 
and 1% 0 2. Interestingly, at near physiological nitrite concentrations (< lpM ) a relaxation 
response was observed under hypoxic conditions. However, this response was totally different to 
the relaxation observed from red blood cells. Whilst red blood cells induced a transient relaxation 
at low 0 2 that was almost instantaneous following the addition o f cells to the organ chamber, 
nitrite alone produced a much slower (over a period o f minutes) and prolonged relaxation. Slow 
relaxations as observed from nitrite are incompatible with the mediation o f hypoxic vasodilatation
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which occurs within the capillary transit time, i.e., is a second or less at rest and a fraction o f that 
during exercise [152].
The relaxation o f nitrite alone was much greater at lower oxygen tension (EC25 ~ 1 pM at 
~ 1% 0 2; ~ lOOpM at 95% 0 2). A similar enhanced responsiveness o f vessels to non oxygen 
dependent nitrovasodilators under hypoxic conditions has previously been demonstrated [144, 
151]. This phenomenon was suggested to bring into question the allosteric based mechanism for 
red blood cell (and specifically SNO-Hb) mediated vasodilatation. This issue was resolved in a 
series of experiments performed in our laboratory which demonstrated that hypoxic 
hyperresponsiveness o f vessels alone does not account for the potentiation o f red blood cell 
induced relaxations observed at lower 0 2 [144]. This was deduced by calculating the fold 
enhancement o f relaxation for GSNO (2.6 ± 0.8-fold; across a range o f  concentrations) and red 
blood cells (7.6 ± 1.7-fold) at ~  1% compared with 95% 0 2. Even accounting for the enhanced 
vessel responsiveness (i.e., 2.6 fold) the red blood cell response was still ~ 5 fold greater at lower 
0 2. In this work the nitrite relaxation response was ~ 3.6 fold greater at ~ 1% 0 2 compared to 
95% 0 2.
Interestingly nitrite relaxation was greater in endothelium denuded than intact rings. This 
suggests that the endothelium acts as a barrier to nitrite induced relaxation. It might be that 
elements within the endothelium react with nitrite, or that endothelial cells in some way repel 
nitrite, limiting its capacity to activate sGC and mediate relaxation. This lends further support (in 
addition to the data in chapter 4 demonstrating the accumulation o f exogenously added nitrite in 
the plasma compartment following its addition to whole blood) to the theory that nitrite is in some 
way inhibited from crossing cell membranes. The fact that the nitrite relaxation response was 
greater in endothelium denuded vessels also highlights potential implications for individuals with 
damaged endothelium whereby nitrite might be able to preferentially act upon the damaged 
regions.
5.5.4 Does Nitrite Enhance Red Blood Cell Induced Relaxation?
The transient relaxation response observed from red blood cells alone was no different 
when exogenous nitrite was added to the organ chamber immediately prior to the red cells. The 
fact that vasodilatory activity was not enhanced in the presence o f nitrite implies that the 
reduction o f nitrite by deoxyhaemoglobin at low 0 2 results in very little ( if  any) free NO
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formation. Whilst these observations imply that extra-cellular nitrite does not play a role in red 
blood cell mediated relaxation response they do not rule out the fact that intra-erythrocytic nitrite 
could account for the rapid burst o f relaxation observed from native red blood cells.
To address this issue red blood cells were isolated from whole blood that had been 
incubated with NO or nitrite (following the same protocol outlined in chapter 4). Red blood cells 
that had been doped with NO or nitrite demonstrated increased transient vasodilator activity at ~ 
1%. The increased relaxation response was dose dependent with both the NO and nitrite additions 
and there was no difference in the relaxation response between the NO and nitrite dosed samples. 
In the previous chapter it was demonstrated that bloods loaded with nitrite had a significantly less 
red blood cell associated nitrite compared to those incubated with NO, whilst red blood cell 
haemoglobin bound NO accumulated to a similar extent. As the same response was observed 
from both NO and nitrite loaded red blood cells this implies that nitrite was not the source o f the 
vasorelaxant response, but it does suggest that haemoglobin-bound NO might have been.
130
Chapter FIVE Blood Vessel Relaxation
SUMMARY
• In endothelium intact vessels red blood cells elicited marked vasoconstriction 
at high oxygen (95% 0 2 ) and prompt vasorelaxation at low oxygen (~ 1% 
02). These responses demonstrate the capacity o f native red blood cells to 
contribute to both hyperoxic vasoconstriction and hypoxic vasodilatation.
• Nitrite alone relaxed thoracic aorta in a dose dependent manner at 95% and 
1% 0 2, however the relaxation response was much greater at lower oxygen 
tension, demonstrating the enhanced responsiveness o f vessels at low 0 2 to 
nitrovasodilators. However, the relaxation response from nitrite was much 
slower and more prolonged than that observed from native red blood cells.
• The addition o f exogenous nitrite to the organ chamber prior to the addition of 
red blood cells did not change the transient red blood cell relaxation response 
observed. This implies that the reduction o f nitrite by deoxyhaemoglobin at 
low 0 2 results in very little ( if  any) free NO formation.
• In the previous chapter it was demonstrated that bloods loaded with nitrite had 
a significantly less red blood cell associated nitrite compared to those 
incubated with NO, whilst red blood cell haemoglobin bound NO 
accumulated to a similar extent. As the same response was observed from 
both NO and nitrite loaded red blood cells this implies that nitrite was not the 
source o f the vasorelaxant response, but it does suggest that haemoglobin- 
bound NO might have been.
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6.0 Introduction
The high energy consumption o f the myocardium is reflected in its oxygen extraction. 
Even at rest ~ 75% of arterially delivered oxygen is extracted by the heart compared to ~ 30-40% 
by skeletal muscle. As a consequence o f the limited extraction reserve greater myocardial oxygen 
demand (during exercise or rapid atrial pacing) has to principally be met by an increase in 
coronary blood flow. This is thought to be mediated primarily by local metabolic vasodilators. 
Several potential candidates have been analysed including adenosine, K +At p  channels, lactate, 
phosphate, potassium, prostaglandins and endothelial NO, none o f which has been found to 
adequately account for the regulatory response [140]. However, the potential role of NO 
metabolites has not previously been addressed.
The theory o f a blood derived NO reserve o f circulating metabolites conserving 
bioactivity has been subject to much interest. At present it is generally agreed that the NO reserve 
can function in an endocrine manner to regulate vascular tone under conditions o f low oxygen, 
acting as a potential mediator o f hypoxic vasodilatation. The NO species involved has been 
subject to intense debate. Two models have developed each emphasizing the significance of 
different metabolites; the ability o f iS'-nitrosohaemoglobin (SNO-Hb) within red blood cells to 
provide bio-available NO and the potential formation o f NO from nitrite mediated by the 
reductive potential o f deoxyhaemoglobin. These metabolite species are proposed to be under the 
regulatory control o f haemoglobin, which acts as the oxygen dependent sensor eliciting the 
vasodilator response.
The heart was identified as an ideal model system in which to assess NO metabolites. 
Given the large oxygen gradient it was possible even at rest to obtain blood samples from 
different sites within the coronary circulation at the extremes o f H b 0 2 sat (%). Furthermore, it 
was possible to manipulate myocardial oxygen demand via rapid atrial pacing whilst 
simultaneously obtaining blood samples.
6.1 Aims
The main aims o f this work were to:
• Identify changes in the NO metabolite pool across the coronary circulation at rest and
under conditions o f increased oxygen demand
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• Assess whether oxygen drives apportion between NO metabolites in vivo and induces a
shift in this balance across a single vascular bed.
• Determine the function o f endothelial NOS and the NO metabolite pool in the regulation
o f vascular tone at rest and under conditions o f increased oxygen demand.
6.2 Subjects
Seven otherwise healthy subjects (3 men and 4 women, mean age 49 ± 15 years) 
undergoing electrophysiology (EP) testing for paroxysmal supraventricular arrhythmias were 
studied. All subjects were in sinus rhythm with no past history o f ischemic heart disease, 
smoking, diabetes mellitus, hypertension (blood pressure > 140/90mmHg) or
hypercholesterolemia (total cholesterol > 5.2mmol/L). All gave fully informed written consent 
approved by the relevant local research ethics committee.
6.3 Protocol
Prior to catheterisation subjects underwent an 8 hour fast during which time they were 
allowed water. Diagnostic left heart catheterisation was performed via per cutaneous right 
femoral approach. A left heart catheter was positioned in the left main coronary artery and two 
further catheters were introduced via the right femoral vein and positioned in the coronary sinus 
and pulmonary artery. A bipolar pacing wire was also placed into the right atrium via the right 
femoral vein. The position o f the sampling catheters was confirmed with contrast injection.
At the outset o f the protocol aminophylline (Phoenix Pharma Ltd) was infused to block 
adenosine receptors. A loading dose o f 5mg/kg was administered via the antecubital vein over a 
period o f 20 minutes, followed by a maintenance dose o f 500pg/kg/hour. Once baseline 
haemodynamic parameters had been maintained for 5 minutes, peripheral blood pressure was 
measured and blood samples ( 10ml syringe) were obtained from the left main coronary artery 
(LMCA), coronary sinus (CS) and pulmonary artery (PA). In terms o f analysis LMCA-CS 
difference was taken to reflect “cross heart” and PA-LMCA “cross lung”. Strictly “cross lung” 
should be measured as PA to pulmonary vein (PV) however it is practically difficult to obtain PV 
samples from normal human subjects.
Blood samples were transferred after blood gas analysis (OSM3 Hemoximeter, 
Radiometer) into 6ml gas tight EDTA vacutainers. These were centrifuged at 600g for 10 
minutes at room temperature. The red cell fraction and plasma were immediately separated, snap
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frozen in liquid nitrogen and stored at -80°C for subsequent analysis. Following baseline 
sampling rapid atrial pacing at 65% and then 85% o f maximal heart rate (calculated as 220 minus 
the subject’s age) was commenced. During each pacing interval blood was sampled (for blood 
gas and metabolite analysis) and an angiogram was taken. After discontinuation of pacing and 
confirmation that blood pressure had returned to levels observed before pacing, L-NMMA 
(Clinalfa) was infused intravenously to block systemic synthesis o f NO from type III NOS. A 
loading dose o f 5mg/kg was administered over seven minutes followed by a maintenance dose of 
50pg/kg/min. Blood pressure was measured for comparison without L-NMMA and the whole 
protocol was repeated with the continued infusion o f L-NMMA (Figure 6.0).
LMCA vessel luminal diameter was later determined at baseline and each pacing interval 
in the absence and presence o f L-NMMA by quantitative analysis o f the angiograms using an 
automated edge detection computer analysis system (Philips QCA software).
2 venflons 
Intravenous 
arrinophylline 
infusion
Left and 
Right 
catheters
Pacing
(right
atrium)
L-N M M A
Blood sampling 
& angiogram I t t
Figure 6.0. Schem atic o f  the pacing protocol Green arrows dem onstrate timing o f  blood 
sampling and  angiograms. These w ere perform ed w ithout and  then w ith L-NMMA at 
baseline and  then during rapid atrial pacing at 65% and  85% o f  m axim um  heart rate.
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6.4 Determination of NO Metabolites
Plasma NOx was measured by fluorimetry as detailed in chapter 2; section 2.1.2. Plasma 
nitrite and plasma protein-bound NO metabolite species were measured by ozone based 
chemiluminescence using the tri-iodide reagent as detailed in chapter 2; section 2.1.4. Red blood 
cell haemoglobin-bound NO and red blood cell associated nitrite were quantified by ozone based 
chemiluminescence using our modified tri-iodide reagent as detailed in chapter 2; section 2.1.5.
6.5 Statistical Analysis
Data are presented as individual data points (with mean) or mean values ± SEM. A two- 
tailed p value o f less than 0.05 was considered statistically significant. Differences between 
means (arterial/venous; baseline/L-NMMA) were compared by paired student t test. A repeat 
measures one way ANOVA was used to compare differences between pacing increments. 
Bivariate correlations were performed using Pearson’s coefficient.
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6 .6  Results
6.6.1 Baseline
6.6.1.1 Blood Oxygenation
Cross heart and cross lung baseline H b 0 2 sat (%) and blood oxygen content (ml/dl) are 
illustrated in figure 6.1. The cross heart oxygen gradient reflects the large oxygen extraction 
across the coronary circulation. Upon the mixing o f CS blood with blood from the systemic 
circulation (to give rise to PA blood) H b 0 2 sat (%) and oxygen content increase to reflect near 
systemic levels, whilst across the lung blood is once more fully oxygenated (> 95% H b 0 2 sat).
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Figure 6.1: B ase line  haem oglobin oxygen  sa tura tion  a n d  oxygen content across the heart 
and  lungs. Individual d a ta  p o in ts  p re se n te d  w ith  mean. **p < 0.01: S tu d en t’s  pa ired  t 
test.
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6 .6 .1.2 NO Metabolites
Across the heart there was no significant net loss or gain o f NO from the total metabolite 
pool (p = 0.2381) (i.e., plasma nitrate, plasma nitrite, plasma protein-bound NO, red blood cell 
haemoglobin-bound NO and red blood cell associated nitrite). However, a significant loss was 
observed across the lungs (p = 0.0145) mainly reflecting a decrease in plasma nitrate (p = 0.0142). 
Excluding plasma nitrate, combined red blood cell and plasma NO remained unchanged across 
both the coronary (p = 0.6973) and pulmonary (p = 0.4054) circuits (Figure 6.2).
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Figure 6.2: Total m etabolite pool, p la sm a  nitrate and  com bined red blood cell and p la sm a  
NO (excluding nitrate) a t baseline. Individual d a ta  po in ts  p resen ted  w ith  mean. *p  < 
0.05; S tu d en t’s  p a ired  t test.
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Red blood cell NO (haemoglobin-bound NO and red blood cell associated nitrite) 
increased across the heart (p = 0.0359) mainly representing a gain in haemoglobin-bound NO (p = 
0.0313). Mirroring this change was a trend towards a decrease in red blood cell associated nitrite 
(p = 0.0938) and plasma NO (p = 0.0011) largely reflecting the potential loss o f plasma nitrite (p 
= 0.1250). The gain in total red blood cell NO and haemoglobin-bound NO across the heart was 
partially reversed on mixing o f systemic venous return with CS blood (to give rise to PA blood). 
Across the lung the effects observed across the heart were completely reversed, with an increase 
in plasma NO (p = 0.0748), plasma nitrite (p = 0.0235) and red blood cell associated nitrite (p = 
0.0260) and a decrease in haemoglobin-bound NO (p = 0.0241) (Figure 6.3).
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6.6.1.3 Correlation of NO Metabolites with Oxygen
At baseline a trend was observed towards a direct correlation between red blood cell 
associated nitrite and H b 0 2 sat (%) and an inverse correlation between haemoglobin-bound NO 
and H b02 sat (%) across all sites sampled, suggestive o f potential interchange between these 
species as a function o f oxygen.
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Figure 6 .4: Relationship betw een  haem oglobin-bound NO, red blood cell associa ted  nitrite 
and haemoglobin oxygen saturation (%). Values p resen ted  a s  m ean ± SEM. Correlation r 
= -0.6138 (p = 0.0067) fo r  haem oglobin-bound NO; r = 0 .4243  (p = 0.0792) fo r  red blood 
cell associated nitrite.
6 .6 .1.4 Baseline with L-NMMA
The administration o f L-NMMA systemically did not change the cross heart H b0 2 sat (%) 
oxygen gradient (67.4 ± 1.2 to 66.7 ± 1 .8  %). However PA H b0 2 sat (%) decreased significantly 
(p = 0.0329; 74.2 ± 1.6 to 70.4 ± 1.8 %) reflecting increased systemic oxygen extraction. 
Coronary artery diameter also decreased significantly whilst systolic, diastolic and mean arterial 
blood pressure increased. The decrease in coronary artery diameter in combination with the 
increase in blood pressure confirms NOS inhibition (Figure 6.5 and Table 6.0).
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Figure 6.5: Systolic and diastolic blood pressure and haemoglobin oxygen saturation at 
baseline and following system ic  NOS inhibition. Infusion o f L-NMMA increased systolic  
and diastolic blood pressu re  (by ~ 11 and 20% respectively) and oxygen extraction from  
the blood in the system ic  circulation by -5%. Data presen ted  as mean  ± SEM. * p  < 0.05; 
**p < 0.01; Students pa ired  t test.
Table 6.0: Physiological da ta  fo r  subjects comparing baseline to L-NMMA infusion. Data 
presented as mean ± SEM. *p  < 0.05; **p  < 0.01; S tudent’s  pa ired  t test.
BASELINE + L-NMMA P Value
Mean Arterial Pressure (mmHg) 91 ± 6 108 ± 3 0.0054 **
Coronary Artery Diameter (mm)
Proximal
Mid
Distal
3.30 ±0.35 
2.52 ±0.38  
2.08 ± 0.40
3.14 ±0.31 
2.40 ± 0.37 
1.99 ± 0.35
0.0655 
0.0297 * 
0.3308
The apportionm ent o f NO between m etabolite species in samples taken during L-NMMA 
infusion was sim ilar to that observed at baseline, with “cross heart” and “cross lung” trends 
essentially unaffected. The only significant difference was a smaller loss o f plasma nitrite across 
the heart following L-NM M A infusion (Table 6.1).
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Table 6.1: C hange in NO (A NO) fo r  each m etabolite across heart* and  “cross lung* 
comparing sub jec ts at baseline w ithout a n d  w ith  L-NMMA infusion. Values p resen ted  as  
m ean ± SEM. * p  < 0.05; S tu d en t’s  pa ired  t test.
A NO BASELINE + L-NMMA P Value
“Cross Heart”
LMCA-CS
Totals
Red blood cell NO + 115±43nM + 172 ± 108 nM 0.7104
Plasma NO - 96 ± 14 nM - 50 ± 19 nM 0.0813
Individual Species
Red blood cell associated nitrite - 59 ± 24 nM ± 28 ± 82 nM 0.5887
Red blood cell Hb-bound NO + 150 ± 4 0  nM + 144 ±75 nM 0.1807
Plasma nitrate + 2.4 ± 1.8 pM + 2.9 ± 0.6 pM 0.9335
Plasma nitrite - 78 ± 25 nM - 48 ± 27 nM 0.0458 *
Plasma protein-bound NO - 1.1 ±2 .4  nM - 0.8 ± 1.0 nM 0.7302
“Cross Lung”
PA-LMCA
Totals
Red blood cell NO - 12 ± 4 4  nM ± 54 ± 45 nM 0.6200
Plasma NO ± 93 ± 44 nM + 55 ± 48 nM 0.3823
Individual Species
Red blood cell associated nitrite ± 61± 15 nM ± 58 ± 43 nM 0.9075
Red blood cell Hb-bound NO - 33 ± 9 nM - 3.4 ± 14 nM 0.1391
Plasma nitrate - 4.0 ± 1.4 pM - 3.7 ± 1.1 pM 0.6833
Plasma nitrite ± 102 ± 1 8  nM ± 107 ± 56 nM 0.9589
Plasma protein-bound NO ± 4.6 ± 3.4 nM ±0.7  ±2.1 nM 0.6149
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6.6.2 Pacing
6.6.2.1 Blood Oxygenation
Pacing the heart had no effect on LMCA or PA H b0 2 sat (%). However CS H b02 sat (%) 
increased significantly from baseline (Figure 6 .6 ). This was reflected in a trend towards a decline 
in the cross heart H b 0 2 sat (%) gradient (Figure 6.7).
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Figure 6 .6 : Coronary s in u s  haemoglobin oxygen saturation w ith  pacing. Values 
p resen ted  as m ean ± SEM. *p < 0.05; One w ay  repeat m easures ANOVA.
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Figure 6.7: Cross heart haemoglobin oxygen saturation gradient w ith  pacing. Values 
presen ted  as m ean  ± SEM.
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6 .6 2 2  Blood Vessel Diameter
Pacing the heart had no significant effect on coronary arterial diameter (proximal, mid or 
distal) although there were trends towards an increase in the mid and distal portions (Figure 6 .8 ).
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6.6.2.3 NO Metabolites
In Vivo Human Model
With pacing the total NO metabolite pool remained unchanged in the CS. In the PA there 
was no change at 65% maximum heart rate but a significant decrease from 65% to 85%. In the 
LMCA the total metabolite pool increased significantly at 65% maximum heart rate and remained 
unchanged at 85%. These patterns o f  metabolite interchange mainly reflect plasma nitrate (which 
makes up the majority o f  the total NO metabolite pool). Excluding nitrate, combined red blood 
cell and plasma NO remained unchanged across all o f  the sampling sites with pacing (Figure 6.9).
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Figure 6.9: Total m etabolite pool, p la sm a  nitrate and combined red blood cell and p lasm a  
NO (excluding nitrate) w ith  pacing. Values p resen ted  as mean ± SEM. *p  < 0.05, **p  < 
0.01; Repeat m easures one w a y  ANOVA.
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Cross heart and cross lung gradients in total NO, plasma nitrate and combined red blood 
cell and plasma NO followed the same patterns during pacing as observed at baseline. The only 
difference was seen at 85% maximum heart rate where the loss o f total NO and plasma nitrate 
observed across the lung at baseline and 65% maximum heart rate reverted to a gain at 85% 
maximum heart rate. This is illustrated in the delta cross lung plasma nitrate gradient with 
increased pacing (Figure 6.10).
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Figure 6 .10: Delta p la sm a  nitrate cross lung w ith  increased pacing. A t baseline (0j and  
65% maximal heart rate p la sm a  nitrate w a s  lost across the lung, however, at 85% there 
w a s a gain. Values p resen ted  as m ean ± SEM. * p  < 0.05; R epeat m easures one w a y  
ANOVA.
Pacing had no significant effect on the concentrations o f plasma NO, plasma nitrite or 
plasma protein-bound NO across the different sampling sites. Consequently, similar cross heart 
and cross lung trends to those observed at baseline were observed, with plasma NO (mainly 
reflecting plasma nitrite) lost across the heart and gained across the lungs (Figure 6.11). Red 
blood cell NO remained essentially unchanged in the LMCA and PA with pacing. However, 
there was a trend towards a decrease in red blood cell NO in the CS (p = 0.0854) (mainly 
reflecting the loss o f haemoglobin-bound NO) (Figure 6.12). This change in CS haemoglobin- 
bound NO reflected the increase in H b 0 2 sat (%) observed in the CS with pacing (Figure 6 .6 ), 
which is suggestive o f  oxygen regulation o f this metabolite species. This relationship is more 
clearly demonstrated in the correlation between H b0 2 sat (%) and haemoglobin-bound NO
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(Figure 6.13). Similar to baseline the increase in haemoglobin-bound NO observed across the 
heart was matched by a loss o f red blood cell nitrite and plasma NO (mainly plasma nitrite) at 
each pacing interval.
450-
400-
350-
300-
250-
200-
150-
100-
7
c
65 850
450-i
400-
350-
300-
250-
2 0 0 -
150-
100 -
50-
i l
850 65
450-1 
400- 
«, .'M I­
'S 300-
J S  250-g S, 200-
«  150-
i  1
- r  1 i
□ r
Pacing heart rate (% maximum) Pacing heart rate (% maximum) Pacing heart rate (% maximum)
<0sJ
■5
■7 S
450 n 
400 
350 
300 
250- 
200 
150 
100 
SO 
0
450-i
400-
350-
300-
250-
200-
150-
1 0 0 -
65 850
I
Pacing heart rate (% maximum) Pacing heart rate (% maximum) Pacing heart rate (% maximum)
30-i
2=
e
« o 
a» z
30-i
1 1
1 2
20 -
10 -c
I o
JS z
30-i
2 0 -S
c
I o  « z
Pacing heart rate (% maximum) Pacing heart rate (% maximum) Pacing heart rate (% maximum)
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Figure 6.12: Baseline RBC NO m etabolites w ith pacing. D ata presen ted  a s mean ± SEM. 
No significant changes w ere  observed  within each sam pling s ite  w ith rapid atrial pacing.
6.6.2A Correlation o f NO Metabolites with Oxygen
Across all sites (including baseline and pacing samples) the data gave rise to a direct 
correlation between red blood cell associated nitrite and HbC>2 sat (%) (p = 0.0288; r = 0.3063) 
and an inverse correlation between haemoglobin-bound NO and Hb02 sat (%) (p = < 0.0001; r = - 
0.6278) (Figure 6.13).
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Figure 6.13: Relationship betw een haem oglobin-bound NO, red blood cell associa ted  
nitrite and  haemoglobin oxygen saturation (%). Individual d a ta  p o in ts  p lo tted . Correlation 
r = -0.6278 (p < 0.0001) fo r  haemoglobin-bound NO; r = 0.3063  (p = 0.0288) fo r  red blood 
cell associated  nitrite; Pearson's correlation.
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6.6.3 Pacing with L-NMMA
6.6.3.1 Blood Oxygenation
Similar trends were observed in blood oxygenation with pacing in the presence o f L- 
NMMA as observed with pacing alone. LMCA H b 0 2 sat (%) remained unchanged whilst PA 
H b 0 2 sat (%) increased non-significantly at the first pacing interval and declined significantly at 
85% maximum heart rate. CS H b 0 2 sat (%) increased with each pacing interval in the same way 
that it increased with pacing alone (Figure 6.14). This was reflected in a significant decline in the 
cross heart H b02 sat (%) gradient (Figure 6.15). No significant differences were observed 
between H b 0 2 sat (%) values compared at each pacing interval with pacing alone and with pacing 
in the presence o f L-NMMA.
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Figure 6 .14: Coronary s in u s  haem oglobin oxygen  sa tura tion  w ith  pac ing  in the  p resence  
o f  L-NMMA. Values p re se n te d  a s  m ean  ± SEM. * p  < 0.05; One w a y  repeat m easures  
ANOVA.
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Figure 6.15: C ross heart haem oglobin  oxygen  sa tura tion  grad ien t w ith  pac ing  in the  
p resence  o f  L-NMMA. V alues p r e se n te d  a s  m ean  ± SEM. * p  < 0.05; One w a y  repeat 
m easures ANOVA.
6.6.3.2 Blood Vessel Diameter
In the presence o f L-NMMA, pacing the heart significantly increased coronary arterial 
diameter at all sites (proximal, mid and distal) (Figure 6.16). Significant differences between 
pacing alone and pacing in the presence o f  L-NMMA were observed in the mid coronary artery 
diameter which was lower at baseline with L-NMMA (p < 0.05) and in the distal coronary artery 
diameter which was higher at maximal pacing with L-NMMA (p < 0.01).
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p  < 0.05; O ne w a y  repea t m ea su re s  ANOVA. D ifferences be tw een  pac ing  alone a n d  
pacing  w ith  L-NMMA; f  < 0.05, f f  < 0.01.
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6.6.3.3 NO Metabolites
The apportionment o f  NO between metabolite species in samples with pacing during L- 
NMMA infusion was similar to that observed with pacing alone, with “cross heart” and “cross 
lung” trends essentially unchanged. The only significant difference was a loss o f plasma nitrate 
across the heart following L-NMMA infusion at the highest pacing interval (Tables 6.2 and 6.3).
Table 6.2: C hange in NO (A NO) fo r  each  m etabolite  *cross heart” a n d  "cross lung” 
comparing 65% m a x im u m  heart rate pac ing  alone w ith  pac ing  a t th e  sa m e  in ten sity  in the  
presence  o f  L-NMMA. Values p re se n te d  a s  m ean  ± SEM.
A NO 65% 65% + L- NMMA P Value
“Cross Heart”
LMCA-CS
Totals
Red blood cell NO + 92 ± 7 nM + 22 ± 75 nM 0.6875
Plasma NO - 66 ± 14 nM - 29 ± 40 nM 0.3207
Individual Species
Red blood cell associated nitrite - 12 ± 2 0  nM - 66 ± 73 nM 1.0000
Red blood cell Hb-bound NO + 102 ± 18 nM + 88 ± 1 0  nM 0.4426
Plasma nitrate + 1.1 ± 0 .7  pM -0.01 ± 1.8 pM 0.8054
Plasma nitrite - 81 ± 2 9  nM - 11 ± 53 nM 0.3788
Plasma protein-bound NO + 11.6 ± 9.6 nM - 1.3 ±2 .9  nM 0.5814
“Cross Lung”
PA-LMCA
Totals
Red blood cell NO + 10 ± 12 nM + 30 ± 88 nM 0.6875
Plasma NO + 45 ± 20 nM + 98 ± 33 nM 0.0690
Individual Species
Red blood cell associated nitrite + 38 ± 12 nM ± 3 8  ± 8 7  nM 0.5625
Red blood cell Hb-bound NO - 34 ± 13 nM - 8 ± 6 nM 0.0740
Plasma nitrate - 4.5 ± 1.1 pM - 1.3 ± 1.1 pM 0.1608
Plasma nitrite + 39 ± 27 nM + 79 ± 35 nM 0.2352
Plasma protein-bound NO + 0.7 ± 5 nM ±5.7  ±2 .6  nM 0.6250
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Table 6.3: C hange in NO (A NO) fo r  each  m etabolite  “cross h ea rt* a n d  “cross lung” 
comparing 85% m axim um  heart rate p ac ing  alone w ith  pac ing  a t the  sa m e  in tensity  in the  
presen ce  o f  L-NMMA. Values p re se n te d  a s  m ean  ± SEM, ** p  < 0.01.
A NO 85% 85% + L- NMMA P Value
“Cross Heart”
LMCA-CS
Totals
Red blood cell NO + 45 ± 39 nM ± 53 ± 29 nM 0.8299
Plasma NO - 50 ± 30 nM - 42 ± 29 nM 0.6842
Individual Species
Red blood cell associated nitrite - 62 ± 28 nM - 24 ± 29 nM 0.8713
Red blood cell Hb-bound NO + 112±34nM ± 77 ± 13 nM 1.0000
Plasma nitrate + 1.3 ±0 .7  pM -3 .8  ±0 .6  pM 0.0028**
Plasma nitrite - 87 ±31 nM - 43 ± 34 nM 0.2636
Plasma protein-bound NO ± 9 ± 4.4 nM - 3.8 ± 2.4 nM 0.2804
“Cross Lung” 
PA-LMCA
Totals
Red blood cell NO - 18 ± 4 9  nM ± 19 ±21 nM 0.3524
Plasma NO ± 57 ± 14 nM ±21 ± 32 nM 0.3226
Individual Species
Red blood cell associated nitrite + 44 ± 35 nM ± 49 ± 21 nM 0.3813
Red blood cell Hb-bound NO - 26 ± 6 nM -31 ± 15 nM 0.2740
Plasma nitrate + 2.4 ± 2.2 pM - 3.3 ± 1.0 pM 0.8233
Plasma nitrite ± 63 ± 1 8  nM ± 42 ± 26 nM 0.5630
Plasma protein-bound NO - 8 ± 5.2 nM - 1.4 ±4 .6  nM 0.0938
6.6.3.4 Correlation o f  NO M etabolites with Oxygen
Once more, across all sites (including baseline and pacing samples) the data gave rise to a 
direct correlation between red blood cell associated nitrite and Hb0 2  sat (%) and an inverse 
correlation between haemoglobin-bound NO and Hb02 sat (%) similar to that observed in the 
absence o f L-NMMA (data not shown).
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6.7 Discussion
6.7.1 Baseline Changes in the NO Metabolite Pool
In healthy human subjects under baseline resting conditions a significant re­
apportionment o f NO metabolites was observed across the coronary circulation that correlated 
with H b02 sat (%). However, no net loss or gain o f NO was observed from the total metabolite 
pool. This NO metabolite equilibrium could be interpreted in one o f  two ways. Either extraction 
o f NO by cardiac tissue was balanced by replenishment from endothelial sources giving the 
overall appearance o f  no net flux from blood metabolite stores into tissue (but potentially 
sufficient NO delivery to contribute to the regulation o f coronary blood flow) or alternatively 
there was no utilisation/consumption o f  NO  from the metabolite pool under baseline resting 
conditions.
Oxygen dependent increases in haemoglobin-bound NO across the coronary circulation 
were matched by decreases in plasma and red blood cell associated nitrite. However, with no net 
loss o f NO from the total m etabolite pool, these changes implied either the consumption o f nitrite 
derived NO being replenished from the endothelium resulting in the formation o f haemoglobin- 
bound NO in venous blood, or the direct exchange o f  NO  between nitrite and haemoglobin as a 
function o f H b 0 2 sat (%), potentially via the deoxyhaemoglobin nitrite reductase reaction. Either 
way the significant re-apportionment o f  NO  between metabolite species across the coronary (and 
pulmonary) vascular beds driven by H b 0 2 sat (%) gradients highlighted the dynamic interplay 
between NO metabolite species throughout these vascular circuits. The metabolite changes which 
occurred in the brief tim e that blood traversed these single vascular beds lends support to the idea 
that NO or a related moiety could in principle be transferred from metabolite stores as a function 
o f oxygen to potentially mediate the regulation o f  vascular tone.
The pattern o f  N O  metabolite interplay observed across the coronary circulation was 
reversed across the pulmonary vascular circuit, reflecting the opposite oxygen gradient. This 
implied a role for the lungs in normalising the NO metabolite equilibrium, adjusting for systemic 
changes in the balance o f  NO metabolite species. As the lungs function to re-oxygenate blood, 
accounting for oxygen consumption throughout the vascular circuit, the same appears true for NO 
metabolites with the restoration o f  the NO metabolite equilibrium prior to the re-transit o f  blood 
around the vasculature.
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The haemoglobin-bound NO metabolite pool has previously been demonstrated to remain 
constant throughout the systemic human circulation, with only the relative levels o f individual 
haemoglobin-bound species changing as a function o f  oxygen tension (or more precisely H b 0 2 sat 
(%)) [70, 81, 83]. However, never before has the relationship between haemoglobin-bound NO 
and oxygen tension been studied over such a substantial oxygen gradient as observed across the 
coronary circulation (H b 0 2 sat ranging from > 95% to ~ 30%). In these measurements 
haemoglobin-bound NO was found to be inversely correlated with H b 0 2 sat (%). Unfortunately it 
was not possible to assess the ratio o f  HbNO to SNO-Hb as a function o f  H b 0 2 sat (%) as these 
individual haemoglobin-bound NO species were not differentiated for reasons outlined previously 
(chapter 3). Nevertheless, these results are in agreement with previous work from our laboratory 
demonstrating gradients in haemoglobin-bound NO metabolite species showing a clear 
dependence on H b 0 2 sat (%). However, it must be acknowledged that this earlier work was 
undertaken utilising the N O  electrode in combination with various sample pre-treatment 
protocols. Although the NO metabolite levels do not agree with values quoted herein (which are 
in fact in very close agreement with recent values reported by other groups using similar 
methodologies, showing aN O :H b  ratio ~ 0.00012 [73, 78, 111, 125]), previously observed trends 
with regard to the correlation with oxygen and a lack o f net NO loss or gain are confirmed [115].
The concentrations o f  red blood cell NO metabolites measured herein within the coronary 
and pulmonary circulations are in very close agreement with the baseline metabolite 
measurements made across the femoral circulation in chapter 4. However, levels o f  coronary and 
pulmonary plasma nitrite appear m uch greater. W ith levels o f plasma nitrite acting as a marker 
for type III NOS NO  production this would infer that the heart could be a major site o f NO 
production.
6.7.2 Effect o f  L-NM M A at Baseline
Systemic administration o f L-NM M A resulted in a significant decrease in coronary artery 
diameter and a significant increase in systolic, diastolic and mean arterial blood pressure, 
confirming NOS inhibition. The decrease in coronary artery diameter with L-NMMA at baseline 
was in support o f  the hypothesis that endothelial derived NO functions to regulate vascular tone 
under baseline conditions in the human coronary microcirculation, as previously demonstrated by 
others [153, 154].
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Surprisingly, L-NMMA had no effect on the apportionment o f  NO to metabolites at each 
sampling site. Consequently the same trends observed at baseline were observed in the presence 
o f L-NMMA, as demonstrated by the similar cross heart and cross lung deltas (Table 6.1). This 
result is consistent with the re-apportionment o f NO between metabolites (independent of 
endothelial NO) as a function o f changes in oxygen across the heart.
6.7.3 Effect o f Rapid Atrial Pacing
Pacing the heart significantly increased CS saturation and decreased the cross heart H b 0 2 
sat (%) gradient. This was somewhat o f a surprise as the increase oxygen demand elicited via 
pacing was expected to lower CS H b 0 2 sat (%). The increased oxygen demand must have been 
met via an increase in blood flow (given the increase in CS H b 0 2 sat (%)). The increase in flow 
would have resulted in greater oxygen delivery but resulted in less exchange o f oxygen, as a result 
o f  the reduction in blood transit time through the coronary circulation. Although pacing did not 
significantly alter blood vessel diameter there were trends towards an increase in the mid and 
distal portions o f the coronary artery.
Changes in the total metabolite pool upon pacing mainly reflected a trend towards 
increasing plasma nitrate levels (Figure 6.8). The only decrease was observed in the PA at 
maximal pacing, resulting in a delta increase in plasma nitrate across the lungs (Figure 6.9). Once 
again the apportionment o f NO to metabolites remained essentially unchanged across the heart 
and lungs with the same trends observed at baseline also seen during pacing. However, with 
increased pacing there was a trend towards a decline in red blood cell NO in the CS, mainly 
reflecting the loss o f haemoglobin-bound NO. This change mirrored the increase in CS H b 0 2 sat 
(%) implying the close regulation o f haemoglobin-bound NO as a function o f oxygen, 
demonstrated by the correlation in Figure 6.11.
6.7.4 Effect o f L-NMMA with Rapid Atrial Pacing
Previous data in human studies have shown inconsistent results concerning the effects of 
NO inhibition on metabolic vasodilatation [154-156]. Whilst coronary artery diameter declined at 
baseline upon the administration o f L-NMMA, upon pacing coronary artery diameter increased at 
least to the same extent as in the absence o f L-NMMA. This implied that the release of
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endothelial NO was not an important factor in pacing-induced arterial dilation in the human 
coronary circulation.
Once more, even during pacing the same trends observed during pacing without L- 
NMMA were observed during pacing in the presence o f L-NMMA. This was demonstrated by 
the similar cross heart and cross lung deltas (Table 6.2). This result is consistent with the re- 
apportionment o f NO between metabolites (independent o f  endothelial NO) as a function o f 
changes in oxygen across the heart.
The only time that conclusions can be made as to whether NO metabolites regulate 
vascular tone is in the presence o f  L-NMMA, when endothelial NO is inhibited. Under these 
conditions for any m etabolite species (such as nitrite) to function to regulate vascular tone, the 
total metabolite pool would have to experience a loss o f NO. However, as no detectable loss o f 
NO was observed at all in the presence o f  L-NMMA at baseline or during rapid atrial pacing, this 
would appear to rule out any function for NO metabolites in the regulation o f coronary vascular 
tone.
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SUM M ARY
• Baseline - Across the coronary circulation there was no net loss o f NO from 
the total metabolite pool, however a significant re-apportionment o f NO 
metabolites was observed that correlated with H b 0 2 sat (%).
• Baseline with L-NMMA - Coronary artery diameter decreased implying a role 
for endothelial NO in the maintenance o f baseline vasodilator tone. The 
apportionment o f  NO  to metabolites at each sampling site remained 
unchanged which is consistent with the re-apportionment o f NO between 
metabolites (independent o f endothelial NO) as a function o f changes in 
oxygen across the heart.
•  Pacing - CS H b 0 2 sat (%) increased whilst there was a trend towards an 
increase in coronary artery diameter. The apportionment o f NO to 
metabolites remained essentially unchanged across the heart and lungs with 
the same trends observed at baseline also seen during rapid pacing.
• Pacing with L-NM M A - Coronary artery diameter increased significantly and 
was no different to that observed during pacing alone implying that 
endothelial N O  does not contribute to pacing induced vasodilatation. The 
same N O  metabolite trends were observed as during pacing alone which is 
consistent with the re-apportionment o f  NO between metabolites (independent 
o f  endothelial NO) as a function o f changes in oxygen across the heart.
•  N o detectable loss o f  NO was observed at all in the presence o f L-NMMA at 
baseline or during rapid atrial pacing which would appear to rule out any 
function for N O  metabolites in the regulation o f coronary vascular tone.
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7.0 Overview
The aims o f this thesis were to develop and establish methods o f measuring baseline 
levels o f NO metabolites in human blood to enable a more comprehensive understanding o f the 
physiological relevance o f these species in the human circulation. The results herein have 
provided important insights into the complexities o f NO metabolites/metabolism. These can be 
summarised as follows:
7.1 NO Metabolite Measurement
Extensive methodological work led to the identification o f a potential confounding factor 
in all measurements o f red blood cell/haemoglobin-bound NO, namely the auto-capture o f NO by 
cell free haem. A means was developed to overcome this issue in one o f the most commonly used 
assay reagents in the NO metabolite field. Subsequently this modified reagent was used to 
analyse red blood cell NO  metabolites in human blood whilst other methods were employed to 
determine plasma NO metabolite species. At the same time protocols were also developed to 
limit the possibility o f biological sample contamination and losses o f unstable NO metabolite 
species. These advances subsequently improved the accuracy and sensitivity o f the NO 
metabolite measurements made.
At the outset o f  this thesis it was expected from previous measurements made within our 
laboratory that baseline metabolite values from human blood samples would be in the pmol/L 
range. Instead the measured concentrations o f all metabolites species (other then nitrate) mainly 
fell within the ~ 10 - 500nmol/L range, in line with measurements made by a number o f groups 
using similar methodologies. Although the baseline metabolite levels measured herein were 
small, it is worth emphasising that:
• Red blood cell and haemoglobin-bound NO were visibly detectable in baseline human 
blood samples (Chapter 2)
• Intricate fluctuations in the levels o f  haemoglobin-bound NO, plasma nitrite and red 
blood cell associated nitrite under the control o f oxygen were clearly measured (Chapter 3 
and 6).
• Significant changes in metabolite species across the coronary and pulmonary circulation 
were plainly evident (Chapter 6)
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•  The major NO metabolite species in human blood were all accounted for, as demonstrated 
by the near 100% recovery o f  exogenously added NO and nitrite to human whole blood 
(Chapter 4).
Whilst the developments herein have improved the accuracy and specificity o f NO 
metabolite measurements made within our laboratory, there are still many issues that remain to be 
resolved within the research field as a whole. One often cited concern relates to the exact 
identification o f metabolite species measured by the major methodologies, including tri-iodide 
and photolysis (the favoured methodologies o f the two main groups in this research field, which 
appear to yield some o f  the most disparate metabolite values). However, as the standards against 
which these measurements are made barely reflect the physiological species they are supposed to 
represent, there would appear little benefit to this exercise. More enlightening would be a direct 
comparison o f measures made by tri-iodide and photolysis from duplicate blood samples.
Progress towards our understanding o f N O  biology hinges on the accuracy and specificity 
o f methods used to measure NO metabolites. It is therefore imperative that closely scrutinised 
methods are utilised by all within this research field. Future aims should address the development 
o f assays with the capacity to measure only the metabolite species o f interest. This specificity 
would minimise the need for sample processing/pre-treatment thus limiting the possibility o f 
contamination, loss o f  less stable metabolite species and disruption to the NO metabolite 
equilibrium. Only when the same metabolite concentrations can be measured by different 
methodologies can we be satisfied that the true levels o f NO metabolites in human blood have 
been quantified.
7.2 NO/Nitrite M etabolism in Human Blood
NO and nitrite metabolism was analysed in human whole blood to identify and compare 
the major metabolic pathways o f  these species. Furthermore the effect o f  oxygen on these 
metabolic pathways was assessed. The results can be summarised as follows:
•  NO and nitrite were metabolised in a similar manner in arterial blood, the major routes 
being, plasma nitrate »  plasma nitrite > red blood cell associated nitrite, with relatively 
little formation o f haemoglobin-bound NO or plasma protein-bound NO. The major 
difference between NO and nitrite metabolism was the relative stability o f exogenously
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added nitrite in arterial whole blood reflected by its accumulation in the plasma 
compartment.
•  In venous blood the apportionment o f  exogenously added NO/nitrite was more evenly 
distributed among the non nitrate metabolite species. However, the main pathways o f 
metabolism remained nitrate »  nitrite > haemoglobin-bound NO > plasma protein-bound 
NO. Interestingly a greater percentage o f  exogenously added NO in comparison to nitrite 
was metabolised to plasma nitrate, plasma protein-bound NO, red blood cell 
haemoglobin-bound NO and red blood cell associated nitrite. However, once more the 
relative stability o f  nitrite was reflected in the fact that a significant proportion o f 
exogenously added nitrite remained in the plasma compartment.
•  The different metabolism o f set amounts o f NO/nitrite in arterial and venous blood 
demonstrates the regulatory function o f  oxygen in determining the relative proportion o f 
species within the metabolite pool.
The fact that nitrite formed the same metabolite species as NO (although not in the same 
proportions) in arterial and venous human whole blood implies the ability o f  this metabolite 
species to act as a potential source from which the metabolite pool could be replenished. The 
relative stability o f  nitrite in comparison to NO (reflected in its accumulation in the plasma 
compartment following addition to both arterial and venous blood) would benefit its function as a 
potential NO reserve in the circulation. Interestingly, the apportionment o f NO and nitrite to the 
various metabolic pathways appeared to be under the direct control o f  oxygen. This regulatory 
control adds to the complexity o f  analysing and interpreting A-V metabolite gradients, i.e., even 
where NO stays constant, any change in oxygen alters the apportionment o f  NO between species.
7.3 Blood Vessel Relaxation
Perhaps the most compelling evidence that NO metabolites function to regulate vascular 
tone is offered by organ chamber bioassay experiments. In this thesis the organ chamber bioassay 
was used to assess whether nitrite could account for the relaxation response observed from native 
red blood cells under hypoxic conditions. The results can be summarised as follows:
•  In endothelium intact vessels native red blood cells were demonstrated to mediate 
vasoconstriction at high oxygen tension and relaxation at low oxygen tension. This 
implicates the red blood cell in the mediation o f hyperoxic vasoconstriction and hypoxic
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vasodilatation in vivo. The red blood cell relaxation response at low oxygen was 
endothelium independent and sGC dependent.
• Nitrite alone was found to relax aortic rings and this was enhanced under hypoxic
conditions. However, the slow and prolonged relaxation response was totally different to 
the transient relaxation observed from native red blood cells.
• Addition o f exogenous nitrite to the organ chambers prior to native red blood cells had no
effect on the transient red blood cell relaxation response observed, implying that
exogenous nitrite plays no part in this and potentially that the reduction o f nitrite by 
deoxyhaemoglobin at very low oxygen tension results in very little ( if  any) free NO 
formation.
•  Whole blood was incubated with nitrite or NO (as in chapter 4, wherein it was 
demonstrated that bloods loaded with nitrite contained significantly less red blood cell 
associated nitrite compared to those incubated with NO, whilst haemoglobin-bound NO 
accumulated to a similar extent). The red blood cells were then injected in the organ 
chamber bioassay at low oxygen tension. The same relaxation response was observed 
from both NO and nitrite loaded red blood cells. This would imply that nitrite was not the 
source o f  the vasorelaxant response, but that haemoglobin bound NO might have been.
These results would appear to rule out the involvement o f  nitrite in the relaxation 
response observed from native red blood cells at low p 0 2 (~ lOmmHg). This is not entirely 
surprising as the deoxyhaemoglobin nitrite reductase reaction is proposed to function maximally 
at haemoglobins P50. This would place its maximal activity at around ~ 30mmHg. The relative 
abundance o f  deoxygenated haem at the low oxygen tensions at which native red blood cells elicit 
a relaxation response would more likely scavenge any free NO (Figure 1.11). These results 
therefore confirm that the red blood cell hypoxic vasodilatory response is unlikely to result from 
direct nitrite reduction to NO. This has relevance to the in vivo setting where red blood cells are 
exposed to a range o f  p 0 2s across a single vascular bed (a discussion returned to below).
7.4 In Vivo Human Study
The heart was identified as an ideal model system in which to assess NO metabolites 
given its high energy consumption (even at rest extracting ~  75% o f  arterially delivered oxygen) 
which provided the opportunity to obtain blood samples at the extremes o f physiologically 
relevant H b 0 2 sat (%). Also it was possible to manipulate oxygen demand via rapid atrial pacing
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(whilst simultaneously obtaining blood samples). The work presented herein is subsequently the 
first to measure NO metabolites across the coronary and pulmonary vascular circulations in 
human subjects. The results can be summarised as follows:
•  At rest, across the coronary circulation, there was no net loss o f  NO from the total 
metabolite pool, however a significant re-apportionment o f NO metabolites was observed 
that correlated with H b 0 2 sat (%). The intravenous infusion o f L-NMMA resulted in a 
decrease in coronary artery diameter (along with an increase in blood pressure confirming 
NOS inhibition) implying a modest role for endothelial NO in the maintenance o f 
baseline vasodilator tone. Interestingly the apportionment o f  NO to metabolites at each 
sampling site remained unchanged. This was consistent with the re-apportionment o f NO 
between metabolites (independent o f endothelial NO) as a function o f  changes in oxygen 
across the heart, without any detectable loss o f  NO, i.e., no utilisation/consumption o f  NO 
moiety from the metabolite pool.
• Pacing the heart resulted in a trend towards an increase in coronary artery diameter. 
Interestingly CS H b 0 2 sat (%) also significantly increased and the cross heart H b 0 2 sat 
(%) gradient decreased (thought to reflect the increase in blood flow through the 
myocardium). The apportionment o f  NO to metabolites remained essentially unchanged 
across the heart and lungs with the same trends observed at baseline also seen during 
pacing. The combination o f pacing and L-NMMA resulted in an increase in coronary 
artery diam eter and CS H b 0 2 sat (%) whilst the cross heart H b 0 2 sat (%) gradient 
decreased once more. The increase in coronary artery diameter was similar to that 
observed in the absence o f L-NM M A implying no role for endothelial NO in pacing 
induced vasodilatation. M ost interestingly, similar NO  metabolite trends were observed 
as during pacing alone (i.e., without L-NM M A) which once more was consistent with the 
re-apportionment o f NO between metabolites (independent o f endothelial NO) as a 
function o f  changes in oxygen across the heart. Furthermore, there was no detectable loss 
o f NO  implying no utilisation/consumption o f NO  from the metabolite pool.
These results demonstrate no detectable loss o f  NO from the metabolite pool at baseline 
or during pacing o f  the heart in the absence or presence o f L-NMMA. Consequently this implies 
that even where red blood cells are exposed to a range o f p 0 2s across a single vascular bed the 
nitrite reduction reaction unlikely contributes to the regulation o f vascular tone via the release and 
utilisation o f free NO, whereas in vitro and in principle, free NO may be produced maximally
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from haemoglobin nitrite reduction at H b 0 2 saturations around 50%. Were this to have occurred 
a loss o f NO would have been expected across the coronary vascular bed. More consistent with 
my results is the re-apportionment o f NO between metabolite species under the direct control o f 
H b 0 2 sat (%).
7.5 Conclusion
From my work the presence o f  a dynamic pool o f  NO metabolites in the human 
circulation under the close regulation o f  oxygen remains. Whereas the range o f  levels is an order 
o f magnitude lower than anticipated at the outset o f  these studies, this potentially means that even 
very small changes might be physiologically relevant. Taken together my work highlights three 
important considerations for future work:
•  Biochemical NO metabolite measurement methodologies should work on the principle 
that ‘simple is best’, i.e., samples should be injected with no manipulation or treatment.
•  Photolysis (am ong other techniques) should be used to yield complementary data to that 
reported herein, potentially providing measures o f  different metabolite species.
• That NO metabolites could contribute to baseline and pathological vessel tone, only that 
the amounts involved would not necessarily result in A-V blood gradients.
I conclude that in the healthy human vasculature NO metabolites would appear to play 
only a limited role in the regulation o f vascular tone. However, in various pathologies wherein 
differences in NO production, the structural components o f  blood (e.g., diabetes), or physiological 
parameters (e.g., decreased H b 0 2 sat (%) in chronic heart disease) might change NO metabolite 
dynamics, this metabolite pool could potentially be o f more significance. Further clinical studies 
which tie together biochemical NO  metabolite measurements with parallel assessments o f 
physiological changes in the vasculature offer the most promising means o f advancing our 
understanding in this research area and it is here I will focus in the immediate future.
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7.6 Publications
S.C. Rogers, A. Khalatbari, B.N. Datta, S. Ellery, V. Paul, M.P. Frenneaux, and P.E. James. NO 
metabolite flux across the human coronary circulation. Cardiovasc Res. (Submitted September 
2006).
S.C. Rogers, A. Khalatbari, P.W. Gapper, M.P. Frenneaux and P.E. James. Detection o f Human 
Red Blood Cell-bound Nitric Oxide. J. Biol. Chem. 280 (29):26720-26728, 2005.
S.K. Jackson, M.P. Thomas, S. Smith, M. Madhani, S.C. Rogers, and P.E. James. In vivo EPR 
spectroscopy: biomedical and potential diagnostic applications. Faraday Discuss. 126: 169-183 
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